# EDGAR Filing Document

**Accession Number:** 0001069530
**File Stem:** 0001493152-25-022066
**Filing Date:** 2025-11
**Character Count:** 377210
**Document Hash:** 695603eef1c37c0cfc80781a778ee6d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-022066.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001493152-25-022066

**CONFORMED SUBMISSION TYPE**: S-3

**PUBLIC DOCUMENT COUNT**: 23

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CASSAVA SCIENCES INC
- **CENTRAL INDEX KEY:** 0001069530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911911336
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291489
- **FILM NUMBER:** 251475163

**BUSINESS ADDRESS:**
- **STREET 1:** 6801 N CAPITAL OF TEXAS HIGHWAY
- **STREET 2:** BUILDING 1; SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78731
- **BUSINESS PHONE:** 512-501-2444

**MAIL ADDRESS:**
- **STREET 1:** 6801 N CAPITAL OF TEXAS HIGHWAY
- **STREET 2:** BUILDING 1; SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78731

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAIN THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20000309

**As filed with the Securities and Exchange Commission on November 12, 2025**

Registration No. 333-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-3**

**REGISTRATION STATEMENT**

**UNDER**

***THE SECURITIES ACT OF 1933***

 ****

**Cassava Sciences, Inc.**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware**<br> **(State or other jurisdiction of**<br> **incorporation or organization)** | **91-1911336**<br> **(I.R.S. Employer**<br> **Identification Number)** |

---

**6801 N. Capital of Texas Highway, Building 1, Suite 300**

**Austin, TX 78731**

(512) 501-2444

**(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)**

R. Christopher Cook

**Chief Operating and Legal Officer**

**6801 N. Capital of Texas Highway, Building 1, Suite 300**

**Austin, TX 78731**

(512) 501-2444

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

**Peter E. Devlin**

**Ferrell M. Keel**

**Jones Day**

**250 Vesey Street**

**New York, New York 10281**

(212) 326-3939

**Approximate date of commencement of proposed sale to the public:** From time to time, after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

 **The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.**

**EXPLANATORY NOTE**

This registration statement contains two prospectuses:

● a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $200,000,000 of the registrant's common stock, preferred stock, depository shares, warrants, rights, debt securities, and units; and

● an "at the market offering" prospectus supplement covering the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $50,000,000 of the registrant's common stock that may be issued and sold under a sales agreement, dated as of November 12, 2025 (the "Sales Agreement"), with Cantor Fitzgerald & Co. (the "Agent").

The base prospectus immediately follows this explanatory note. The "at the market offering" prospectus supplement immediately follows the base prospectus. The common stock that may be offered, issued and sold by the registrant under the "at the market offering" prospectus supplement is included in the $200,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the Sales Agreement with the Agent, any portion of the $50,000,000 included in the "at the market offering" prospectus supplement that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares of common stock are sold under the Sales Agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.

**The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

**SUBJECT TO COMPLETION, DATED NOVEMBER 12, 2025**

**PROSPECTUS**

 **$200,000,000** 

**Common Stock** 

**Preferred Stock** 

**Depositary Shares** 

**Warrants**

**Rights**

**Debt Securities** 

**Units**

From time to time, we may offer and sell, in one or more offerings, in amounts, at prices and on terms determined at the time of any such offering, common stock, preferred stock, depositary shares, warrants, debt securities, and rights to purchase such securities, either individually or in units, in an aggregate amount of $200,000,000. The securities we may offer may be convertible into or exercisable or exchangeable for other securities.

This prospectus describes some of the general terms that may apply to these securities. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement, which will describe the method and the terms of the offering. We will provide you with the specific amount, price and terms of the applicable offered securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. You should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you purchase any of our securities being offered.

Our common stock is listed on the Nasdaq Capital Market under the symbol "SAVA." On November 11, 2025, the closing price of our common stock on the Nasdaq Capital Market was $3.11 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, of the securities covered by the applicable prospectus supplement.

We may offer and sell the securities in amounts, at prices and on terms determined at the time of offering. We may sell the securities directly to you, through agents we select, or through underwriters and dealers we select. If we use agents, underwriters or dealers to sell the securities, we will name them and describe their compensation in a prospectus supplement. In addition, the underwriters may overallot a portion of the securities. For additional information regarding the methods of sale of our securities, you should refer to the section entitled "Plan of Distribution" in this prospectus.

**Investing in our securities involves risk. Please carefully review the information under "Risk Factors" beginning on page 3 of this prospectus as well as the risks and uncertainties contained in the applicable prospectus supplement and any related free writing prospectus, and in other documents that are incorporated by reference into this prospectus or the applicable prospectus supplement.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

This prospectus is dated , 2025.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [About This Prospectus](#J_001) | 1 |
| [Cassava Sciences, Inc.](#J_002) | 2 |
| [Risk Factors](#J_003) | 3 |
| [Forward-Looking Statements](#J_004) | 4 |
| [Use of Proceeds](#J_005) | 5 |
| [Description of Capital Stock](#J_006) | 6 |
| [Description of the Depositary Shares](#J_007) | 9 |
| [Description of the Warrants](#J_008) | 11 |
| [Description of Rights](#J_009) | 13 |
| [Description of the Debt Securities](#J_010) | 14 |
| [Description of the Units](#J_011) | 24 |
| [Plan of Distribution](#J_012) | 25 |
| [Legal Matters](#J_013) | 27 |
| [Experts](#J_014) | 27 |
| [Where You Can Find More Information](#J_015) | 27 |
| [Information Incorporated by Reference](#J_016) | 27 |

---

i

**About This Prospectus**

This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), using a "shelf" registration process. Under this shelf process, we may, from time to time, offer or sell any combination of the securities described in this prospectus in one or more offerings. Before purchasing any securities, you should read this prospectus and any applicable prospectus supplement together with the additional information described under the headings "Where You Can Find More Information" and "Information Incorporated by Reference." References in this prospectus to "our company," "we," "our," "Cassava Sciences" and "us" refer to Cassava Sciences, Inc.

This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to, update or change information contained in the prospectus or in the documents incorporated by reference in the prospectus. To the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement.

The prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the initial public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the securities.

You should rely only on the information contained or incorporated by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus, any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable.

**Cassava Sciences, Inc.**

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat central nervous system disorders, such as Tuberous Sclerosis Complex ("TSC")-related epilepsy. Our novel science is based on affecting the activity of a critical protein in the brain for patients with certain central nervous system disorders, such as TSC.

We combine innovative technology with new insights in neurobiology to develop novel solutions targeting central nervous system disorders, such as TSC-related epilepsy. Our strategy is to leverage our unique scientific/clinical platform to develop first-in-class programs for treating central nervous system disorders.

We were incorporated in Delaware in May 1998. Our principal executive offices are located at 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, 78731 and our telephone number at that address is (512) 501-2444.

**Risk Factors**

An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading "Risk Factors" in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q, which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also negatively affect our operations.

**Forward-Looking Statements**

This prospectus and the registration statement of which it forms a part, any prospectus supplement, any related issuer free writing prospectus and the documents incorporated by reference into these documents contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements deal with our current plans, intentions, beliefs and expectations and statements of future economic performance. Statements containing terms such as "believe," "do not believe," "plan," "expect," "intend," "estimate," "anticipate," "could," "may," "continue," "should," "potential," or the negative of these words and other phrases of similar meaning are considered to contain uncertainty and are forward-looking statements. In addition, from time to time we or our representatives have made or will make forward-looking statements orally or in writing. Furthermore, such forward-looking statements may be included in various filings that we make with the SEC, or press releases or oral statements made by or with the approval of one of our authorized executive officers. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. Factors that might cause actual results to differ include, but are not limited to, those set forth under Item 1A, "Risk Factors," and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation," in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q and in our future filings made with the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this prospectus, any prospectus supplement or any related issuer free writing prospectus, which reflect management's opinions only as of their respective dates. Except as required by law, we undertake no obligation to revise or publicly release the results of any revisions to any forward-looking statements. You are advised, however, to consult any additional disclosures we have made or will make in our reports to the SEC on Forms 10-K, 10-Q and 8-K. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this prospectus, any prospectus supplement or any related issuer free writing prospectus.

**Use of Proceeds**

Unless otherwise indicated in the prospectus supplement, the net proceeds from the sale of securities offered by this prospectus will be used for general corporate purposes and working capital requirements, which may include, among other things, capital expenditures, licensing or acquiring intellectual property or technologies, and possible investments in and acquisitions of complementary businesses or partnerships. We have not allocated a specific portion of the net proceeds for any particular use at this time. As a result, unless otherwise indicated in the prospectus supplement, our management will have broad discretion to allocate the net proceeds of the offerings. Pending their ultimate use, we intend to invest the net proceeds in certain securities, including commercial paper, government and non-government debt securities and/or money-market funds that invest in such securities, in each case, consistent with the Company's investment policy.

**Description of Capital Stock**

**General**

As of the date of this prospectus, our authorized capital stock consists of 130,000,000 shares. Those shares consist of 120,000,000 shares designated as common stock, par value $0.001, and 10,000,000 shares designated as preferred stock, par value $0.001. The only equity securities currently outstanding are shares of common stock. As of November 10, 2025, there were 48,307,896 shares of common stock issued and outstanding.

The following is a summary of the material provisions of the common stock and preferred stock provided for in our amended and restated certificate of incorporation and bylaws. For additional detail about our capital stock, please refer to our amended and restated certificate of incorporation and bylaws, each as amended, copies of which are incorporated by reference into the registration statement to which this prospectus relates.

**Common stock**

The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably any dividends that may be declared from time to time by the board of directors out of funds legally available for that purpose. However, we are not currently paying any dividends. In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable, and any shares of common stock to be issued upon an offering pursuant to this prospectus and the related prospectus supplement will be fully paid and nonassessable upon issuance.

Our common stock is listed on the Nasdaq Capital Market under the symbol "SAVA." The transfer agent and registrar for the common stock is Computershare Shareowner Services LLC. Its address is Computershare C/O Shareholder Services, 150 Royall Street, Canton, MA 02021.

**Preferred stock**

The following description of preferred stock and the description of the terms of any particular series of preferred stock that we choose to issue hereunder and that will be set forth in the related prospectus supplement are not complete. These descriptions are qualified in their entirety by reference to our amended and restated certificate of incorporation and the certificate of designation relating to that series. The rights, preferences, privileges and restrictions of the preferred stock of each series will be fixed by the certificate of designation relating to that series. The related prospectus supplement will contain a description of certain U.S. federal income tax consequences relating to the purchase and ownership of the series of preferred stock that is described therein.

We currently have no shares of preferred stock outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of the common stock.

The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the holders of common stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock.

The prospectus supplement for a series of preferred stock will specify:

● the maximum number of shares;

● the designation of the shares;

● the annual dividend rate, if any, whether the dividend rate is fixed or variable, the date or dates on which dividends will accrue, the dividend payment dates, whether dividends will be cumulative, and whether the dividends will be payable in cash or in kind;

● the price and the terms and conditions for redemption, if any, including redemption at our option or at the option of the holders, including the time period for redemption, and any accumulated dividends or premiums;

● the liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs;

● any sinking fund or similar provision, and, if so, the terms and provisions relating to the purpose and operation of the fund;

● the terms and conditions, if any, for conversion or exchange of shares of any other class or classes of our capital stock or any series of any other class or classes, or of any other series of the same class, or any other securities or assets, including the price or the rate of conversion or exchange and the method, if any, of adjustment;

● the voting rights; and

● any or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or restrictions.

Preferred stock will be fully paid and nonassessable upon issuance.

**Anti-takeover effects of some provisions of Delaware law**

Provisions of Delaware law and our currently in effect amended and restated certificate of incorporation and amended bylaws could make the acquisition of our company through a tender offer, a proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement of its terms.

We are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years following the date the person became an interested stockholder, unless:

● Prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

● The stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

● On or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.

Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An "interested stockholder" is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation's outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

**Anti-takeover effects of provisions of our charter documents**

Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation provides that directors may be removed with cause by the affirmative vote of the holders of the outstanding shares of common stock.

Our amended and restated certificate of incorporation requires that certain amendments of the amended and restated certificate of incorporation and certain amendments by the stockholders of our bylaws require the approval of at least 66 2/3% of the voting power of all outstanding stock. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could delay changes in our management.

Our amended bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. In addition, stockholders who seek to bring a nomination pursuant to Rule 14a-19 of the Exchange Act must provide evidence that such stockholder has complied with the requirements of Rule 14a-19, including certain notice requirements established in our amended bylaws, at least eight business days prior to the meeting. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper form, of his or her intention to bring that business before the meeting. The amended bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of our company.

Our amended bylaws provide that only our board of directors, the chairman of the board, the president or the chief executive officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of the board of directors by calling a special meeting of stockholders prior to such time as a majority of the board of directors believed or the chief executive officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual meeting.

Our amended and restated certificate of incorporation does not allow stockholders to act by written consent without a meeting. Without the availability of stockholder's actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a stockholders' meeting. The holder would have to obtain the consent of a majority of the board of directors, the chairman of the board or the chief executive officer to call a stockholders' meeting and satisfy the notice periods determined by the board of directors.

**Description of the Depositary Shares**

**General**

At our option, we may elect to offer fractional shares of preferred stock, rather than full shares of preferred stock. If we do elect to offer fractional shares of preferred stock, we will issue receipts for depositary shares and each of these depositary shares will represent a fraction of a share of a particular series of preferred stock, as specified in the applicable prospectus supplement. Each owner of a depositary share will be entitled, in proportion to the applicable fractional interest in shares of preferred stock underlying that depositary share, to all rights and preferences of the preferred stock underlying that depositary share. These rights may include dividend, voting, redemption and liquidation rights.

The shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act as depositary, under a deposit agreement by and among us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares.

The depositary shares will be evidenced by depositary receipts issued pursuant to the depositary agreement. Holders of depositary receipts agree to be bound by the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges.

The summary of terms of the depositary shares contained in this prospectus is not complete, and is subject to modification in any prospectus supplement for any issuance of depositary shares. You should refer to the forms of the deposit agreement, our amended and restated certificate of incorporation and the certificate of designation that are, or will be, filed with the SEC for the applicable series of preferred stock.

**Dividends**

The depositary will distribute cash dividends or other cash distributions, if any, received in respect of the series of preferred stock underlying the depositary shares to the record holders of depositary receipts in proportion to the number of depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the preferred stock.

In the event of a distribution other than in cash, the depositary will distribute property received by it to the record holders of depositary receipts that are entitled to receive the distribution, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary, with our approval, may adopt another method for the distribution, including selling the property and distributing the net proceeds to the holders.

**Liquidation preference**

If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary liquidation, dissolution or winding up, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement.

**Redemption**

If a series of preferred stock underlying the depositary shares is subject to redemption, the depositary shares will be redeemed from the proceeds received by the depositary resulting from the redemption, in whole or in part, of the preferred stock held by the depositary. Whenever we redeem any preferred stock held by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares representing the preferred stock so redeemed. The depositary will mail the notice of redemption to the record holders of the depositary receipts promptly upon receiving the notice from us and not fewer than 20 or more than 60 days, unless otherwise provided in the applicable prospectus supplement, prior to the date fixed for redemption of the preferred stock.

**Voting**

Upon receipt of notice of any meeting at which the holders of preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts underlying the preferred stock. Each record holder of those depositary receipts on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of preferred stock underlying that holder's depositary shares. The record date for the depositary will be the same date as the record date for the preferred stock. The depositary will, to the extent practicable, vote the preferred stock underlying the depositary shares in accordance with these instructions. We will agree to take all action that may be deemed necessary by the depositary in order to enable the depositary to vote the preferred stock in accordance with these instructions. The depositary will not vote the preferred stock to the extent that it does not receive specific instructions from the holders of depositary receipts.

**Withdrawal of preferred stock**

Owners of depositary shares will be entitled to receive upon surrender of depositary receipts at the principal office of the depositary and payment of any unpaid amount due to the depositary, the number of whole shares of preferred stock underlying their depositary shares.

Partial shares of preferred stock will not be issued. Holders of preferred stock will not be entitled to deposit the shares under the deposit agreement or to receive depositary receipts evidencing depositary shares for the preferred stock.

**Amendment and termination of the deposit agreement**

The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement between the depositary and us. However, any amendment which materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment has been approved by at least a majority of the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if:

● all outstanding depositary shares have been redeemed; or

● there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the holders of depositary shares.

**Charges of depositary**

We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangement. We will also pay charges of the depositary in connection with:

● the initial deposit of the preferred stock;

● the initial issuance of the depositary shares;

● any redemption of the preferred stock; and

● all withdrawals of preferred stock by owners of depositary shares.

Holders of depositary receipts will pay transfer, income and other taxes and governmental charges and other specified charges as provided in the deposit agreement for their accounts. If these charges have not been paid, the depositary may:

● refuse to transfer depositary shares;

● withhold dividends and distributions; and

● sell the depositary shares evidenced by the depositary receipt.

**Miscellaneous**

The depositary will forward to the holders of depositary receipts all reports and communications we deliver to the depositary that we are required to furnish to the holders of the preferred stock. In addition, the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock.

Neither the depositary nor we will be liable if either the depositary or we are prevented or delayed by law or any circumstance beyond the control of either the depositary or us in performing our respective obligations under the deposit agreement. Our obligations and the depositary's obligations will be limited to the performance in good faith of our or the depositary's respective duties under the deposit agreement. Neither the depositary nor we will be obligated to prosecute or defend any legal proceeding in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. The depositary and we may rely on:

● written advice of counsel or accountants;

● information provided by holders of depositary receipts or other persons believed in good faith to be competent to give such information; and

● documents believed to be genuine and to have been signed or presented by the proper party or parties.

**Resignation and removal of depositary**

The depositary may resign at any time by delivering a notice to us. We may remove the depositary at any time. Any such resignation or removal will take effect upon the appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60 days after delivery of the notice for resignation or removal. The successor depositary must be a bank and trust company having its principal office in the United States of America and having a combined capital and surplus of at least $50,000,000.

**U.S. federal income tax consequences**

Owners of the depositary shares will be treated for U.S. federal income tax purposes as if they were owners of the preferred stock underlying the depositary shares. As a result, owners will be entitled to take into account for U.S. federal income tax purposes any deductions to which they would be entitled if they were holders of such preferred stock. No gain or loss will be recognized for U.S. federal income tax purposes upon the withdrawal of preferred stock in exchange for depositary shares. The tax basis of each share of preferred stock to an exchanging owner of depositary shares will, upon such exchange, be the same as the aggregate tax basis of the depositary shares exchanged. The holding period for preferred stock in the hands of an exchanging owner of depositary shares will include the period during which such person owned such depositary shares.

**Description of the Warrants**

**General**

We may issue warrants for the purchase of our debt securities, preferred stock or common stock, or any combination thereof. Warrants may be issued independently or together with our debt securities, preferred stock or common stock and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the warrants. The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series.

**Debt warrants**

The prospectus supplement relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt warrants, including the following:

● the title of the debt warrants;

● the offering price for the debt warrants, if any;

● the aggregate number of the debt warrants;

● the designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of the debt warrants;

● if applicable, the date from and after which the debt warrants and any debt securities issued with them will be separately transferable;

● the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property;

● the dates on which the right to exercise the debt warrants will commence and expire;

● if applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time;

● whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon exercise of the debt warrants will be issued in registered or bearer form;

● information with respect to book-entry procedures, if any; the currency or currency units in which the offering price, if any, and the exercise price are payable;

● the antidilution provisions of the debt warrants, if any;

● the redemption or call provisions, if any, applicable to the debt warrants;

● any provisions with respect to the holder's right to require us to repurchase the warrants upon a change in control or similar event; and

● any additional terms of the debt warrants, including procedures, and limitations relating to the exchange, exercise and settlement of the debt warrants.

Debt warrant certificates will be exchangeable for new debt warrant certificates of different denominations. Debt warrants may be exercised at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise of their debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable upon exercise and will not be entitled to payment of principal or any premium, if any, or interest on the debt securities purchasable upon exercise.

The prospectus supplement relating to a particular issue of warrants to purchase debt securities will contain a description of certain U.S. federal income tax consequences relating to the purchase and ownership of the warrants described therein.

**Equity warrants**

The prospectus supplement relating to a particular series of warrants to purchase our common stock or preferred stock, including preferred stock underlying depositary shares, will describe the terms of the warrants, including the following:

● the title of the warrants;

● the offering price for the warrants, if any;

● the aggregate number of warrants;

● the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants;

● if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each security;

● if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable;

● the number of shares of common stock or preferred stock that may be purchased upon exercise of a warrant and the exercise price for the warrants;

● the dates on which the right to exercise the warrants shall commence and expire;

● if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;

● the currency or currency units in which the offering price, if any, and the exercise price are payable;

● the antidilution provisions of the warrants, if any;

● the redemption or call provisions, if any, applicable to the warrants;

● any provisions with respect to the holder's right to require us to repurchase the warrants upon a change in control or similar event; and

● any additional terms of the warrants, including procedures, and limitations relating to the exchange, exercise and settlement of the warrants.

Holders of equity warrants will not be entitled:

● to vote, consent or receive dividends;

● receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or

● exercise any rights as stockholders of us.

The prospectus supplement relating to a particular series of warrants to purchase our common stock or preferred stock, including preferred stock underlying depositary shares, will contain a description of certain U.S. federal income tax consequences relating to the purchase and ownership of the warrants described therein.

**Description of Rights**

We may issue rights to purchase our debt securities, common stock, preferred stock or other securities. These rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the rights in such offering. In connection with any offering of such rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.

Each series of rights will be issued under a separate rights agreement which we will enter into with a bank or trust company, as rights agent, all which will be set forth in the relevant offering material. The rights agent will act solely as our agent in connection with the certificates relating to the rights and will not assume any obligation or relationship of agency or trust with any holders of rights certificates or beneficial owners of rights.

The following description is a summary of selected provisions relating to rights that we may offer. The summary is not complete. When rights are offered in the future, a prospectus supplement, information incorporated by reference or a free writing prospectus, as applicable, will explain the particular terms of those securities and the extent to which these general provisions may apply. The specific terms of the rights as described in a prospectus supplement, information incorporated by reference, or free writing prospectus will supplement and, if applicable, may modify or replace the general terms described in this section.

This summary and any description of rights in the applicable prospectus supplement, information incorporated by reference or free writing prospectus is subject to and is qualified in its entirety by reference to the rights agreement and the rights certificates. We will file each of these documents, as applicable, with the SEC and incorporate them by reference as an exhibit to the registration statement of which this prospectus is a part on or before the time we issue a series of rights. See "Where You Can Find More Information" and "Information Incorporated by Reference" below for information on how to obtain a copy of a document when it is filed.

The applicable prospectus supplement, information incorporated by reference or free writing prospectus may describe:

● in the case of a distribution of rights to our stockholders, the date of determining the stockholders entitled to the rights distribution;

● in the case of a distribution of rights to our stockholders, the number of rights issued or to be issued to each stockholder;

● the exercise price payable for the underlying debt securities, common stock, preferred stock or other securities upon the exercise of the rights;

● the number and terms of the underlying debt securities, common stock, preferred stock or other securities which may be purchased per each right;

● the extent to which the rights are transferable;

● the date on which the holder's ability to exercise the rights shall commence, and the date on which the rights shall expire;

● the extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities;

● if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of such rights; and

● any other terms of the rights, including, but not limited to, the terms, procedures, conditions and limitations relating to the exchange and exercise of the rights.

The provisions described in this section, as well as those described under "Description of Debt Securities" below and "Description of Capital Stock" above, will apply, as applicable, to any rights we offer.

**Description of the Debt Securities**

The debt securities may be either secured or unsecured and will either be our senior debt securities or our subordinated debt securities. The debt securities will be issued under one or more separate indentures between us and a trustee to be specified in an accompanying prospectus supplement. Senior debt securities will be issued under a senior indenture and subordinated debt securities will be issued under a subordinated indenture. Together, the senior indenture and the subordinated indenture are called indentures in this description. This prospectus, together with the applicable prospectus supplement, will describe the terms of a particular series of debt securities.

The following is a summary of selected provisions and definitions of the indentures and debt securities to which any prospectus supplement may relate. The summary of selected provisions of the indentures and the debt securities appearing below is not complete and is subject to, and qualified entirely by reference to, all of the provisions of the applicable indenture and certificates evidencing the applicable debt securities. For additional information, you should look at the applicable indenture and the certificate evidencing the applicable debt security that is filed as an exhibit to the registration statement that includes the prospectus. In this description of the debt securities, the words "Cassava Sciences," "we," "us," or "our" refer only to Cassava Sciences, Inc. and not to any of our subsidiaries, unless we expressly state or the context otherwise requires.

The following description sets forth selected general terms and provisions of the applicable indenture and debt securities to which any prospectus supplement may relate. Other specific terms of the applicable indenture and debt securities will be described in the applicable prospectus supplement. If any particular terms of the indenture or debt securities described in a prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus supplement.

**General**

Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series.

We are not limited as to the amount of debt securities we may issue under the indentures. Unless otherwise provided in a prospectus supplement, a series of debt securities may be reopened to issue additional debt securities of such series.

The prospectus supplement relating to a particular series of debt securities will set forth:

● whether the debt securities are senior or subordinated;

● the offering price;

● the title;

● any limit on the aggregate principal amount;

● the person who shall be entitled to receive interest, if other than the record holder on the record date;

● the date or dates the principal will be payable;

● the interest rate or rates, which may be fixed or variable and payable in cash or in kind, if any, the date from which interest will accrue, the interest payment dates and the regular record dates, or the method for calculating the dates and rates;

● the place where payments may be made;

● any mandatory or optional redemption provisions or sinking fund provisions and any applicable redemption or purchase prices associated with these provisions;

● if issued other than in denominations of U.S. $1,000 or any multiple of U.S. $1,000, the denominations in which the debt securities shall be issuable;

● if applicable, the method for determining how the principal, premium, if any, or interest will be calculated by reference to an index or formula;

● if other than U.S. currency, the currency or currency units in which principal, premium, if any, or interest will be payable and whether we or a holder may elect payment to be made in a different currency;

● the portion of the principal amount that will be payable upon acceleration of maturity, if other than the entire principal amount;

● if the principal amount payable at stated maturity will not be determinable as of any date prior to stated maturity, the amount or method for determining the amount which will be deemed to be the principal amount;

● if applicable, whether the debt securities shall be subject to the defeasance provisions described below under "Satisfaction and discharge; defeasance" or such other defeasance provisions specified in the applicable prospectus supplement for the debt securities;

● any conversion or exchange provisions;

● whether the debt securities will be issuable in the form of a global security;

● any subordination provisions applicable to the subordinated debt securities if different from those described below under "Subordinated debt securities;"

● any paying agents, authenticating agents, security registrars or other agents for the debt securities, if other than the trustee;

● any provisions relating to any security provided for the debt securities, including any provisions regarding the circumstances under which collateral may be released or substituted;

● any deletions of, or changes or additions to, the events of default, acceleration provisions or covenants;

● any provisions relating to guaranties for the securities and any circumstances under which there may be additional obligors; and

● any other specific terms of such debt securities.

Unless otherwise specified in the prospectus supplement, the debt securities will be registered debt securities. Debt securities may be sold at a substantial discount below their stated principal amount, bearing no interest or interest at a rate which, at the time of issuance, is below market rates. The applicable prospectus supplement will include a description of certain U.S. federal income tax consequences relating to the purchase and ownership of the debt securities, including, if applicable, material U.S. federal income tax consequences relating to the purchase and ownership of debt securities issued, or deemed to be issued, at a discount of more than a de minimis amount.

**Exchange and transfer**

Debt securities may be transferred or exchanged at the office of the security registrar or at the office of any transfer agent designated by us.

We will not impose a service charge for any transfer or exchange, but we may require holders to pay any tax or other governmental charges associated with any transfer or exchange.

In the event of any partial redemption of debt securities of any series, we will not be required to:

● issue, register the transfer of, or exchange, any debt security of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption and ending at the close of business on the day of the mailing; or

● register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except the unredeemed portion being redeemed in part.

We will appoint the trustee as the initial security registrar. Any transfer agent, in addition to the security registrar initially designated by us, will be named in the prospectus supplement. We may designate additional transfer agents or change transfer agents or change the office of the transfer agent. However, we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

**Global securities**

The debt securities of any series may be represented, in whole or in part, by one or more global securities. Each global security will:

● be registered in the name of a depositary, or its nominee, that we will identify in a prospectus supplement;

● be deposited with the depositary or nominee or custodian; and

● bear any required legends.

No global security may be exchanged in whole or in part for debt securities registered in the name of any person other than the depositary or any nominee unless:

● the depositary has notified us that it is unwilling or unable to continue as depositary or has ceased to be qualified to act as depositary;

● an event of default is continuing with respect to the debt securities of the applicable series; or

● any other circumstance described in a prospectus supplement has occurred permitting or requiring the issuance of any such security.

As long as the depositary, or its nominee, is the registered owner of a global security, the depositary or nominee will be considered the sole owner and holder of the debt securities represented by the global security for all purposes under the indentures. Except in the above limited circumstances, owners of beneficial interests in a global security will not be:

● entitled to have the debt securities registered in their names;

● entitled to physical delivery of certificated debt securities; or

● considered to be holders of those debt securities under the indenture.

Payments on a global security will be made to the depositary or its nominee as the holder of the global security. Some jurisdictions have laws that require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to transfer beneficial interests in a global security.

Institutions that have accounts with the depositary or its nominee are referred to as "participants." Ownership of beneficial interests in a global security will be limited to participants and to persons that may hold beneficial interests through participants. The depositary will credit, on its book-entry registration and transfer system, the respective principal amounts of debt securities represented by the global security to the accounts of its participants.

Ownership of beneficial interests in a global security will be shown on and effected through records maintained by the depositary, with respect to participants' interests, or any participant, with respect to interests of persons held by participants on their behalf.

Payments, transfers and exchanges relating to beneficial interests in a global security will be subject to policies and procedures of the depositary. The depositary policies and procedures may change from time to time. Neither any trustee nor we will have any responsibility or liability for the depositary's or any participant's records with respect to beneficial interests in a global security.

**Payment and paying agents**

Unless otherwise indicated in a prospectus supplement, the provisions described in this paragraph will apply to the debt securities. Payment of interest on a debt security on any interest payment date will be made to the person in whose name the debt security is registered at the close of business on the regular record date. Payment on debt securities of a particular series will be payable at the office of a paying agent or paying agents designated by us. However, at our option, we may pay interest by mailing a check to the record holder. The trustee will be designated as our initial paying agent.

We may also name any other paying agents in a prospectus supplement. We may designate additional paying agents, change paying agents or change the office of any paying agent. However, we will be required to maintain a paying agent in each place of payment for the debt securities of a particular series.

All moneys paid by us to a paying agent for payment on any debt security that remain unclaimed for a period ending the earlier of:

● 10 business days prior to the date the money would be turned over to the applicable state; or

● at the end of two years after such payment was due,

will be repaid to us thereafter. The holder may look only to us for such payment.

**No protection in the event of a change of control**

Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction, whether or not such transaction results in a change in control.

**Covenants**

Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will not contain any financial or restrictive covenants.

**Consolidation, merger and sale of assets**

Unless we indicate otherwise in a prospectus supplement with respect to a particular series of debt securities, we may not consolidate with or merge into any other person (other than a subsidiary of us), in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to, any person (other than a subsidiary of us), unless:

● the successor entity, if any, is a U.S. corporation, limited liability company, partnership, trust or other business entity;

● the successor entity assumes our obligations on the debt securities and under the indentures;

● immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and

● certain other conditions specified in the indenture are met.

**Events of default**

Unless we indicate otherwise in a prospectus supplement, the following will be events of default for any series of debt securities under the indentures:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) we
 fail to pay principal of or any premium on any debt security of that series when due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) we
 fail to pay any interest on any debt security of that series for 60 days after it becomes
 due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) we
 fail to deposit any sinking fund payment when due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) we
 fail to perform any other covenant in the indenture and such failure continues for 90 days
 after we are given the notice required in the indentures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) certain
 events involving our bankruptcy, insolvency or reorganization.

Additional or different events of default applicable to a series of debt securities may be described in a prospectus supplement. An event of default of one series of debt securities is not necessarily an event of default for any other series of debt securities.

The trustee may withhold notice to the holders of any default, except defaults in the payment of principal, premium, if any, interest, any sinking fund installment on, or with respect to any conversion right of, the debt securities of such series. However, the trustee must consider it to be in the interest of the holders of the debt securities of such series to withhold this notice.

Unless we indicate otherwise in a prospectus supplement, if an event of default, other than an event of default described in clause (5) above, shall occur and be continuing with respect to any series of debt securities, either the trustee or the holders of at least a 25 percent in aggregate principal amount of the outstanding securities of that series may declare the principal amount and premium, if any, of the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, to be due and payable immediately.

Unless we indicate otherwise in a prospectus supplement, if an event of default described in clause (5) above shall occur, the principal amount and premium, if any, of all the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, will automatically become immediately due and payable. Any payment by us on the subordinated debt securities following any such acceleration will be subject to the subordination provisions described below under "Subordinated debt securities."

Notwithstanding the foregoing, each indenture will provide that we may, at our option, elect that the sole remedy for an event of default relating to our failure to comply with our obligations described under the section entitled "Reports" below or our failure to comply with the requirements of Section 314(a)(1) of the Trust Indenture Act will for the first 180 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the relevant series of debt securities at an annual rate equal to (i) 0.25% of the principal amount of such series of debt securities for the first 90 days after the occurrence of such event of default and (ii) 0.50% of the principal amount of such series of debt securities from the 91st day to, and including, the 180th day after the occurrence of such event of default, which we call "additional interest." If we so elect, the additional interest will accrue on all outstanding debt securities from and including the date on which such event of default first occurs until such violation is cured or waived and shall be payable on each relevant interest payment date to holders of record on the regular record date immediately preceding the interest payment date. On the 181st day after such event of default (if such violation is not cured or waived prior to such 181st day), the debt securities will be subject to acceleration as provided above. In the event we do not elect to pay additional interest upon any such event of default in accordance with this paragraph, the debt securities will be subject to acceleration as provided above.

In order to elect to pay the additional interest as the sole remedy during the first 180 days after the occurrence of any event of default relating to the failure to comply with the reporting obligations in accordance with the preceding paragraph, we must notify all holders of debt securities and the trustee and paying agent of such election prior to the close of business on the first business day following the date on which such event of default occurs. Upon our failure to timely give such notice or pay the additional interest, the debt securities will be immediately subject to acceleration as provided above.

After acceleration, the holders of a majority in aggregate principal amount of the outstanding securities of that series may, under certain circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal, or other specified amounts or interest, have been cured or waived.

Other than the duty to act with the required care during an event of default, the trustee will not be obligated to exercise any of its rights or powers at the request of the holders unless the holders shall have offered to the trustee reasonable indemnity. Generally, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee.

A holder of debt securities of any series will not have any right to institute any proceeding under the indentures, or for the appointment of a receiver or a trustee, or for any other remedy under the indentures, unless:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) the
 holder has previously given to the trustee written notice of a continuing event of default
 with respect to the debt securities of that series;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) the
 holders of at least 25 percent in aggregate principal amount of the outstanding debt securities
 of that series have made a written request and have offered reasonable indemnity to the trustee
 to institute the proceeding; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) the
 trustee has failed to institute the proceeding and has not received direction inconsistent
 with the original request from the holders of a majority in aggregate principal amount of
 the outstanding debt securities of that series within 60 days after the original request.

Holders may, however, sue to enforce the payment of principal, premium or interest on any debt security on or after the due date or to enforce the right, if any, to convert any debt security (if the debt security is convertible) without following the procedures listed in (1) through (3) above.

We will furnish the trustee an annual statement from our officers as to whether or not we are in default in the performance of the conditions and covenants under the indenture and, if so, specifying all known defaults.

**Modification and waiver**

Unless we indicate otherwise in a prospectus supplement, the applicable trustee and we may make modifications and amendments to an indenture with the consent of the holders of a majority in aggregate principal amount of the outstanding securities of each series affected by the modification or amendment.

We may also make modifications and amendments to the indentures for the benefit of holders without their consent, for certain purposes including, but not limited to:

● providing for our successor to assume the covenants under the indenture;

● adding covenants or events of default;

● making certain changes to facilitate the issuance of the securities;

● securing the securities;

● providing for a successor trustee or additional trustees;

● curing any ambiguities or inconsistencies;

● providing for guaranties of, or additional obligors on, the securities;

● permitting or facilitating the defeasance and discharge of the securities; and

● other changes specified in the indenture.

However, neither the trustee nor we may make any modification or amendment without the consent of the holder of each outstanding security of that series affected by the modification or amendment if such modification or amendment would:

● change the stated maturity of any debt security;

● reduce the principal, premium, if any, or interest on any debt security or any amount payable upon redemption or repurchase, whether at our option or the option of any holder, or reduce the amount of any sinking fund payments;

● reduce the principal of an original issue discount security or any other debt security payable on acceleration of maturity;

● change the place of payment or the currency in which any debt security is payable;

● impair the right to enforce any payment after the stated maturity or redemption date;

● if subordinated debt securities, modify the subordination provisions in a materially adverse manner to the holders;

● adversely affect the right to convert any debt security if the debt security is a convertible debt security; or

● change the provisions in the indenture that relate to modifying or amending the indenture.

**Satisfaction and discharge; defeasance**

We may be discharged from our obligations on the debt securities, subject to limited exceptions, of any series that have matured or will mature or be redeemed within one year if we deposit enough money with the trustee to pay all the principal, interest and any premium due to the stated maturity date or redemption date of the debt securities.

Each indenture contains a provision that permits us to elect either or both of the following:

● we may elect to be discharged from all of our obligations, subject to limited exceptions, with respect to any series of debt securities then outstanding. If we make this election, the holders of the debt securities of the series will not be entitled to the benefits of the indenture, except for the rights of holders to receive payments on debt securities or the registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated debt securities.

● we may elect to be released from our obligations under some or all of any financial or restrictive covenants applicable to the series of debt securities to which the election relates and from the consequences of an event of default resulting from a breach of those covenants.

To make either of the above elections, we must irrevocably deposit in trust with the trustee enough money to pay in full the principal, interest and premium on the debt securities. This amount may be made in cash and/or U.S. government obligations or, in the case of debt securities denominated in a currency other than U.S. dollars, cash in the currency in which such series of securities is denominated and/or foreign government obligations. As a condition to either of the above elections, for debt securities denominated in U.S. dollars we must deliver to the trustee an opinion of counsel that the holders of the debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the action.

With respect to debt securities of any series that are denominated in a currency other than United States dollars, "foreign government obligations" means:

● direct obligations of the government that issued or caused to be issued the currency in which such securities are denominated and for the payment of which obligations its full faith and credit is pledged, or, with respect to debt securities of any series which are denominated in Euros, direct obligations of certain members of the European Union for the payment of which obligations the full faith and credit of such members is pledged, which in each case are not callable or redeemable at the option of the issuer thereof; or

● obligations of a person controlled or supervised by or acting as an agency or instrumentality of a government described in the bullet above the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by such government, which are not callable or redeemable at the option of the issuer thereof.

**Reports**

The indentures provide that any reports or documents that we file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act will be filed with the trustee within 15 days after the same is filed with the SEC. Documents filed by us with the SEC via the EDGAR system will be deemed filed with the trustee as of the time such documents are filed with the SEC.

**Notices**

Notices to holders will be given by mail to the addresses of the holders in the security register.

**Governing law**

The indentures and the debt securities will be governed by, and construed under, the laws of the State of New York.

**No personal liability of directors, officers, employees and stockholders**

No incorporator, stockholder, employee, agent, officer, director or subsidiary of ours will have any liability for any obligations of ours, or because of the creation of any indebtedness under the debt securities, the indentures or supplemental indentures. The indentures provide that all such liability is expressly waived and released as a condition of, and as a consideration for, the execution of such indentures and the issuance of the debt securities.

**Regarding the trustee**

The indentures limit the right of the trustee, should it become our creditor, to obtain payment of claims or secure its claims.

The trustee will be permitted to engage in certain other transactions with us. However, if the trustee acquires any conflicting interest, and there is a default under the debt securities of any series for which it is trustee, the trustee must eliminate the conflict or resign.

**Subordinated debt securities**

The following provisions will be applicable with respect to each series of subordinated debt securities, unless otherwise stated in the prospectus supplement relating to that series of subordinated debt securities.

The indebtedness evidenced by the subordinated debt securities of any series is subordinated, to the extent provided in the subordinated indenture and the applicable prospectus supplement, to the prior payment in full, in cash or other payment satisfactory to the holders of senior debt, of all senior debt, including any senior debt securities.

Upon any distribution of our assets upon any dissolution, winding up, liquidation or reorganization, whether voluntary or involuntary, marshalling of assets, assignment for the benefit of creditors, or in bankruptcy, insolvency, receivership or other similar proceedings, payments on the subordinated debt securities will be subordinated in right of payment to the prior payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt.

In the event of any acceleration of the subordinated debt securities of any series because of an event of default with respect to the subordinated debt securities of that series, holders of any senior debt would be entitled to payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt before the holders of subordinated debt securities are entitled to receive any payment or distribution.

In addition, the subordinated debt securities will be structurally subordinated to all indebtedness and other liabilities of our subsidiaries, including trade payables and lease obligations. This occurs because our right to receive any assets of our subsidiaries upon their liquidation or reorganization, and your right to participate in those assets, will be effectively subordinated to the claims of that subsidiary's creditors, including trade creditors, except to the extent that we are recognized as a creditor of such subsidiary. If we are recognized as a creditor of that subsidiary, our claims would still be subordinate to any security interest in the assets of the subsidiary and any indebtedness of the subsidiary senior to us.

We are required to promptly notify holders of senior debt or their representatives under the subordinated indenture if payment of the subordinated debt securities is accelerated because of an event of default.

Under the subordinated indenture, we may also not make payment on the subordinated debt securities if:

● a default in our obligations to pay principal, premium, if any, interest or other amounts on our senior debt occurs and the default continues beyond any applicable grace period, which we refer to as a payment default; or

● any other default occurs and is continuing with respect to designated senior debt that permits holders of designated senior debt to accelerate its maturity, which we refer to as a non-payment default, and the trustee receives a payment blockage notice from us or some other person permitted to give the notice under the subordinated indenture.

We will resume payments on the subordinated debt securities:

● in case of a payment default, when the default is cured or waived or ceases to exist, and

● in case of a nonpayment default, the earlier of when the default is cured or waived or ceases to exist or 179 days after the receipt of the payment blockage notice.

No new payment blockage period may commence on the basis of a nonpayment default unless 365 days have elapsed from the effectiveness of the immediately prior payment blockage notice. No nonpayment default that existed or was continuing on the date of delivery of any payment blockage notice to the trustee shall be the basis for a subsequent payment blockage notice.

As a result of these subordination provisions, in the event of our bankruptcy, dissolution or reorganization, holders of senior debt may receive more, ratably, and holders of the subordinated debt securities may receive less, ratably, than our other creditors. The subordination provisions will not prevent the occurrence of any event of default under the subordinated indenture.

The subordination provisions will not apply to payments from money or government obligations held in trust by the trustee for the payment of principal, interest and premium, if any, on subordinated debt securities pursuant to the provisions described under the section entitled "Satisfaction and discharge; defeasance," if the subordination provisions were not violated at the time the money or government obligations were deposited into trust.

If the trustee or any holder receives any payment that should not have been made to them in contravention of subordination provisions before all senior debt is paid in full in cash or other payment satisfactory to holders of senior debt, then such payment will be held in trust for the holders of senior debt.

Senior debt securities will constitute senior debt under the subordinated indenture.

Additional or different subordination provisions may be described in a prospectus supplement relating to a particular series of debt securities.

**Definitions**

"Designated senior debt" means our obligations under any particular senior debt in which the instrument creating or evidencing the same or the assumption or guarantee thereof, or related agreements or documents to which we are a party, expressly provides that such indebtedness shall be designated senior debt for purposes of the subordinated indenture. The instrument, agreement or other document evidencing any designated senior debt may place limitations and conditions on the right of such senior debt to exercise the rights of designated senior debt.

"Indebtedness" means the following, whether absolute or contingent, secured or unsecured, due or to become due, outstanding on the date of the indenture for such series of securities or thereafter created, incurred or assumed:

● our indebtedness evidenced by a credit or loan agreement, note, bond, debenture or other written obligation;

● all of our obligations for money borrowed;

● all of our obligations evidenced by a note or similar instrument given in connection with the acquisition of any businesses, properties or assets of any kind,

● our obligations:

● as lessee under leases required to be capitalized on the balance sheet of the lessee under generally accepted accounting principles, or

● as lessee under leases for facilities, capital equipment or related assets, whether or not capitalized, entered into or leased for financing purposes;

● all of our obligations under interest rate and currency swaps, caps, floors, collars, hedge agreements, forward contracts or similar agreements or arrangements;

● all of our obligations with respect to letters of credit, bankers' acceptances and similar facilities, including reimbursement obligations with respect to the foregoing;

● all of our obligations issued or assumed as the deferred purchase price of property or services, but excluding trade accounts payable and accrued liabilities arising in the ordinary course of business;

● all obligations of the type referred to in the above clauses of another person, the payment of which, in either case, we have assumed or guaranteed, for which we are responsible or liable, directly or indirectly, jointly or severally, as obligor, guarantor or otherwise, or which are secured by a lien on our property; and

● renewals, extensions, modifications, replacements, restatements and refundings of, or any indebtedness or obligation issued in exchange for, any such indebtedness or obligation described in the above clauses of this definition.

"Senior debt" means the principal of, premium, if any, and interest, including all interest accruing subsequent to the commencement of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such proceeding, and rent payable on or in connection with, and all fees and other amounts payable in connection with, our indebtedness. However, senior debt shall not include:

● any debt or obligation if its terms or the terms of the instrument under which or pursuant to which it is issued expressly provide that it shall not be senior in right of payment to the subordinated debt securities or expressly provide that such indebtedness is on the same basis or "junior" to the subordinated debt securities; or

● debt to any of our subsidiaries, a majority of the voting stock of which is owned, directly or indirectly, by us.

"Subsidiary" means a corporation more than 50% of the outstanding voting stock of which is owned, directly or indirectly, by us or by one or more or our other subsidiaries or by a combination of us and our other subsidiaries. For purposes of this definition, "voting stock" means stock or other similar interests which ordinarily has or have voting power for the election of directors, or persons performing similar functions, whether at all times or only so long as no senior class of stock or other interests has or have such voting power by reason of any contingency.

**Description of the Units**

**General**

At our option, we may elect to issue units comprised of common stock, preferred stock, depositary shares, warrants, debt securities, or any combination thereof. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

The summary of terms of the units contained in this section of the prospectus is not complete, and is subject to modification in any prospectus supplement for any issuance of Units. We will describe in the applicable prospectus supplement the terms of the series of units, including:

● the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;

● Any provisions of the governing unit agreement that differ from those described below; and

● Any provisions for the issuance, settlement, transfer or exchange of the units or of the securities comprising the units.

In addition, the provisions described under "Description of Capital Stock," "Description of the Depositary Shares," "Description of the Warrants" and "Description of the Debt Securities" will apply to each unit and to any common stock, preferred stock, debt security or warrants included in each unit, respectively.

**Issuance in Series**

We may issue units in such amounts and in such numerous distinct series as we determine.

**Enforceability of Rights by Holders of Units**

Any unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.

**Title**

We, any unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary.

**Outstanding Units**

We have no outstanding units.

**Plan of Distribution**

We may sell the securities offered through this prospectus (1) to or through underwriters or dealers, (2) directly to purchasers, including our affiliates, (3) through agents, or (4) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus supplement will include the following information:

● the terms of the offering;

● the names of any underwriters or agents;

● the name or names of any managing underwriter or underwriters;

● the purchase price of the securities;

● the net proceeds from the sale of the securities;

● any delayed delivery arrangements;

● any underwriting discounts, commissions and other items constituting underwriters' compensation;

● any initial public offering price;

● any discounts or concessions allowed or reallowed or paid to dealers; and

● any commissions paid to agents.

**Sale through underwriters or dealers**

If underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers.

If dealers are used in the sale of securities offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the dealers and the terms of the transaction.

**Direct sales and sales through agents**

We may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.

We may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.

**Underwriter, dealer or agent discounts and commissions**

Underwriters, dealers or agents may receive compensation in the form of discounts, concessions or commissions from us or our purchasers as their agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under the Securities Act. As a result, discounts, commissions, or profits on resale received by the underwriters, dealers or agents may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any such underwriter, dealer or agent, and describe any compensation received by them from us. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. The maximum commission or discount to be received by any underwriter, dealer or agent will not be greater than eight percent (8%) of the maximum gross proceeds of the securities that may be sold under this prospectus.

**Delayed delivery contracts**

If the prospectus supplement indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those contracts.

**Market making, stabilization and other transactions**

Unless the applicable prospectus supplement states otherwise, each series of offered securities will be a new issue and will have no established trading market. We may elect to list any series of offered securities on an exchange. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.

Any underwriter may also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange Act. Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.

Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time.

**Derivative transactions and hedging**

We, the underwriters or other agents may engage in derivative transactions involving the securities. These derivatives may consist of short sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold or resell securities acquired and purchase options or futures on the securities and other derivative instruments with returns linked to or related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security lending or repurchase agreements with the underwriters or agents. The underwriters or agents may affect the derivative transactions through sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions by others. The underwriters or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives, securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out any related open borrowings of the securities.

**Electronic auctions**

We may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities directly to the public, with or without the involvement of agents, underwriters or dealers, while utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of such securities, you should pay particular attention to the description of that system we will provide in a prospectus supplement.

Such electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such securities are sold. These bidding or ordering systems may present to each bidder, on a so-called "real-time" basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted, and whether a bidder's individual bids would be accepted, prorated or rejected. For example, in the case of a debt security, the clearing spread could be indicated as a number of "basis points" above an index treasury note. Of course, many pricing methods can and may also be used.

Upon completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction.

**General information**

Agents, underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under the Securities Act.

**Legal Matters**

The validity of the securities offered by this prospectus will be passed upon for Cassava Sciences by Jones Day. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that will be named in the applicable prospectus supplement.

**Experts****

The consolidated financial statements of Cassava Sciences, Inc., appearing in Cassava Sciences, Inc. Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**Where You Can Find More Information**

We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet by visiting our website at www.www.cassavasciences.com. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information and materials contained on our website, except for our SEC filings expressly described below, are not part of this prospectus and are not incorporated by reference into this prospectus.

**Information Incorporated By Reference**

The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed "filed" pursuant to the General Instructions of Form 8-K):

● our Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm) for the fiscal year ended December 31, 2024;

● our Quarterly Reports on Form 10-Q for the quarters ended [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm) , [June 30, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925026686/sava20250630_10q.htm) and [September 30, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925034427/sava20250930_10q.htm) ;

● our Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1069530/000143774925011848/sava20250403_def14a.htm) , filed with the SEC on April 14, 2025, to the extent incorporated by reference in our Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm) for the fiscal year ended December 31, 2024;

● our Current Reports on Form 8-K filed with the SEC on [January 7, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm) , [February 27, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/sava20250224_8k.htm) , [March 11, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/sava20250310_8k.htm) , [March 25, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm) , [April 21, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/sava20250418_8k.htm) , [May 27, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/sava20250523_8k.htm) , [August 4, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/f8k_080425.htm) , [October 22, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/sava20251020_8k.htm) and [October 24, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925031674/sava20251024_8k.htm) ; and

● the description of our common stock contained in [Exhibit 4.2](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/ex_756945.htm) of our Annual Report on Form 10-K as filed with the SEC on March 3, 2025, and any further amendment or report filed hereafter for the purpose of updating such description pursuant to Section 12(b) of the Exchange Act.

We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the filing of the initial registration statement and prior to effectiveness of the registration statement and the completion or termination of the offering, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.

We will provide at no cost to each person who requests, including any beneficial owner, to whom this prospectus is delivered a copy of any document we incorporate by reference, excluding all exhibits to such incorporated documents (unless we have specifically incorporated by reference such exhibits either in this prospectus or in the incorporated document). You may request a copy of these filings by telephoning us at (512) 501-2444 or by writing us at the following address:

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway, Building 1, Suite 300

Austin, TX 78731

United States of America

Attn: Investor Relations

![](forms-3_001.jpg)

**$200,000,000**

**Common Stock** 

**Preferred Stock** 

**Depositary Shares** 

**Warrants**

**Rights**

**Debt Securities** 

**Units**

**PROSPECTUS**

, 2025

**The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

**SUBJECT TO COMPLETION, DATED NOVEMBER 12, 2025**

**PROSPECTUS SUPPLEMENT**

**Up to $50,000,000**

**Common Stock**

We have entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (the "Sales Agreement"), with Cantor Fitzgerald & Co, ("Cantor"), relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to $50,000,000 through Cantor, acting as "Sales Agent," pursuant to this prospectus supplement and the accompanying prospectus.

Our common stock is listed on the Nasdaq Capital Market under the symbol "SAVA." On November 11, 2025, the closing price of our common stock on the Nasdaq Capital Market was $3.11 per share.

Sales of shares of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). Subject to the terms of the Sales Agreement, Cantor is not required to sell any specific number or dollar amounts of securities but will act as our Sales Agent using commercially reasonable best efforts consistent with its normal trading and sales practices on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

We will pay Cantor up to 3.0% of the aggregate sales price received by it from each sale of common stock sold through it acting as Sales Agent. In connection with the sale of our common stock on our behalf, Cantor will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor against certain civil liabilities, including liabilities under the Securities Act. See "Plan of Distribution" beginning on page S-11 of this prospectus supplement for more information regarding our arrangements with Cantor.

**Investing in our common stock involves risks. See "Risk Factors" beginning on page S-3 of this prospectus supplement and page 3 of the accompanying prospectus, and the risks set forth under the caption "Item 1A. Risk Factors" included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q and in the documents that are incorporated by reference into this prospectus supplement.** 

**Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

![](forms-3_002.jpg)

**The date of this prospectus supplement is , 2025.**

**TABLE OF CONTENTS**

**Prospectus Supplement**

**Prospectus Supplement**

---

| | |
|:---|:---|
|  | **Page** |
| [About This Prospectus Supplement](#f_001) | S-i |
| [Statement Regarding Forward-Looking Information](#a_017) | S-ii |
| [Prospectus Supplement Summary](#a_018) | S-1 |
| [Risk Factors](#a_019) | S-3 |
| [Use of Proceeds](#a_020) | S-6 |
| [Dilution](#a_021) | S-7 |
| [Material U.S. Federal Income Tax Consequences to Non-U.S. Holders](#a_023) | S-8 |
| [Plan of Distribution](#a_024) | S-11 |
| [Where You Can Find More Information](#a_025) | S-12 |
| [Information Incorporated by Reference](#a_026) | S-13 |
| [Legal Matters](#a_027) | S-14 |
| [Experts](#a_028) | S-14 |

---

**ABOUT THIS PROSPECTUS SUPPLEMENT**

This prospectus supplement and the accompanying prospectus form part of a registration statement on Form S-3 that we filed with the SEC, using a "shelf" registration process relating to the common stock described in this prospectus supplement. Before buying any of the common stock that we are offering, we urge you to carefully read this entire prospectus supplement and the accompanying prospectus, together with the documents incorporated by reference that are described under the headings "Where You Can Find More Information" and "Information Incorporated by Reference" on pages S-12 and S-13 of this prospectus supplement. These documents contain important information that you should consider when making your investment decision.

This prospectus supplement describes the terms of this offering and adds to and updates information contained in the accompanying prospectus. The accompanying prospectus provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to this prospectus supplement and the accompanying prospectus combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus, on the other hand, you should rely on the information contained in this prospectus supplement.

You should rely only on the information contained or incorporated by reference in this prospectus. We have not, and the Sales Agent has not, authorized anyone to provide additional information or information different from that contained or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we, nor the Sales Agent, take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus in any jurisdiction where it is unlawful to make such offer or solicitation. Neither the delivery of this prospectus nor the sale of shares of common stock means that information contained or incorporated by reference in this prospectus is correct after its respective dates. These documents do not constitute an offer to sell or solicitation of any offer to buy these shares of common stock in any circumstances under which the offer or solicitation is unlawful.

Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to "Cassava Sciences," "we," "us," "our" or "the Company" are to Cassava Sciences, Inc.

S-i

**Statement Regarding Forward-Looking Information**

This prospectus supplement and the documents incorporated by reference in this prospectus supplement contains certain statements that are considered forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" or the negatives of these terms or other comparable terminology.

The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to statements about:

● the safety profile or treatment benefits, if any, of simufilam;

● our ability to conduct planned preclinical studies of simufilam relating to epilepsy in Tuberous Sclerosis Complex ("TSC");

● our ability to initiate an initial proof-of-concept clinical study of simufilam in TSC-related epilepsy in first-half 2026;

● our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at central nervous system disorders, including TSC-related epilepsy;

● our ability to successfully carry out our obligations under our License Agreement with Yale, for which we have assumed all responsibility for global development and commercialization for simufilam for the treatment of TSC-related epilepsy;

● our plans or ability to expand therapeutic indications for simufilam outside of Alzheimer's disease;

● our reliance on third-party contractors to conduct all of our clinical and non-clinical trials and to make drug supply, or their ability to do so on-time or on-budget;

● limitations around the interpretation of data from any studies that are not randomized controlled trials;

● the impact of pre-clinical findings on our ability to develop our product candidates;

● the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;

● the safety, efficacy, or potential therapeutic benefits of our product candidates;

● our use of exploratory 'research use only' non-safety related biomarkers in our clinical studies;

● our ability to file for and obtain regulatory approval of our product candidates;

● our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;

● the potential future revenues of our product candidates, if approved and commercialized;

● the market acceptance of our product candidates, if approved and commercialized;

● the pricing and reimbursement of our product candidates, if approved and commercialized;

● the utility of protection, or the sufficiency, of our intellectual property;

S-ii

● our potential competitors or competitive products for therapeutic areas we may elect to pursue;

● our need to raise new capital from time to time to finance our operations and the impact of macroeconomic conditions on our ability to effectively raise capital;

● our use of multiple third-party vendors and collaborators, including a Clinical Research Organization ("CRO"), to conduct clinical and non-clinical studies of our lead product candidate;

● expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;

● our expenses or incurred costs increasing by material amounts in excess of budgeted amounts due to unexpected cost overruns, imperfect forecasting, increased scope of activities or other causes;

● fluctuations in our financial or operating results;

● our operating losses, anticipated operating and capital expenditures and legal expenses;

● expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;

● the development and maintenance of our internal information systems and infrastructure;

● our ability to minimize the likelihood and impact of adverse cybersecurity incidents in our information systems and infrastructure;

● our ability to attract and retain personnel;

● existing or emerging regulations and regulatory developments in the United States and other jurisdictions in which we operate;

● our expectations regarding the appropriate size and scope of our operations;

● the sufficiency and expected use of our cash resources, including the proceeds, if any, from this offering, to continue to fund our operations;

● potential future agreements with third parties in connection with the commercialization of our product candidates;

● the accuracy of our estimates regarding expenses, loss contingency reserves, capital requirements, and needs for additional financing;

● assumptions and estimates used for our disclosures regarding stock-based compensation;

S-iii

● potential impacts of reductions-in-force at government agencies, including FDA, whose engagement with us in the drug development process is critical for the advancement of our investigational product candidates;

● the expense, timing and outcome of pending or future litigation or other legal proceedings and claims (including U.S. government inquiries) including the potential for negotiated settlements of such matters; and

● litigation, claims or other uncertainties that may arise from allegations made against us or our former employees or collaborators and the potential resolution of same.

Please also refer to the section entitled "Risk Factors" in our most recent Annual Report on Form 10- and in any of our subsequently filed Quarterly Reports on Form 10-Q, as such risk factors may be further amended, updated or modified periodically in our reports filed with the SEC, for further information on these and other risks affecting us.

We caution you not to place undue reliance on forward-looking statements because our future results may differ materially from those expressed or implied by them. We do not undertake to update any forward-looking statement, whether written or oral, relating to the matters discussed in this prospectus supplement, except as required by law.

This prospectus supplement may also contain statistical data and drug information received from our independent consultants or based on industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data and information. You are cautioned not to give undue weight to such data and information.

Our research programs in neurodegeneration have historically benefited from scientific and financial support from the National Institutes of Health ("NIH"). The contents of this prospectus supplement are solely our responsibility and do not necessarily represent any official views of NIH, the Department of Health and Human Services, or any other agency of the United States government, or any of our vendors, collaborators or unrelated third-parties.

All our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates are approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned that subsequent results may differ materially.

S-iv

**Prospectus Supplement Summary**

*This summary highlights information contained elsewhere in this prospectus supplement or incorporated by reference in this prospectus supplement. This summary does not contain all of the information that you should consider before making an investment decision. Before making an investment decision, you should read carefully in its entirety this prospectus supplement, including the matters discussed in "Risk Factors" in this prospectus supplement, our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Reports on Form 10-Q, as such risk factors may be amended, updated or modified periodically in our reports filed with the SEC and the financial data and related notes and the reports incorporated by reference in this prospectus supplement.*

**Company Overview**

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat central nervous system disorders, such as TSC-related epilepsy. Our novel science is based on affecting the activity of a critical protein in the brain for patients with certain central nervous system disorders, such as TSC.

We combine innovative technology with new insights in neurobiology to develop novel solutions targeting central nervous system disorders, such as TSC-related epilepsy. Our strategy is to leverage our unique scientific/clinical platform to develop first-in-class programs for treating central nervous system disorders.

Our lead therapeutic product candidate, called simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

**Corporate Information**

We were incorporated in Delaware in May 1998. Our principal executive offices are located at 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, 78731, and our telephone number at that address is (512) 501-2444.

Additional information regarding our company is set forth in documents on file with the SEC and incorporated by reference in this prospectus supplement, as described below under the sections entitled "Where You Can Find More Information" and "Information Incorporated by Reference."

**The Offering**

---

| | |
|:---|:---|
| **Issuer** | Cassava Sciences, Inc., a Delaware corporation. |
| **Common Stock Offered** | Up to $50,000,000 million of our common stock, par value $0.001 per share. |
| **Common Stock to be Outstanding Immediately After This Offering<sup>(1)</sup>** | Up to 16,077,170 shares, assuming sales of 16,077,170 shares of our common stock in this offering at an offering price of $3.11 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on November 11, 2025. The actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur. |
| **Plan of Distribution** | "At the market offering" that may be made from time to time on the Nasdaq Capital Market or other existing trading market for our common stock through or to the Agent, as sales agent or principal. See "Plan of Distribution" on page S-11. |
| **Use of Proceeds** | We intend to use the net proceeds, if any, from the sale of the shares that we may offer under this prospectus supplement, after deducting commissions and estimated offering expenses, for general corporate purposes and working capital requirements, including development of simufilam, our lead product candidate for the treatment of TSC-related epilepsy. See "Use of Proceeds" on page S-6. |
| **Risk Factors** | Before deciding to invest in shares of our common stock, you should read carefully the risks set forth under the caption "Risk Factors" beginning on page S-3 of this prospectus supplement and page 3 of the accompanying prospectus, and the risks set forth under the caption "Item 1A. Risk Factors" included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q and in the documents that are incorporated by reference into this prospectus supplement for certain considerations relevant to an investment in our common stock. |
| **Nasdaq Capital Market symbol** | SAVA |
| **Transfer agent and registrar** | Computershare Shareowner Services LLC |

---

(1) Based on 48,307,896 shares of our common stock outstanding as of September 30, 2025, and excludes, as of that date, the following:

 

● 4,109,093 shares of common stock issuable upon exercise of outstanding options having a weighted-average exercise price of $15.23 per share;

● 7,142 shares of common stock issuable upon the vesting and settlement of outstanding performance awards;

● 610,022 shares of common stock reserved for issuance and available for future grant under our 2018 Omnibus Incentive Plan; and

● 58,017 shares of common stock reserved for issuance and available for future grant under our 2000 Employee Stock Purchase Plan.

**Risk Factors**

*An investment in our common stock is subject to risk. Our business, financial condition, and results of operations could be materially adversely affected by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. Before you decide to invest in our common stock, you should carefully read this prospectus summary in its entirety and carefully consider the risks described herein and "Risk Factors" in the accompanying prospectus, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q, as such risks may be amended, updated or modified periodically in our reports filed with the SEC, and the financial data and related notes and the reports incorporated by reference herein or therein, as well as the other information included in and incorporated by reference in this prospectus supplement.*

**Risks Related to this Offering and Our Common Stock** 

**We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.**

Our management has broad discretion in the application of the net proceeds from this offering, and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Our management could spend the net proceeds from this offering in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.

**You could lose all of your investment.**

An investment in our common stock is speculative and involves a high degree of risk. Potential investors should be aware that the value of an investment in us may go down as well as up. In addition, there can be no certainty that the market value of an investment in us will fully reflect its underlying value. You could lose your entire investment.

**We may issue preferred stock with rights senior to our common stock.**

Our certificate of incorporation authorize the issuance of shares of preferred stock without stockholder approval. These shares may have dividend, voting, liquidation and other rights and preferences that are senior to the rights of our common stock. In addition, such shares of preferred stock may be convertible into common stock. Conversion of preferred stock into our common stock may dilute the value of our common stock, which may adversely affect the value of your common stock.

**If you purchase shares of common stock sold in this offering, you will incur immediate and substantial dilution.**

If you purchase shares of our common stock in this offering, you will experience substantial and immediate dilution in the pro forma net tangible book value per share after giving effect to this offering because the price that you pay will be substantially greater than the pro forma net tangible book value per share of the common stock that you acquire. For more information, see "Dilution" on page S-7.

You may experience future dilution under our equity incentive plans, and when we otherwise issue additional shares of common stock as a result of future equity offerings or other equity issuances.

**You may experience future dilution as a result of future equity offerings or other equity issuances.**

In order to raise additional capital, we may in the future offer and issue additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. In addition, we have also registered all of the shares of common stock that we may issue under our stock option and employee stock purchase plans, and as of September 30, 2025, there were 4,109,093 shares of common stock issuable upon the exercise of stock options outstanding under our stock option plans at a weighted average exercise price of $15.23 per share, 7,142 shares of common stock issuable upon the vesting and settlement of outstanding performance awards, 610,022 additional shares of common stock were reserved for potential future issuance under our 2018 Omnibus Incentive Plan, and an aggregate of 58,017 shares of common stock were reserved for potential future issuance under our 2000 Employee Stock Purchase Plan. You will incur dilution upon the grant of any shares pursuant to such plan, upon vesting of any stock awards under any such plan, or upon exercise of any such outstanding options.

**A substantial amount of our common stock may be sold in the market following this offering, which may depress the market price for our common stock.**

Sales of a substantial number of shares of our common stock in the public market following this offering could cause the market price of our common stock to decline. Although there can be no assurance that any of the $50,000,000 of shares being offered under this prospectus supplement will be sold or the price at which any such shares might be sold, assuming that an aggregate of 16,077,170 shares of our common stock are sold during the term of the sales agreement with the Agent, at a price of $3.11 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on November 11, 2025, upon completion of this offering, based on our shares outstanding as of September 30, 2025, we will have outstanding an aggregate of 64,385,066 shares of common stock outstanding, assuming no exercise of outstanding stock options and no purchases of stock under our employee stock purchase plan. A substantial majority of the outstanding shares of our common stock are, and all of the shares sold in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities Act, unless these shares are owned or purchased by "affiliates" as that term is defined in Rule 144 under the Securities Act.

**The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares.**

Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future. For example, the market price of our common stock has fluctuated from an intra-day low of $1.15 to an intra-day high of $33.98 over the 12 months preceding the date of this prospectus supplement. This volatility may affect the price at which you could sell shares of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including those described elsewhere in this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein. Some of the factors that may cause the market price of our common stock to fluctuate include:

● the success of existing or new competitive products or technologies;

● the timing and results of clinical studies for our current product candidates and any future product candidates that we may develop;

● failure or discontinuation of any of our product development and research programs;

● results of preclinical studies, clinical studies, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;

● regulatory or legal developments in the United States and other countries;

● developments or disputes concerning patent applications, issued patents, or other proprietary rights;

● the recruitment or departure of key personnel;

● the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;

● the results of our efforts to develop additional product candidates or products;

● actual or anticipated changes in estimates as to financial results or development timelines;

● announcement or expectation of additional financing efforts;

● sales of our common stock by us, our insiders, or other stockholders;

● short selling of our common stock, in which a seller sells shares of our common stock that the seller has borrowed from a third party, which often occurs when a short seller expects the price of our common stock to decline;

● variations in our financial results or those of companies that are perceived to be similar to us;

● changes in estimates or recommendations by securities analysts, if any, that cover our common stock;

● market conditions in the pharmaceutical and biotechnology sectors;

● general economic, industry, and market conditions; and

● securities litigation, regardless of merit.

In recent years, the stock market in general, Nasdaq, and the markets for pharmaceutical and biotechnology companies, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company's securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we are currently and may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management's attention and resources from our business.

**A possible "short squeeze" due to a sudden increase in demand of our common stock that largely exceeds supply may lead to further price volatility in our common stock.**

Investors may purchase shares of our common stock to hedge existing exposure in our common stock or to speculate on the price of our common stock. Speculation on the price of our common stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our common stock for delivery to lenders of our common stock. Those repurchases may in turn, dramatically increase the price of our common stock until investors with short exposure are able to purchase additional shares of common stock to cover their short position. This is often referred to as a "short squeeze." A short squeeze could lead to volatile price movements in shares of our common stock that are not directly correlated to the performance or prospects of our company and once investors purchase the shares necessary to cover their short position the price of our common stock may decline.

**Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.**

Other than our special non-dividend distributions in December 2010 and December 2012, we have not paid cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.

**Use of Proceeds**

We intend to use the net proceeds, if any, from the sale of the shares that we may offer under this prospectus supplement, after deducting commissions and estimated offering expenses, for general corporate purposes and working capital requirements, including development of simufilam, our lead product candidate for the treatment of TSC-related epilepsy. This represents our best estimate of the manner in which we will use any net proceeds we receive from this offering based on the status of our business, but we have not allocated a specific portion of the net proceeds for any particular use at this time. For example, while we do not have any current plans or understandings to do so, we may also use a portion of the net proceeds from this offering for capital expenditures, licensing or acquiring intellectual property or technologies, or to fund possible investments in and acquisitions of complementary businesses or partnerships. We will have broad discretion in the application of any net proceeds we receive from this offering, and we could use any such proceeds for purposes other than those currently contemplated.

Pending their ultimate use, we intend to invest the net proceeds in a variety of securities, which may include commercial paper, government and non-government debt securities and/or money market funds that invest in such securities, in each case, consistent with the Company's investment policy.

**Dilution**

If you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering.

Net tangible book value per share is determined by subtracting our total liabilities from our total tangible assets, which is total assets less intangible assets, and dividing this amount by the number of shares of common stock outstanding. The historical net tangible book value of our common stock, as of September 30, 2025, was approximately $81.4 million, or $1.69 per share, based on 48,307,896 shares of our common stock outstanding as of September 30, 2025 as reported in our Quarterly Report on Form 10-Q for the period ending September 30, 2025. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.

After giving effect to the sale of shares of common stock in this offering at an assumed offering price of $3.11 per share, and after deducting estimated commissions and offering expenses payable by us, our as adjusted net tangible book value at September 30, 2025 would have been approximately $129.9 million, or $2.02 per share. This represents an immediate dilution of $1.09 per share to new investors purchasing shares of common stock in this offering. The following table illustrates this dilution:

---

| | | |
|:---|:---|:---|
| Assumed offering price per share |  | $3.11 |
| Net tangible book value per share as of September 30, 2025 | $1.69 |  |
| Increase in net tangible book value per share attributable to the offering | $0.33 |  |
| As adjusted net tangible book value per share after giving effect to this offering |  | $2.02 |
| As adjusted dilution per share to investors participating in this offering |  | $1.09 |

---

The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase our common stock. To the extent that any of these outstanding options are exercised or we issue additional shares under our equity incentive plans, there will be further dilution to new investors. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.

The above discussion and table are based on 48,307,896 shares of our common stock outstanding as of September 30, 2025 and excludes, as of that date, the following:

● 4,109,093 shares of common stock issuable upon exercise of outstanding options having a weighted-average exercise price of $15.23 per share;

● 7,142 shares of common stock issuable upon the vesting and settlement of outstanding performance awards;

● 610,022 shares of common stock reserved for issuance and available for future grant under our 2018 Omnibus Incentive Plan; and

● 58,017 shares of common stock reserved for issuance and available for future grant under our 2000 Employee Stock Purchase Plan.

**MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS**

The following is a general discussion of the material U.S. federal income tax considerations related to the acquisition, ownership, and disposition of our common stock by a non-U.S. holder, as defined below, that acquires our common stock pursuant to this offering, but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This discussion is based on the current provisions of the Internal Revenue Code of 1986, as amended, or the Code, applicable Treasury regulations promulgated thereunder, judicial opinions, and published rulings of the Internal Revenue Service, or the IRS, all as in effect on the date of this prospectus and all of which are subject to change or differing interpretations, possibly with retroactive effect, which may result in tax consequences different from those discussed below. We have not sought, and will not seek, any ruling from the IRS or any opinion of counsel with respect to the tax considerations discussed herein, and there can be no assurance that the IRS will not take a position contrary to those discussed below or that any position taken by the IRS will not be sustained.

This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular investor in light of the investor's individual circumstances. In addition, this discussion does not address (i) U.S. federal non-income tax laws, such as the gift or estate tax laws, (ii) state, local or non-U.S. tax considerations, (iii) the special tax rules that may apply to certain investors, including, without limitation, banks, insurance companies, financial institutions, controlled foreign corporations, passive foreign investment companies, regulated investment companies, real estate investment trusts, broker-dealers, grantor trusts, personal holding companies, taxpayers who have elected mark-to-market accounting, tax-exempt entities, pension plans, entities or arrangements classified as partnerships for U.S. federal income tax purposes or other pass-through entities or an investor in such entities or arrangements, persons that own (directly, indirectly, or constructively) 5% or more of our common stock (except as set forth below) or U.S. expatriates or former long-term residents of the United States, (iv) the special tax rules that may apply to an investor that acquires, holds, or disposes of our common stock as part of a straddle, hedge, constructive sale, conversion or other integrated transaction, or (v) the effect, if any, of any alternative minimum tax, the special tax accounting rules under Section 451(b) of the Code, or the Medicare contribution tax imposed on net investment income. This discussion assumes that a non-U.S. holder will hold our common stock issued pursuant to this offering as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment).

As used in this discussion, the term "United States person" means a person that is, or is treated for U.S. federal income tax purposes as, (i) a citizen or individual resident of the United States, (ii) a corporation created or organized in the United States or under the laws of the United States or any state thereof or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source or (iv) a trust if (A) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons have the authority to control all substantial decisions of the trust, or (B) it has in effect a valid election under applicable Treasury regulations to be treated as a United States person. As used in this summary, the term "non-U.S. holder" means a beneficial owner of our common stock that is, for U.S. federal income tax purposes, neither a United States person nor a partnership (or an entity or arrangement classified as a partnership).

The tax treatment of an entity or arrangement treated as a partnership for U.S. federal income tax purposes and each partner thereof will generally depend upon the status and activities of the partnership and such partner and certain determinations made at the partner level. An investor that is treated as a partnership for U.S. federal income tax purposes or a partner in such partnership should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to the partnership's acquisition, ownership and disposition of our common stock.

EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSIDERATIONS RELATED TO THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL ESTATE AND GIFT TAX LAWS, AND ANY APPLICABLE INCOME TAX TREATY.

**Distributions on Common Stock**

If we pay cash or distribute property to non-U.S. holders of our common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the non-U.S. holder's adjusted tax basis in our common stock. Any remaining excess will be treated as gain from the sale or exchange of the common stock and will be treated as described under "—Gain on Sale, Exchange or Other Taxable Disposition of Common Stock" below.

Dividends paid to a non-U.S. holder that are not effectively connected with the non-U.S. holder's conduct of a trade or business in the United States generally will be subject to withholding of U.S. federal income tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty. A non-U.S. holder that wishes to claim the benefit of a reduced withholding rate under an applicable income tax treaty generally will be required to submit to the applicable withholding agent a properly completed IRS Form W-8BEN or IRS Form W-8BEN-E (or appropriate successor form), as applicable, and certify under penalties of perjury that such non-U.S. holder is not a United States person and is eligible for the benefits of the applicable income tax treaty. These forms may need to be periodically updated. In the case of a non-U.S. holder that is an entity, applicable Treasury regulations and the relevant tax treaty may provide rules to determine whether, for purposes of determining the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If a non-U.S. holder holds our common stock through a financial institution or other intermediary, such non-U.S. holder generally will be required to provide the appropriate documentation to the financial institution or other intermediary.

Dividends that are effectively connected with a non-U.S. holder's conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States) generally are exempt from U.S. federal withholding tax. In order to obtain this exemption, a non-U.S. holder must provide the applicable withholding agent a properly completed IRS Form W-8ECI (or appropriate successor form) certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are subject to U.S. federal income tax on a net-income basis at the regular graduated U.S. federal income tax rates generally applicable to a United States person. Dividends received by a corporate non-U.S. holder that are effectively connected with such non-U.S. holder's conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States) may be subject to an additional branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty).

If a non-U.S. holder is eligible for a reduced rate of or an exemption from withholding tax pursuant to an income tax treaty but does not timely provide the required certification, then such non-U.S. holder generally may obtain a refund of any excess amounts withheld if such non-U.S. holder timely files an appropriate claim for refund with the IRS. Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.

**Gain on Sale, Exchange or Other Taxable Disposition of Common Stock**

Subject to the discussion below regarding backup withholding and FATCA, as defined below, any gain recognized by a non-U.S. holder on a sale, exchange or other taxable disposition of our common stock generally will not be subject to U.S. federal income or withholding tax unless:

● the gain is effectively connected with the conduct of a trade or business of the non-U.S. holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States),

● the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met, or

● we are or have been at any time during the shorter of the five-year period ending on the date of disposition and the period that the non-U.S. holder held the common stock a U.S. real property holding corporation, or a USRPHC, for U.S. federal income tax purposes, the non-U.S. holder is not eligible for an exemption under an applicable income tax treaty and either (i) our common stock is not be regularly traded on an established securities market during the calendar year in which the disposition occurs or (ii) such non-U.S. holder held more than 5% of our common stock at any time during the relevant period (as described below).

Gain that is described in the first bullet point above generally will be subject to U.S. federal income tax at the regular graduated U.S. federal income tax rates generally applicable to a United States person. A non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty).

A non-U.S. holder described in the second bullet point above generally will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on any gain derived from the sale, exchange or other taxable disposition, which may be offset by certain U.S.-source capital losses of the non-U.S. holder, provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses.

With respect to the third bullet point above, a U.S. corporation generally is a USRPHC if the fair market value of its U.S. real property interests (as defined in the Code and applicable Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. We believe that we are not currently and do not anticipate becoming a USRPHC for U.S. federal income tax purposes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance that we are not currently and will not become a USRPHC in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a non-U.S. holder of our common stock will not be subject to U.S. federal income tax if our common stock is regularly traded, as defined by applicable Treasury regulations, on an established securities market during the calendar year in which the disposition occurs and such non-U.S. holder has held at all times during the shorter of the five-year period ending on the date of disposition or the non-U.S. holder's holding period, actually or constructively, 5% or less of our common stock. If a non-U.S. holder holds or held (at any time during the relevant period) more than 5% of our common stock and if we were a USRPHC at any time during the relevant period, such non-U.S. holder generally will be subject to U.S. federal income tax on the net gain derived from a taxable disposition at the income tax rates generally applicable to a United States person. Our common stock is currently listed on the NASDAQ and we believe that, for as long as our common stock continues to be so listed, our common stock will be treated as "regularly traded on an established securities market."

Non-U.S. holders are urged to consult their own tax advisors regarding the potential applicability of these rules as well as any income tax treaty in their particular circumstances.

**Information Reporting and Backup Withholding**

The amount of dividends paid to a non-U.S. holder on our common stock and the tax, if any, withheld with respect to those dividends generally must be reported annually to the IRS and to such non-U.S. holder of our common stock. Copies of the information returns reporting those dividends and withholding may also be made available to the tax authorities in the country in which the non-U.S. holder is a resident under the provisions of an applicable income tax treaty or agreement. Information reporting also is generally required with respect to the proceeds from sales and other dispositions of our common stock to or through the U.S. office (and in certain cases, the foreign office) of a broker, unless the non-U.S. holder establishes that it is not a United States person.

Under some circumstances, Treasury regulations require backup withholding, currently at a rate of 24%, on reportable payments with respect to our common stock. A non-U.S. holder generally may eliminate the requirement for U.S. federal backup withholding by providing the applicable withholding agent certification of its foreign status, under penalties of perjury, on a duly executed applicable IRS Form W-8BEN or IRS Form W-8BEN-E (or appropriate successor form), as applicable, or by otherwise establishing an exemption. Notwithstanding the foregoing, U.S. federal backup withholding may apply if the payor has actual knowledge, or reason to know, that the non-U.S. holder is a United States person. Backup withholding is not an additional tax. Rather, the amount of any U.S. federal backup withholding generally will be allowed as a credit against a non-U.S. holder's U.S. federal income tax liability, if any, and may entitle such non-U.S. holder to a refund, provided that certain required information is timely furnished to the IRS. Non-U.S. holders are urged to consult their own tax advisors regarding the application of backup withholding and the availability of, and procedure for, obtaining an exemption from backup withholding in their particular circumstances.

**FATCA Withholding**

Under Sections 1471 through 1474 of the Code and the Treasury regulations and administrative guidance issued thereunder, commonly referred to as FATCA, a "non-financial foreign entity" or "foreign financial institution" generally will be subject to a 30% withholding tax on dividends paid on our common stock and gross proceeds from the sale or other taxable disposition of our common stock (whether such entity or institution is the beneficial owner of our common stock or acting as an intermediary), unless (i) if the non-U.S. holder is a "non-financial foreign entity," it provides the applicable withholding agent with certain documentation relating to its substantial U.S. owners, or otherwise certifies that it does not have any substantial U.S. owners, (ii) if the non-U.S. holder is a "foreign financial institution," it enters into an agreement with the Department of Treasury to, among other things, report certain information regarding its accounts with or debt and equity interests held by certain United States persons and withhold tax with respect to certain account holders and holders of debt and equity interests, and it establishes its compliance with these rules by providing to the applicable withholding agent an IRS Form W-8BEN, W-8BEN-E, or other applicable IRS Form W-8 (or an appropriate successor form) or (iii) the non-U.S. holder otherwise qualifies for an exemption from these rules and establishes such exemption by providing the applicable withholding agent with an IRS Form W-8BEN, W-8BEN-E, or other applicable IRS Form W-8 (or an appropriate successor form). However, the IRS has issued proposed Treasury regulations that eliminate FATCA withholding on payments of gross proceeds (but not on payments of dividends). Pursuant to the preamble to the proposed Treasury regulations, any applicable withholding agent may (but is not required to) rely on this proposed change to FATCA withholding until final Treasury regulations are issued or until the proposed Treasury regulations are withdrawn. The rules relating to FATCA described above may be modified by an applicable intergovernmental agreement between the United States and the jurisdiction in which the non-U.S. holder is a resident or is organized.

We will not pay any additional amounts to non-U.S. holders with respect to any amounts withheld, including pursuant to FATCA. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of such taxes. Non-U.S. holders should consult their own tax advisors regarding how FATCA may apply to their ownership and disposition of our common stock.

**Plan of Distribution**

We have entered into the Sales Agreement with Cantor. Pursuant to this prospectus supplement, we may offer and sell shares of our common stock having an aggregate gross sales price of up to $50.0 million from time to time through Cantor acting as sales agent. A copy of the Sales Agreement has been filed as an exhibit to our registration statement on Form S-3 of which this prospectus supplement forms a part.

Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor may sell shares of our common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct the Cantor not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor may suspend the offering of common stock upon notice and subject to other conditions.

We will pay Cantor commissions, in cash, for its service in acting as agent in the sale of our common stock. Cantor will be entitled to compensation at a commission rate of up to 3.0% of the sales price per share sold under the Sales Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor for certain specified expenses, including the fees and disbursements of their legal counsel in an amount not to exceed $125,000 and certain ongoing expenses. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor under the terms of the Sales Agreement, will be approximately $315,000.

Settlement for sales of shares of our common stock will occur on the first business day following the date on which any sales are made, or on some other date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

Cantor will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common stock under the terms and subject to the conditions set forth in the Sales Agreement. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act.

The offering of shares of our common stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein.

Cantor and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement.

This prospectus supplement and the accompanying prospectus may be made available in electronic format on a website maintained by Cantor and Cantor may distribute this prospectus supplement and the accompanying prospectus electronically.

**Where You Can Find More Information**

We have filed with the SEC a registration statement under the Securities Act that registers the securities offered hereby. The registration statement, including the exhibits and schedules attached thereto and the information incorporated by reference therein, contains additional relevant information about the securities and our company, which we are allowed to omit from this prospectus supplement pursuant to the rules and regulations of the SEC. In addition, we file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, can also be accessed free of charge through the Internet by visiting our website at www.cassavasciences.com. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

Information and materials contained on our website, except for the SEC filings expressly described above, are neither incorporated by reference into this prospectus supplement nor a part hereof or any other document we file with or furnish to the SEC.

**INformation incorporated by reference**

The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed "filed" pursuant to the General Instructions of Form 8-K):

● our Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm) for the fiscal year ended December 31, 2024;

● our Quarterly Reports on Form 10-Q for the quarters ended [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm) , [June 30, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925026686/sava20250630_10q.htm) and [September 30, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925034427/sava20250930_10q.htm) ;

● our Definitive Proxy Statement on [Schedule 14A](https://www.sec.gov/Archives/edgar/data/1069530/000143774925011848/sava20250403_def14a.htm) , filed with the SEC on April 14, 2025, to the extent incorporated by reference in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024;

● our Current Reports on Form 8-K filed with the SEC on [January 7, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm) , [February 27, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/sava20250224_8k.htm) , [March 11, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/sava20250310_8k.htm) , [March 25, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm) , [April 21, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/sava20250418_8k.htm) , [May 27, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/sava20250523_8k.htm) , [August 4, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/f8k_080425.htm) , [October 22, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/sava20251020_8k.htm) and [October 24, 2025](https://www.sec.gov/Archives/edgar/data/1069530/000143774925031674/sava20251024_8k.htm) ; and

● the description of our common stock contained in [Exhibit 4.2](https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/ex_756945.htm) of our Annual Report on Form 10-K as filed with the SEC on March 3, 2025, and any further amendment or report filed hereafter for the purpose of updating such description pursuant to Section 12(b) of the Exchange Act.

We also incorporate by reference into this prospectus supplement additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the filing of the initial registration statement and prior to effectiveness of the registration statement and the completion or termination of the offering, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus supplement or the accompanying prospectus is deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.

We will provide at no cost to each person who requests, including any beneficial owner, to whom this prospectus is delivered a copy of any document we incorporate by reference, excluding all exhibits to such incorporated documents (unless we have specifically incorporated by reference such exhibits either in this prospectus or in the incorporated document). You may request a copy of these filings by telephoning us at (512) 501-2444 or by writing us at the following address:

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway, Building 1, Suite 300

Austin, TX 78731

United States of America

Attn: Investor Relations

**Legal Matters**

Certain legal matters in connection with this offering will be passed upon for us by Jones Day. Cantor Fitzgerald & Co. is being represented in connection with this offering by Cooley LLP, New York, New York.

**Experts**

The consolidated financial statements of Cassava Sciences, Inc., appearing in Cassava Sciences, Inc. Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

 **Up to $50,000,000** 

**Common Stock**

**PROSPECTUS SUPPLEMENT**

![](forms-3_002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**, 2025**

**Part II**

**Information Not Required in the Prospectus**

**Item 14. Other Expenses of Issuance and Distribution**

The aggregate estimated expenses (other than underwriting discounts and commissions) which will be paid or have been paid by Cassava Sciences in connection with a distribution of securities registered hereby are as follows:

---

| | |
|:---|:---|
| Securities and Exchange Commission registration fee | $27620 |
| Accounting fees and expenses | (1) |
| Legal fees and expenses | (1) |
| Printing expenses | (1) |
| Transfer agent fees and expenses | (1) |
| Miscellaneous | (1) |
| Total | $(1) |

---

(1) These
 fees are calculated based on the securities offered and the number of issuances and accordingly
 cannot be estimated at this time.

**Item 15. Indemnification of Directors and Officers**

Our amended and restated certificate of incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal liability of directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. Our amended and restated certificate of incorporation and bylaws provide that we shall indemnify our directors and executive officers and may indemnify our employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.

Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of the corporation against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.

We have entered into indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws, and intend to enter into indemnification agreements with any new directors and executive officers in the future.

We have purchased and intend to maintain insurance on behalf of any person who is or was a director or officer of our company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

See also the undertakings set out in our response to Item 17 herein.

**Item 16. Exhibits**

The following exhibits are filed herewith or incorporated by reference herein:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit No.** | **Exhibit No.** | <br>**Description** | **Form** | **Filing Date** | **Exhibit No.** | <br>**Filed Herewith** |
| 1.1 | \* | Form of Underwriting Agreement |  |  |  |  |
| 1.2 |  | [Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated November 12, 2025, between Cassava Sciences, Inc. and Cantor Fitzgerald & Co.](ex1-2.htm) |  |  |  | X |
| 3.1 |  | [Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm) | 10-Q | 7/29/2005 | 3.1 |  |
| 3.2 |  | [Certificate of Amendment of Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm) | 8-K | 5/8/2017 | 3.1 |  |
| 3.3 |  | [Certificate of Amendment of Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm) | 10-K | 3/29/2019 | 3.3 |  |
| 3.4 |  | [Amended and Restated Bylaws of Cassava Sciences, Inc.](https://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm) | 8-K | 9/13/2023 | 3.4 |  |
| 4.1 |  | [Form of Senior Indenture](https://www.sec.gov/Archives/edgar/data/1069530/000149315221003199/ex4-5.htm) | S-3 | 2/10/2021 | 4.5 |  |
| 4.2 |  | [Form of Subordinated Indenture](https://www.sec.gov/Archives/edgar/data/1069530/000149315221003199/ex4-6.htm) | S-3 | 2/10/2021 | 4.6 |  |
| 4.3 |  | [Form of Senior Debt Security (included in Exhibit 4.1)](https://www.sec.gov/Archives/edgar/data/1069530/000149315221003199/ex4-5.htm) | S-3 | 2/10/2021 | 4.7 |  |
| 4.4 |  | [Form of Subordinated Debt Security (included in Exhibit 4.2)](https://www.sec.gov/Archives/edgar/data/1069530/000149315221003199/ex4-6.htm) | S-3 | 2/10/2021 | 4.8 |  |
| 4.5 |  | [Specimen Common Stock Certificate](https://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm) | 10-Q | 8/12/2019 | 4.1 |  |
| 4.6 | \* | Form of Certificate of Designation |  |  |  |  |
| 4.7 | \* | Form of Preferred Stock Certificate |  |  |  |  |
| 4.8 | \* | Form of Deposit Agreement |  |  |  |  |
| 4.9 | \* | Form of Depositary Receipt (included in Exhibit 4.8) |  |  |  |  |
| 4.10 | \* | Form of Warrant Agreement |  |  |  |  |
| 4.11 | \* | Form of Warrant Certificate |  |  |  |  |
| 4.12 | \* | Form of Subscription Rights Agreement |  |  |  |  |
| 4.13 | \* | Form of Unit Agreement |  |  |  |  |
| 5.1 |  | [Opinion of Jones Day relating to the base prospectus](ex5-1.htm) |  |  |  | X |
| 5.2 |  | [Opinion of Jones Day relating to the "at the market offering" prospectus supplement](ex5-2.htm) |  |  |  | X |
| 23.1 |  | [Consent of Independent Registered Public Accounting Firm](ex23-1.htm) |  |  |  | X |
| 23.2 |  | [Consent of Jones Day (included in Exhibit 5.1)](ex5-1.htm) |  |  |  | X |
| 23.3 |  | [Consent of Jones Day (included in Exhibit 5.2)](ex5-2.htm) |  |  |  | X |
| 24.1 |  | [Power of Attorney (set forth on the signature page of this registration statement)](#a_029) |  |  |  | X |
| 25.1 | \*\* | Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939, as amended\* |  |  |  |  |
| 25.2 | \*\* | Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939, as amended\* |  |  |  |  |
| 107 |  | [Filing Fee Tables](ex107.htm) |  |  |  | X |

---

\* To be filed by amendment or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and incorporated herein by reference.

\*\* To be filed pursuant to Rule 305(b)(2) of the Trust Indenture Act, as amended.

**Item 17. Undertakings**

(a) The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To
 include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To
 reflect in the prospectus any facts or events arising after the effective date of the registration
 statement (or the most recent post-effective amendment thereof) which, individually or in
 the aggregate, represent a fundamental change in the information set forth in the registration
 statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
 offered (if the total dollar value of securities offered would not exceed that which was
 registered) and any deviation from the low or high end of the estimated maximum offering
 range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)
 if, in the aggregate, the changes in volume and price represent no more than a 20 percent
 change in the maximum aggregate offering price set forth in the "Calculation of Registration
 Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To
 include any material information with respect to the plan of distribution not previously
 disclosed in the registration statement or any material change to such information in the
 registration statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If
 the registrant is relying on Rule 430B,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof. *Provided*, *however*, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to the effective date; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer and sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any
 preliminary prospectus or prospectus of the undersigned registrant relating to the offering
 required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any
 free writing prospectus relating to the offering prepared by or on behalf of the undersigned
 registrant or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The
 portion of any other free writing prospectus relating to the offering containing material
 information about the undersigned registrant or its securities provided by or on behalf of
 the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any
 other communication that is an offer in the offering made by the undersigned registrant to
 the purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding), is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(c) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section 305(b)(2) of the Trust Indenture Act.

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on the 12th day of November, 2025.

---

| | |
|:---|:---|
| **CASSAVA SCIENCES, INC.** | **CASSAVA SCIENCES, INC.** |
| By: | */s/ Richard Barry* |
| Name: | Richard J. Barry |
| Title: | President and Chief Executive Officer |

---

**Power of Attorney**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard Barry and Eric Schoen, or either of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign the Registration Statement filed herewith and any or all amendments to said Registration Statement (including pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and otherwise), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents the full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Richard J. Barry* | President, Chief Executive Officer and Director | November 12, 2025 |
| Richard J. Barry | (Principal Executive Officer) |  |
| */s/ Eric J. Schoen* | Chief Financial Officer (Principal Financial Officer and | November 12, 2025 |
| Eric J. Schoen | Principal Accounting Officer) |  |
| */s/ Robert Anderson, Jr.* | Director | November 12, 2025 |
| Robert Anderson, Jr. |  |  |
| */s/ Dawn Carter Bir* | Director | November 12, 2025 |
| Dawn Carter Bir |  |  |
| */s/ Pierre Gravier* | Director | November 12, 2025 |
| Pierre Gravier |  |  |
| */s/ Robert Gussin* | Director | November 12, 2025 |
| Robert Gussin, Ph.D. |  |  |
| */s/ Claude Nicaise* | Director | November 12, 2025 |
| Claude Nicaise, M.D. |  |  |
| */s/ Michael O'Donnell* | Director | November 12, 2025 |
| Michael O'Donnell |  |  |
| */s/ Patrick Scannon* | Director | November 12, 2025 |
| Patrick Scannon, M.D., Ph.D. |  |  |

---

## Exhibit 1.2

**Exhibit 1.2**

**CASSAVA SCIENCES, INC.**<br> Shares of Common Stock

(par value $0.001 per share)

**Controlled Equity Offering<sup>SM</sup>**

**<u>Sales Agreement</u>**

November 12, 2025

Cantor Fitzgerald & Co.

110 East 59<sup>th</sup> Street

New York, NY 10022

Ladies and Gentlemen:

Cassava Sciences, Inc., a Delaware corporation (the "**<u>Company</u>**"), confirms its agreement (this "**<u>Agreement</u>**") with Cantor Fitzgerald & Co. (the "**<u>Agent</u>**"), as follows:

1. <u>Issuance and Sale of Shares</u>. The Company agrees that, from time to time during the term of this
 Agreement, on the terms and subject to the conditions set forth herein, it may issue and
 sell to or through the Agent, as sales agent or principal, shares of common stock (the "  **<u>Placement Shares</u>**") of the Company, par value $0.001 per share (the "  **<u>Common Stock</u>** "); *provided*, *however*, that in no event shall the Company
 issue or sell through the Agent such number or dollar amount of Placement Shares that would
 (a) exceed the number or dollar amount of shares of Common Stock registered on the effective
 Registration Statement (as defined below) pursuant to which the offering is being made, (b)
 exceed the number of authorized but unissued shares of Common Stock (less shares of Common
 Stock issuable upon exercise, conversion or exchange of any outstanding securities of the
 Company or otherwise reserved from the Company's authorized capital stock), (c) exceed
 the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3
 (including General Instruction I.B.6 thereof, if applicable) or (d) exceed the number or
 dollar amount of shares of Common Stock for which the Company has filed a Prospectus Supplement
 (as defined below) (the lesser of (a), (b), (c) and (d), the "  **<u>Maximum Amount</u>** ").
 Notwithstanding anything to the contrary contained herein, the parties hereto agree that
 compliance with the limitations set forth in this <u>Section 1</u> on the amount of Placement
 Shares issued and sold under this Agreement shall be the sole responsibility of the Company
 and that the Agent shall have no obligation in connection with such compliance. The offer
 and sale of Placement Shares through the Agent will be effected pursuant to the Registration
 Statement (as defined below) filed by the Company and which will be declared effective by
 the Securities and Exchange Commission (the "  **<u>Commission</u>**") or will
 otherwise become effective in accordance with the Securities Act (as defined below), although
 nothing in this Agreement shall be construed as requiring the Company to use the Registration
 Statement to issue Common Stock.

The Company has filed or will file, in accordance with the provisions of the Securities Act of 1933, as amended (the "**<u>Securities Act</u>**"), and the rules and regulations thereunder (the "**<u>Securities Act Regulations</u>**"), with the Commission a registration statement on Form S-3, including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the "**<u>Exchange Act</u>**"), and the rules and regulations thereunder. The Company has prepared a prospectus or a prospectus supplement to the base prospectus included as part of the registration statement, which prospectus or prospectus supplement relates to the Placement Shares to be issued from time to time by the Company (the "**<u>Prospectus Supplement</u>**"). The Company will furnish to the Agent, for use by the Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares to be issued from time to time by the Company. Except where the context otherwise requires, such registration statement(s), including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations, and any one or more additional effective registration statements on Form S-3 from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus Supplement), with respect to the Placement Shares, is herein called the "**<u>Registration Statement</u>**." The base prospectus or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented, if necessary, by the Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations, together with the then issued Issuer Free Writing Prospectus(es) (as defined below), is herein called the "**<u>Prospectus</u>**."

Any reference herein to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the documents, if any, incorporated by reference therein (the "**<u>Incorporated Documents</u>**"), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms "amend," "amendment" or "supplement" with respect to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, "**<u>EDGAR</u>**").

2. <u>Placements</u>.
 Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a "  **<u>Placement</u>** "),
 it will notify the Agent by email notice (or other method mutually agreed to by the parties)
 of the number of Placement Shares to be issued, the time period during which sales are requested
 to be made, any limitation on the number of Placement Shares that may be sold in any one
 day and any minimum price below which sales may not be made (a "  **<u>Placement Notice</u>** "),
 the form of which is attached hereto as <u>Schedule 1</u>. The Placement Notice shall originate
 from any of the individuals from the Company set forth on <u>Schedule 3</u> (with a copy
 to each of the other individuals from the Company listed on such schedule), and shall be
 addressed to each of the individuals from the Agent set forth on <u>Schedule 3</u>, as such <u>Schedule 3</u> may be amended from time to time. The Placement Notice shall be effective
 unless and until (i) the Agent declines to accept the terms contained therein for any reason,
 in its sole discretion, (ii) the entire amount of the Placement Shares thereunder have been
 sold, (iii) the Company suspends or terminates the Placement Notice (including, without limitation,
 by issuing a subsequent Placement Notice with parameters superseding those on an earlier
 dated Placement Notice) or (iv) this Agreement has been terminated under the provisions of <u>Section 12</u>. The amount of any discount, commission or other compensation to be paid
 by the Company to the Agent in connection with the sale of the Placement Shares shall be
 calculated in accordance with the terms set forth in <u>Schedule 2</u>. It is expressly acknowledged
 and agreed that neither the Company nor the Agent will have any obligation whatsoever with
 respect to a Placement or any Placement Shares unless and until the Company delivers a Placement
 Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the
 terms set forth above, and then only upon the terms specified therein and herein. In the
 event of a conflict between the terms of this Agreement and the terms of a Placement Notice,
 the terms of the Placement Notice will control.

3. <u>Sale of Placement Shares by the Agent</u>. Subject to the provisions of <u>Section 5(a)</u>, the
 Agent, for the period specified in the Placement Notice, will use its commercially reasonable
 efforts consistent with its normal trading and sales practices and applicable state and federal
 laws, rules and regulations and the rules of the Nasdaq Capital Market (the "  **<u>Exchange</u>** "),
 to sell the Placement Shares up to the amount specified in, and otherwise in accordance with
 the terms of, such Placement Notice. The Agent will provide written confirmation to the Company
 no later than the opening of the Trading Day (as defined below) immediately following the
 Trading Day on which it has made sales of Placement Shares hereunder setting forth the number
 of Placement Shares sold on such day, the compensation payable by the Company to the Agent
 pursuant to <u>Section 2</u> with respect to such sales, and the Net Proceeds (as defined
 below) payable to the Company, with an itemization of the deductions made by the Agent (as
 set forth in <u>Section 5(b)</u>) from the gross proceeds that it receives from such sales.
 Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any
 method permitted by law deemed to be an "at the market offering" as defined in
 Rule 415(a)(4) of the Securities Act Regulations. "  **<u>Trading Day</u>** "
 means any day on which Common Stock is traded on the Exchange.

4. <u>Suspension of Sales</u>. The Company or the Agent may, upon notice to the other party in writing (including
 by email correspondence to each of the individuals of the other party set forth on <u>Schedule 3</u>, if receipt of such correspondence is actually acknowledged by any of the individuals
 to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately
 by verifiable facsimile transmission or email correspondence to each of the individuals of
 the other party set forth on <u>Schedule 3</u>), suspend any sale of Placement Shares (a
 "  **<u>Suspension</u>** "); *provided*, *however*, that such Suspension
 shall not affect or impair any party's obligations with respect to any Placement Shares
 sold hereunder prior to the receipt of such notice. While a Suspension is in effect any obligation
 under <u>Sections 7(l)</u>, <u>7(m)</u>, and <u>7(n)</u> with respect to the delivery of
 certificates, opinions, or comfort letters to the Agent, shall be waived. Each of the parties
 agrees that no such notice under this <u>Section 4</u> shall be effective against any other
 party unless it is made to one of the individuals named on <u>Schedule 3</u> hereto, as such
 Schedule may be amended from time to time. Notwithstanding any other provision of this Agreement,
 during any period in which the Company is in possession of material non-public information,
 the Company and the Agent agree that (i) no sale of Placement Shares will take place, (ii)
 the Company shall not request the sale of any Placement Shares, and (iii) the Agent shall
 not be obligated to sell or offer to sell any Placement Shares.

5. <u>Sale and Delivery to the Agent; Settlement</u>.

(a) <u>Sale of Placement Shares</u> *.* On the basis of the representations and warranties herein
 contained and subject to the terms and conditions herein set forth, upon the Agent's
 acceptance of the terms of a Placement Notice, and unless the sale of the Placement Shares
 described therein has been declined, suspended, or otherwise terminated in accordance with
 the terms of this Agreement, the Agent, for the period specified in the Placement Notice,
 will use its commercially reasonable efforts consistent with its normal trading and sales
 practices and applicable law and regulations to sell such Placement Shares up to the amount
 specified, and otherwise in accordance with the terms of such Placement Notice. The Company
 acknowledges and agrees that (i) there can be no assurance that the Agent will be successful
 in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the
 Company or any other person or entity if it does not sell Placement Shares for any reason
 other than a failure by the Agent to use its commercially reasonable efforts consistent with
 its normal trading and sales practices and applicable law and regulations to sell such Placement
 Shares as required under this Agreement and (iii) the Agent shall be under no obligation
 to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise
 agreed by the Agent and the Company.

(b) <u>Settlement of Placement Shares</u> *.* Unless otherwise specified in the applicable Placement Notice,
 settlement for sales of Placement Shares will occur on the first (1st) Trading Day following
 the date on which such sales are made (each, a "  **<u>Settlement Date</u>** ").
 The Agent shall notify the Company of each sale of Placement Shares no later than the opening
 of the Trading Day immediately following the Trading Day on which it has made sales of Placement
 Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement Date
 against receipt of the Placement Shares sold (the "  **<u>Net Proceeds</u>** ")
 will be equal to the aggregate sales price received by the Agent, after deduction for (i)
 the Agent's commission, discount or other compensation for such sales payable by the
 Company pursuant to <u>Section 2</u> hereof, and (ii) any transaction fees imposed by any
 Governmental Authority in respect of such sales.

(c) <u>Delivery of Placement Shares</u>. On or before each Settlement Date, the Company will, or will cause
 its transfer agent to, electronically transfer the Placement Shares being sold by crediting
 the Agent's or its designee's account (provided the Agent shall have given the
 Company written notice of such designee on (in which case no later than the opening of trading
 on the Exchange on such date) or prior to the Settlement Date) at The Depository Trust Company
 through its Deposit and Withdrawal at Custodian System or by such other means of delivery
 as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradable,
 transferable, registered shares in good deliverable form. On each Settlement Date, the Agent
 will deliver the related Net Proceeds in same day funds to an account designated by the Company
 on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer
 agent (if applicable), defaults in its obligation to deliver Placement Shares on a Settlement
 Date, the Company agrees that in addition to and in no way limiting the rights and obligations
 set forth in <u>Section 10(a)</u> hereto, it will (i) hold the Agent harmless against any
 loss, claim, damage, or expense (including reasonable and documented legal fees and expenses),
 as incurred, arising out of or in connection with such default by the Company or its transfer
 agent (if applicable) and (ii) pay to the Agent any commission, discount, or other compensation
 to which it would otherwise have been entitled absent such default.

(d) <u>Denominations; Registration</u> *.* The Placement Shares shall be issued in book-entry and registered
 in such names as the Agent may request in writing at least one full Business Day (as defined
 below) before the applicable Settlement Date.

(e) <u>Limitations on Offering Size</u> *.* Under no circumstances shall the Company cause or request the
 offer or sale of any Placement Shares if, after giving effect to the sale of such Placement
 Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to this Agreement
 would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement,
 the Maximum Amount and (B) the amount authorized from time to time to be issued and sold
 under this Agreement by the Company's board of directors, a duly authorized committee
 thereof or one or more duly authorized executive officers of the Company, acting individually
 or together, and notified to the Agent in writing. Under no circumstances shall the Company
 cause or request the offer or sale of any Placement Shares pursuant to this Agreement at
 a price lower than the minimum price authorized from time to time by the Company's
 board of directors, a duly authorized committee thereof or a duly authorized executive committee.
 Further, under no circumstances shall the Company cause or permit the aggregate offering
 amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

6. <u>Representations and Warranties of the Company</u>. The Company represents and warrants to, and agrees with
 the Agent that as of the date of this Agreement and as of each Applicable Time (as defined
 below):

(a) <u>Registration Statement and Prospectus</u>. The Company and the transactions contemplated by this Agreement
 meet the requirements for and comply with the applicable conditions set forth in Form S-3
 (including General Instructions I.A and I.B) under the Securities Act. The Registration Statement
 has been or will be filed with the Commission and will be declared effective by the Commission,
 or will otherwise become effective, under the Securities Act prior to the issuance of any
 Placement Notices by the Company. As of each Applicable Time, the Registration Statement
 is effective. The Prospectus Supplement will name the Agent as the agent in the section entitled
 "Plan of Distribution." The Company has not received, and has no notice of, any
 order of the Commission preventing or suspending the use of the Registration Statement, or
 threatening or instituting proceedings for that purpose. The Registration Statement and the
 offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415
 under the Securities Act and comply in all material respects with said Rule. Any statutes,
 regulations, contracts or other documents that are required to be described in the Registration
 Statement or the Prospectus or to be filed as exhibits to the Registration Statement have
 been so described in all material respects or filed. Copies of the Registration Statement,
 the Prospectus, and any such amendments or supplements and all documents incorporated by
 reference therein that were filed with the Commission on or prior to the date of this Agreement
 have been delivered, or are available through EDGAR, to the Agent and its counsel. The Company
 has not distributed and, prior to the later to occur of each Settlement Date and completion
 of the distribution of the Placement Shares, will not distribute any offering material in
 connection with the offering or sale of the Placement Shares other than the Registration
 Statement and the Prospectus and any Issuer Free Writing Prospectus to which the Agent has
 consented. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and
 is currently listed on the Exchange under the trading symbol "SAVA." Except in
 each case as disclosed in the Registration Statement or the Prospectus, the Company has taken
 no action designed to, or likely to have the effect of, terminating the registration of the
 Common Stock under the Exchange Act, delisting the Common Stock from the Exchange, nor has
 the Company received any notification that the Commission or the Exchange is contemplating
 terminating such registration or listing. To the Company's knowledge, it is in compliance
 with all applicable listing requirements of the Exchange.

(b) <u>No Misstatement or Omission</u>. The Registration Statement, when it became or becomes effective,
 and the Prospectus, and any amendment or supplement thereto, on the date of such Prospectus
 or amendment or supplement, conformed and will conform in all material respects with the
 requirements of the Securities Act. At each Settlement Date, the Registration Statement and
 the Prospectus, as of such date, will conform in all material respects with the requirements
 of the Securities Act. The Registration Statement, when it became or becomes effective, did
 not, and will not, contain an untrue statement of a material fact or omit to state a material
 fact required to be stated therein or necessary to make the statements therein not misleading.
 The Prospectus and any amendment or supplement thereto, on the date thereof and at each Applicable
 Time (as defined below), did not or will not include an untrue statement of a material fact
 or omit to state a material fact necessary to make the statements therein, in light of the
 circumstances under which they were made, not misleading. The documents incorporated by reference
 in the Prospectus or any Prospectus Supplement did not, and any further documents filed and
 incorporated by reference therein will not, when filed with the Commission, contain an untrue
 statement of a material fact or omit to state a material fact required to be stated in such
 document or necessary to make the statements in such document, in light of the circumstances
 under which they were made, not misleading. The foregoing shall not apply to statements in,
 or omissions from, any such document made in reliance upon, and in conformity with, information
 furnished to the Company by the Agent in writing specifically for use in the preparation
 thereof, it being understood and agreed that the only such information furnished by the Agent
 to the Company consists of "Agent Information" as defined below.

(c) <u>Conformity with the Securities Act and Exchange Act</u>. The Registration Statement, the Prospectus,
 any Issuer Free Writing Prospectus or any amendment or supplement thereto, and the documents
 incorporated by reference in the Registration Statement, the Prospectus or any amendment
 or supplement thereto, when such documents were or are filed with the Commission under the
 Securities Act or the Exchange Act or became or become effective under the Securities Act,
 as the case may be, conformed or will conform in all material respects with the requirements
 of the Securities Act and the Exchange Act, as applicable.

(d) <u>Financial Information</u>. The consolidated financial statements of the Company included or incorporated
 by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses,
 if any, together with the related notes and schedules, present fairly, in all material respects,
 the consolidated financial position of the Company and the Subsidiaries (as defined below)
 as of the dates indicated and the consolidated results of operations, cash flows and changes
 in stockholders' equity of the Company for the periods specified and have been prepared
 in compliance with the requirements of the Securities Act and Exchange Act and in conformity
 with U.S. Generally Accepted Accounting Principles ("  **<u>GAAP</u>**") applied
 on a consistent basis during the periods involved, except (i) the unaudited interim financial
 statements, which are subject to normal year-end adjustments and do not contain certain footnotes,
 as permitted by the applicable rules of the Commission and (ii) as otherwise disclosed therein;
 the other financial and statistical data with respect to the Company and the Subsidiaries
 (as defined below) contained or incorporated by reference in the Registration Statement,
 the Prospectus and the Issuer Free Writing Prospectuses, if any, are accurately and fairly
 presented in all material respects and prepared on a basis consistent with the financial
 statements and books and records of the Company; there are no financial statements (historical
 or pro forma) that are required to be included or incorporated by reference in the Registration
 Statement, or the Prospectus that are not included or incorporated by reference as required;
 the Company and the Subsidiaries (as defined below) do not have any material liabilities
 or obligations, direct or contingent (including any off-balance sheet obligations), not described
 in the Registration Statement (excluding the exhibits thereto), and the Prospectus; and all
 disclosures contained or incorporated by reference in the Registration Statement, the Prospectus
 and the Issuer Free Writing Prospectuses, if any, regarding "non-GAAP financial measures"
 (as such term is defined by the rules and regulations of the Commission) comply in all material
 respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
 Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language
 included or incorporated by reference in the Registration Statement and the Prospectus fairly
 presents the information called for in all material respects and has been prepared in accordance
 with the Commission's rules and guidelines applicable thereto.

(e) <u>Conformity with EDGAR Filing</u>. The Prospectus delivered to the Agent for use in connection with the
 sale of the Placement Shares pursuant to this Agreement will be identical to the versions
 of the Prospectus created to be transmitted to the Commission for filing via EDGAR, except
 to the extent permitted by Regulation S-T.

(f) <u>Organization</u>.
 The Company and each of its Subsidiaries are duly organized, validly existing as a corporation
 or other legal entity and in good standing under the laws of their respective jurisdictions
 of organization. The Company and each of its Subsidiaries are duly licensed or qualified
 as a foreign corporation for transaction of business and in good standing under the laws
 of each other jurisdiction in which their respective ownership or lease of property or the
 conduct of their respective businesses requires such license or qualification, and have all
 corporate power and authority necessary to own or hold their respective properties and to
 conduct their respective businesses as described in the Registration Statement and the Prospectus,
 except where the failure to be so qualified or in good standing or have such power or authority
 would not, individually or in the aggregate, have a material adverse effect or would reasonably
 be expected to have a material adverse effect on or affecting the assets, business, operations,
 earnings, properties, condition (financial or otherwise), prospects, stockholders'
 equity or results of operations of the Company and the Subsidiaries taken as a whole, or
 prevent or materially interfere with consummation of the transactions contemplated hereby
 (a "  **<u>Material Adverse Effect</u>** ").

(g) <u>Subsidiaries</u>.
 The subsidiaries set forth on <u>Schedule 4</u> (collectively, the "  **<u>Subsidiaries</u>** "),
 are the Company's only significant subsidiaries (as such term is defined in Rule 1-02
 of Regulation S-X promulgated by the Commission). Except as set forth in the Registration
 Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity
 interests of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance,
 right of first refusal or other restriction, and all the equity interests of the Subsidiaries
 are validly issued and are fully paid, nonassessable and free of preemptive and similar rights.
 No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends
 to the Company, from making any other distribution on such Subsidiary's capital stock,
 from repaying to the Company any loans or advances to such Subsidiary from the Company or
 from transferring any of such Subsidiary's property or assets to the Company or any
 other Subsidiary of the Company.

(h) <u>No Violation or Default</u>. Neither the Company nor any of its Subsidiaries is (i) in violation
 of its charter or by-laws or similar organizational documents; (ii) in default, and no event
 has occurred that, with notice or lapse of time or both, would constitute such a default,
 in the due performance or observance of any term, covenant or condition contained in any
 indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
 the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries
 is bound or to which any of the property or assets of the Company or any of its Subsidiaries
 are subject; or (iii) in violation of any law or statute or any judgment, order, rule or
 regulation of any Governmental Authority, except, in the case of each of clauses (ii) and
 (iii) above, for any such violation or default that would not, individually or in the aggregate,
 have a Material Adverse Effect. To the Company's knowledge, no other party under any
 material contract or other agreement to which it or any of its Subsidiaries is a party is
 in default in any respect thereunder where such default would have a Material Adverse Effect.

(i) <u>No Material Adverse Effect</u>. Subsequent to the respective dates as of which information is
 given in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses,
 if any (including any document deemed incorporated by reference therein), there has not been
 (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably
 expects will result in a Material Adverse Effect, (ii) any transaction which is material
 to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability,
 direct or contingent (including any off-balance sheet obligations), incurred by the Company
 or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole,
 (iv) any material change in the capital stock or outstanding long-term indebtedness of the
 Company or any of its Subsidiaries or (v) any dividend or distribution of any kind declared,
 paid or made on the capital stock of the Company or any Subsidiary, other than in each case
 above in the ordinary course of business or as otherwise disclosed in the Registration Statement
 or Prospectus (including any document deemed incorporated by reference therein).

(j) <u>Capitalization</u>.
 The issued and outstanding shares of capital stock of the Company have been validly issued,
 are fully paid and nonassessable and, other than as disclosed in the Registration Statement
 or the Prospectus, are not subject to any preemptive rights, rights of first refusal or similar
 rights. The Company has an authorized, issued and outstanding capitalization as set forth
 in the Registration Statement and the Prospectus as of the dates referred to therein (other
 than the grant of additional equity awards under the Company's equity incentive plans
 described in the Registration Statement or the Prospectus, or changes in the number of outstanding
 shares of Common Stock of the Company due to the issuance of shares upon the exercise or
 conversion of securities exercisable for, or convertible into, Common Stock outstanding on
 the date hereof) and such authorized capital stock conforms to the description thereof set
 forth in the Registration Statement and the Prospectus. The description of the securities
 of the Company in the Registration Statement and the Prospectus is complete and accurate
 in all material respects. Except as disclosed in or contemplated by the Registration Statement
 or the Prospectus, as of the date referred to therein, the Company does not have outstanding
 any options to purchase, or any rights or warrants to subscribe for, or any securities or
 obligations convertible into, or exchangeable for, or any contracts or commitments to issue
 or sell, any shares of capital stock or other securities.

(k) <u>Authorization; Enforceability</u>. The Company has full legal right, power and authority to enter into this
 Agreement and perform the transactions contemplated hereby. This Agreement has been duly
 authorized, executed and delivered by the Company and is a legal, valid and binding agreement
 of the Company enforceable in accordance with its terms, except to the extent that enforceability
 may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
 creditors' rights generally and by general equitable principles.

(l) <u>Authorization of Placement Shares</u>. The Placement Shares, when issued and delivered pursuant to the
 terms approved by the board of directors of the Company or a duly authorized committee thereof,
 a duly authorized executive committee or one or more duly authorized executive officers of
 the Company, acting individually or together, against payment therefor as provided herein,
 will be duly and validly authorized and issued and fully paid and nonassessable, free and
 clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory
 or contractual preemptive rights, resale rights, rights of first refusal or other similar
 rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement
 Shares, when issued, will conform in all material respects to the description thereof set
 forth in or incorporated into the Prospectus.

(m) <u>No Consents Required</u>. No consent, approval, authorization, order, registration or qualification
 of or with any Governmental Authority is required for the execution, delivery and performance
 by the Company of this Agreement, the issuance and sale by the Company of the Placement Shares,
 except for such consents, approvals, authorizations, orders and registrations or qualifications
 as may be required under applicable state securities laws or by the by-laws and rules of
 the Financial Industry Regulatory Authority ("  **<u>FINRA</u>**") or the Exchange
 in connection with the sale of the Placement Shares by the Agent.

(n) <u>No Preferential Rights</u>. Except as set forth in the Registration Statement and the Prospectus,
 (i) no person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the
 Securities Act (each, a "  **<u>Person</u>** "), has the right, contractual or
 otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares
 of any other capital stock or other securities of the Company, (ii) no Person has any preemptive
 rights, resale rights, rights of first refusal, rights of co-sale, or any other rights (whether
 pursuant to a "poison pill" provision or otherwise) to purchase any Common Stock
 or shares of any other capital stock or other securities of the Company, (iii) no Person
 has the right to act as an underwriter or as a financial advisor to the Company in connection
 with the offer and sale of the Placement Shares, and (iv) no Person has the right, contractual
 or otherwise, to require the Company to register under the Securities Act any Common Stock
 or shares of any other capital stock or other securities of the Company, or to include any
 such shares or other securities in the Registration Statement or the offering contemplated
 thereby, whether as a result of the filing or effectiveness of the Registration Statement
 or the sale of the Placement Shares as contemplated thereby or otherwise.

(o) <u>Independent Public Accounting Firm</u>. Ernst & Young LLP (the "  **<u>Accountant</u>** "),
 whose report on the consolidated financial statements of the Company is filed with the Commission
 as part of the Company's most recent Annual Report on Form 10-K filed with the Commission
 and incorporated by reference into the Registration Statement and the Prospectus, are and,
 during the periods covered by their report, were an independent registered public accounting
 firm within the meaning of the Securities Act and the Public Company Accounting Oversight
 Board (United States). To the Company's knowledge, the Accountant is not in violation
 of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the "  **<u>Sarbanes-Oxley Act</u>**") with respect to the Company.

(p) <u>Enforceability of Agreements</u>. All agreements between the Company and third parties expressly referenced
 in the Prospectus are legal, valid and binding obligations of the Company enforceable in
 accordance with their respective terms, except to the extent that (i) enforceability may
 be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
 creditors' rights generally and by general equitable principles and (ii) the indemnification
 provisions of certain agreements may be limited by federal or state securities laws or public
 policy considerations in respect thereof.

(q) <u>No Litigation</u>. Except as set forth in the Registration Statement or the Prospectus, there
 are no actions, suits or proceedings by or before any Governmental Authority pending, nor,
 to the Company's knowledge, any audits or investigations by or before any Governmental
 Authority to which the Company or a Subsidiary is a party or to which any property of the
 Company or any of its Subsidiaries is the subject that, individually or in the aggregate,
 would have a Material Adverse Effect and, to the Company's knowledge, no such actions,
 suits, proceedings, audits or investigations are threatened or contemplated by any Governmental
 Authority or threatened by others; and (i) there are no current or pending investigations,
 actions, suits or proceedings by or before any Governmental Authority that are required under
 the Securities Act to be described in the Prospectus that are not so described; and (ii)
 there are no contracts or other documents that are required under the Securities Act to be
 filed as exhibits to the Registration Statement that are not so filed.

(r) <u>Licenses and Permits</u>. Except as set forth in the Registration Statement or the Prospectus, the
 Company and the Subsidiaries possess or have obtained, all licenses, certificates, consents,
 orders, approvals, permits and other authorizations issued by, and have made all declarations
 and filings with, the appropriate Governmental Authorities (including, without limitation,
 the United States Food and Drug Administration (the "  **<u>FDA</u>**") and
 the European Medicines Agency (the "  **<u>EMA</u>** ")) that are necessary for
 the ownership or lease of their respective properties or the conduct of their respective
 businesses as described in the Registration Statement and the Prospectus (the "  **<u>Permits</u>** "),
 except where the failure to possess, obtain or make the same would not, individually or in
 the aggregate, have a Material Adverse Effect. Except as disclosed in the Registration Statement
 or the Prospectus, neither the Company nor any Subsidiary has received written notice of
 any proceeding relating to revocation or modification of any such Permit or has any reason
 to believe that such Permit will not be renewed in the ordinary course, except where the
 failure to obtain any such renewal would not, individually or in the aggregate, have a Material
 Adverse Effect.

(s) <u>Intellectual Property</u>. Except as set forth in the Registration Statement or the Prospectus, the Company
 believes it and the Subsidiaries own or possess adequate enforceable rights to use all patents,
 patent applications, trademarks (both registered and unregistered), service marks, trade
 names, trademark registrations, service mark registrations, copyrights, licenses and know-how
 (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
 information, systems or procedures) (collectively, the "  **<u>Intellectual Property</u>** "),
 necessary for the conduct of their respective businesses as conducted as of the date hereof
 or as currently proposed to be conducted, or to the development, manufacture, operation and
 sale of any products and services sold or proposed to be sold by any of the Company or any
 Subsidiary, except to the extent that the failure to own or possess adequate rights to use
 such Intellectual Property would not, individually or in the aggregate, have a Material Adverse
 Effect; neither the Company nor any Subsidiary has received any written notice of any claim
 of infringement or conflict which asserted Intellectual Property rights of others, which
 infringement or conflict, if the subject of an unfavorable decision, would have a Material
 Adverse Effect; there are no pending, or to the Company's knowledge, threatened judicial
 proceedings or interference proceedings challenging the Company's or any Subsidiary's
 rights in or to, the validity of, the enforceability of, or the scope of any of the Company's
 or any Subsidiary's patents, patent applications or proprietary information; the Company
 is not aware of any other entity or individual that has any right or claim in any of the
 Company's or any Subsidiary's patents, patent applications or any patent to be
 issued therefrom by virtue of any contract, license or other agreement entered into between
 such entity or individual and the Company, any Subsidiary or by any non-contractual obligation,
 other than by written licenses granted by the Company; the Company and the Subsidiaries have
 taken all reasonable steps to protect, maintain and safeguard the material Intellectual Property
 owned by the Company or any Subsidiary, including the execution of appropriate nondisclosure,
 confidentiality agreements, invention assignment agreements, and invention assignments with
 their employees. to the Company's knowledge, no employee of the Company or any Subsidiary
 is or has been in violation of any term of any employment contract, patent disclosure agreement,
 invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
 agreement or any restrictive covenant to or with a former employer where the basis of such
 violation relates to such employee's employment with the Company or any Subsidiary;
 the Company has not received any written notice of any claim challenging the rights of the
 Company or any Subsidiary in or to any Intellectual Property owned, licensed or optioned
 by the Company or any Subsidiary which claim, if the subject of an unfavorable decision would
 result in a Material Adverse Effect. The Company's or any Subsidiary's patents
 are subsisting, have not lapsed, and have not been adjudged by a court of competent jurisdiction
 invalid or unenforceable, in whole or in part; the Company's or any Subsidiary's
 patent applications are subsisting and have not been abandoned; and the duty of candor and
 good faith as required by the United States Patent and Trademark Office during the prosecution
 of the Company's or any Subsidiary's patents and patent applications has been
 complied with. The Company and the Subsidiaries have complied with the terms of each agreement
 pursuant to which Intellectual Property has been licensed to the Company or any Subsidiary,
 and all such agreements are in full force and effect.

(t) <u>Clinical Studies</u>. All animal and other preclinical studies and clinical trials conducted by the
 Company or on behalf of the Company were, and, if still pending are, to the Company's
 knowledge, being conducted in all material respects in compliance with all Applicable Laws
 (as defined below) and in accordance with experimental protocols, procedures and controls
 generally used by qualified experts in the preclinical study and clinical trials of new drugs
 and biologics as applied to comparable products to those being developed by the Company;
 the descriptions of the results of such preclinical studies and clinical trials contained
 in the Registration Statement and the Prospectus are accurate in all material respects, and,
 except as set forth in the Registration Statement and the Prospectus, the Company has no
 knowledge of any other clinical trials or preclinical studies, the results of which reasonably
 call into question the clinical trial or preclinical study results described or referred
 to in the Registration Statement and the Prospectus when viewed in the context in which such
 results are described; and the Company has not received any written notices or correspondence
 from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the
 termination or suspension of any preclinical studies or clinical trials conducted by or on
 behalf of the Company that are described in the Registration Statement and the Prospectus
 or the results of which are referred to in the Registration Statement and the Prospectus.

(u) <u>Compliance Program</u>. The Company has established and administers a compliance program applicable
 to the Company, to assist the Company and the directors, officers and employees of the Company
 in complying with applicable regulatory guidelines (including, without limitation, those
 administered by the FDA, the EMA, and any other Governmental Authority performing functions
 similar to those performed by the FDA or the EMA); except where such noncompliance would
 not reasonably be expected to have a Material Adverse Effect.

(v) <u>Market Capitalization</u>. At the time the Registration Statement was or will be originally declared,
 or otherwise become, effective, and at the time the Company's most recent Annual Report
 on Form 10-K was filed with the Commission, the Company met or will meet the then applicable
 requirements for the use of Form S-3 under the Securities Act, including, but not limited
 to, General Instruction I.B.1 of Form S-3. The aggregate market value of the outstanding
 voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company
 held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144,
 those that directly, or indirectly through one or more intermediaries, control, or are controlled
 by, or are under common control with, the Company) (the "  **<u>Non-Affiliate Shares</u>** "),
 was equal to or greater than $75 million (calculated by multiplying (x) the highest price
 at which the common equity of the Company closed on the Exchange within 60 days of the date
 of this Agreement times (y) the number of Non-Affiliate Shares). The Company is not a shell
 company (as defined in Rule 405 under the Securities Act) and has not been a shell company
 for at least 12 calendar months previously.

(w) <u>FINRA Matters</u>. The information provided to the Agent by the Company, its counsel, and its officers
 and directors for purposes of the Agent's compliance with applicable FINRA rules in
 connection with the offering of the Shares is true and complete in all material respects.
 The Company qualifies as an "experienced issuer" (within the meaning of FINRA
 Rule 5110(j)(6) for purposes of the exemption from filing under FINRA Rule 5110(h)(1)(C)).

(x) <u>No Material Defaults</u>. Neither the Company nor any of the Subsidiaries has defaulted on any
 installment on indebtedness for borrowed money or on any rental on one or more long-term
 leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.
 The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act
 since the filing of its last Annual Report on Form 10-K, indicating that it (i) has failed
 to pay any dividend or sinking fund installment on preferred stock or (ii) has defaulted
 on any installment on indebtedness for borrowed money or on any rental on one or more long-term
 leases, which defaults, individually or in the aggregate, could reasonably be expected to
 have a Material Adverse Effect.

(y) <u>Certain Market Activities</u>. Neither the Company, nor any of the Subsidiaries, nor any of their
 respective directors, officers or controlling persons has taken, directly or indirectly,
 any action designed, or that has constituted or would reasonably be expected to cause or
 result in, under the Exchange Act or otherwise, the stabilization or manipulation of the
 price of any security of the Company to facilitate the sale or resale of the Placement Shares.

(z) <u>Broker/Dealer Relationships</u>. Neither the Company nor any of the Subsidiaries (i) is required to register
 as a "broker" or "dealer" in accordance with the provisions of the
 Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls
 or is a "person associated with a member" or "associated person of a member"
 (within the meaning set forth in the FINRA Manual).

(aa) <u>No Reliance</u>. The Company has not relied upon the Agent or legal counsel for the Agent for
 any legal, tax or accounting advice in connection with the offering and sale of the Placement
 Shares.

(bb) <u>Taxes</u>.
 The Company and each of its Subsidiaries have filed all federal, state, local and foreign
 tax returns which have been required to be filed and paid all taxes shown thereon through
 the date hereof, to the extent that such taxes have become due and are not being contested
 in good faith, except where the failure to so file or pay would not have a Material Adverse
 Effect. Except as otherwise disclosed in or contemplated by the Registration Statement or
 the Prospectus, no tax deficiency has been determined adversely to the Company or any of
 its Subsidiaries which has had, or would have, individually or in the aggregate, a Material
 Adverse Effect. The Company has no knowledge of any federal, state or other governmental
 tax deficiency, penalty or assessment which has been or might be asserted or threatened against
 it which would have a Material Adverse Effect.

(cc) <u>Title to Real and Personal Property</u>. Except as set forth in the Registration Statement or the
 Prospectus, the Company and its Subsidiaries have good and marketable title in fee simple
 to all items of real property owned by them, good and valid title to all personal property
 described in the Registration Statement or Prospectus as being owned by them that are material
 to the businesses of the Company and its Subsidiaries, in each case free and clear of all
 liens, encumbrances and claims, except those matters that (i) do not materially interfere
 with the use made and proposed to be made of such property by the Company and any of its
 Subsidiaries or (ii) would not, individually or in the aggregate, have a Material Adverse
 Effect. Any real or personal property described in the Registration Statement or Prospectus
 as being leased by the Company and any of its Subsidiaries is held by them under valid, existing
 and enforceable leases, except those that (A) do not materially interfere with the use made
 or proposed to be made of such property by the Company or any of its Subsidiaries or (B)
 would not be reasonably expected, individually or in the aggregate, to have a Material Adverse
 Effect.

(dd) <u>Environmental Laws</u>. Except as set forth in the Registration Statement or the Prospectus, the Company
 and its Subsidiaries (i) are in compliance with any and all applicable federal, state, local
 and foreign laws, rules, regulations, decisions and orders relating to the protection of
 human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
 or contaminants (collectively, "  **<u>Environmental Laws</u>** "); (ii) have
 received and are in compliance with all permits, licenses or other approvals required of
 them under applicable Environmental Laws to conduct their respective businesses as described
 in the Registration Statement and the Prospectus; and (iii) have not received notice of any
 actual or potential liability for the investigation or remediation of any disposal or release
 of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case
 of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to
 receive required permits, licenses, other approvals or liability as would not, individually
 or in the aggregate, have a Material Adverse Effect.

(ee) <u>Disclosure Controls</u>. The Company's internal control over financial reporting is a process
 designed to provide reasonable assurance regarding the reliability of financial reporting
 and the preparation of financial statements for external purposes in accordance with GAAP.
 The Company's internal control over financial reporting includes those policies and
 procedures that: pertain to the maintenance of records that, in reasonable detail, accurately
 and fairly reflect our transactions and dispositions of our assets; provide reasonable assurance
 that transactions are recorded as necessary to permit preparation of financial statements
 in accordance with GAAP, and that our receipts and expenditures are being made only in accordance
 with authorizations of our management and board of directors; and provide reasonable assurance
 regarding prevention or timely detection of unauthorized acquisition, use, or disposition
 of our assets that could have a material effect on the financial statements. The Company's
 internal control over financial reporting is effective and the Company is not aware of any
 material weaknesses in its internal control over financial reporting (other than as set forth
 in the Prospectus). Since the date of the latest audited financial statements of the Company
 included in the Prospectus, there has been no change in the Company's internal control
 over financial reporting that has materially affected, or is reasonably likely to materially
 affect, the Company's internal control over financial reporting (other than as set
 forth in the Prospectus). The Company has established disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure
 controls and procedures to ensure that material information relating to the Company and each
 of its Subsidiaries is made known to the certifying officers by others within those entities,
 particularly during the period in which the Company's Annual Report on Form 10-K or
 Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company's
 certifying officers have evaluated the effectiveness of the Company's disclosure controls
 and procedures as of a date within 90 days prior to the filing date of the Form 10-K for
 the fiscal year most recently ended (such date, the "  **<u>Evaluation Date</u>** ").
 The Company presented in its Form 10-K for the fiscal year most recently ended the conclusions
 of the certifying officers about the effectiveness of the disclosure controls and procedures
 based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
 been no significant changes in the Company's internal controls (as such term is defined
 in Item 307(b) of Regulation S-K under the Securities Act) or, to the Company's knowledge,
 in other factors that could significantly affect the Company's internal controls. To
 the knowledge of the Company, the Company's "internal controls over financial
 reporting" and "disclosure controls and procedures" are effective.

(ff) <u>Sarbanes-Oxley</u>.
 There is and has not been, on the part of the Company or, to the Company's knowledge,
 the Company's directors and officers, in their capacities as such, any failure to comply
 in all material respects with any applicable provisions of the Sarbanes-Oxley Act and the
 rules and regulations promulgated thereunder. Each of the principal executive officer and
 the principal financial officer of the Company (or each former principal executive officer
 of the Company and each former principal financial officer of the Company as applicable)
 has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with
 respect to all reports, schedules, forms, statements and other documents required to be filed
 by it or furnished by it to the Commission. For purposes of the preceding sentence, "principal
 executive officer" and "principal financial officer" shall have the meanings
 given to such terms in the Sarbanes-Oxley Act.

(gg) <u>Finder's Fees</u>. Neither the Company nor any of the Subsidiaries has incurred any liability for
 any finder's fees, brokerage commissions or similar payments in connection with the
 transactions herein contemplated, except as may otherwise exist with respect to the Agent
 pursuant to this Agreement.

(hh) <u>Labor Disputes</u>. No labor disturbance by or dispute with employees of the Company or any of
 its Subsidiaries exists or, to the knowledge of the Company, is threatened which would result
 in a Material Adverse Effect.

(ii) <u>Investment Company Act</u>. Neither the Company nor any of the Subsidiaries is or, after giving effect
 to the offering and sale of the Placement Shares, will be an "investment company"
 or an entity "controlled" by an "investment company," as such terms
 are defined in the Investment Company Act of 1940, as amended (the "  **<u>Investment Company Act</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;(jj) <u>Operations</u>.
 The operations of the Company and its Subsidiaries are and have been conducted at all times
 in compliance with applicable financial record keeping and reporting requirements of the
 Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
 statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules
 and regulations thereunder and any related or similar rules, regulations or guidelines, issued,
 administered or enforced by any Governmental Authority (collectively, the "  **<u>Money Laundering Laws</u>** "); and no action, suit or proceeding by or before any Governmental
 Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering
 Laws is pending or, to the knowledge of the Company, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;(kk) <u>Off-Balance Sheet Arrangements</u>. There are no transactions, arrangements and other relationships between
 and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates
 and any unconsolidated entity, including, but not limited to, any structured finance, special
 purpose or limited purpose entity (each, an "  **<u>Off-Balance Sheet Transaction</u>** ")
 that could reasonably be expected to affect materially the Company's liquidity or the
 availability of or requirements for its capital resources, including those Off-Balance Sheet
 Transactions described in the Commission's Statement about Management's Discussion
 and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321;
 FR-61), required to be described in the Prospectus which have not been described as required.

(ll) <u>Underwriter Agreements</u>. The Company is not a party to any agreement with an agent or underwriter
 for any other "at the market" or continuous equity transaction.

&nbsp;&nbsp;&nbsp;&nbsp;(mm) <u>ERISA</u>.
 To the knowledge of the Company, each material employee benefit plan, within the meaning
 of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended ("  **<u>ERISA</u>** "),
 that is maintained, administered or contributed to by the Company or any of its affiliates
 for employees or former employees of the Company and any of its Subsidiaries has been maintained
 in material compliance with its terms and the requirements of any applicable statutes, orders,
 rules and regulations, including but not limited to ERISA and the Internal Revenue Code of
 1986, as amended (the "  **<u>Code</u>** "); no prohibited transaction, within
 the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would
 result in a material liability to the Company with respect to any such plan excluding transactions
 effected pursuant to a statutory or administrative exemption; and for each such plan that
 is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no "accumulated
 funding deficiency" as defined in Section 412 of the Code has been incurred, whether
 or not waived, and the fair market value of the assets of each such plan (excluding for these
 purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued
 under such plan determined using reasonable actuarial assumptions.

(nn) <u>Forward-Looking Statements</u>. No forward-looking statement (within the meaning of Section 27A of the Securities
 Act and Section 21E of the Exchange Act) (a "  **<u>Forward-Looking Statement</u>** ")
 contained in the Registration Statement and the Prospectus has been made or reaffirmed without
 a reasonable basis or has been disclosed other than in good faith.

(oo) <u>Agent Purchases</u>. The Company acknowledges and agrees that the Agent has informed the Company
 that the Agent may, to the extent permitted under the Securities Act and the Exchange Act,
 purchase and sell Common Stock for its own account while this Agreement is in effect, *provided*,
 that the Company shall not be deemed to have authorized or consented to any such purchases
 or sales by the Agent.

(pp) <u>Margin Rules</u>. Neither the issuance, sale and delivery of the Placement Shares nor the application
 of the proceeds thereof by the Company as described in the Registration Statement and the
 Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve
 System or any other regulation of such Board of Governors.

(qq) <u>Insurance</u>.
 The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts
 and covering such risks as the Company and each of its Subsidiaries reasonably believe are
 adequate for the conduct of their properties and as is customary for companies engaged in
 similar businesses in similar industries.

(rr) <u>No Improper Practices</u>. (i) Neither the Company nor the Subsidiaries, nor any director,
 officer, or employee of the Company or any Subsidiary nor, to the Company's knowledge,
 any agent, affiliate or other person acting on behalf of the Company or any Subsidiary
 has, in the past five years, made any unlawful contributions to any candidate for any political
 office (or failed fully to disclose any contribution in violation of applicable law) or made
 any contribution or other payment to any official of, or candidate for, any federal, state,
 municipal, or foreign office or other person charged with similar public or quasi-public
 duty in violation of any applicable law or of the character required to be disclosed in the
 Prospectus; (ii) no relationship, direct or indirect, exists between or among the Company
 or any Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers
 and stockholders of the Company or any Subsidiary, on the other hand, that is required by
 the Securities Act to be described in the Registration Statement and the Prospectus that
 is not so described; (iii) no relationship, direct or indirect, exists between or among the
 Company or any Subsidiary or any affiliate of them, on the one hand, and the directors, officers,
 or stockholders of the Company or any Subsidiary, on the other hand, that is required by
 the rules of FINRA to be described in the Registration Statement and the Prospectus that
 is not so described; (iv) except as described in the Registration Statement and the Prospectus,
 there are no material outstanding loans or advances or material guarantees of indebtedness
 by the Company or any Subsidiary to or for the benefit of any of their respective officers
 or directors or any of the members of the families of any of them; and (v) the Company has
 not offered, or caused any placement agent to offer, Common Stock to any person with the
 intent to influence unlawfully (A) a customer or supplier of the Company or any Subsidiary
 to alter the customer's or supplier's level or type of business with the Company
 or any Subsidiary or (B) a trade journalist or publication to write or publish favorable
 information about the Company or any Subsidiary or any of their respective products or services,
 and, (vi) neither the Company nor any Subsidiary nor any director, officer or employee
 of the Company or any Subsidiary nor, to the Company's knowledge, any agent,
 affiliate or other person acting on behalf of the Company or any Subsidiary has (A) violated
 or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act
 of 1977, as amended, or any other applicable anti-bribery or anti-corruption law (collectively,
 "  **<u>Anti-Corruption Laws</u>** "), (B) promised, offered, provided, attempted
 to provide or authorized the provision of anything of value, directly or indirectly, to any
 person for the purpose of obtaining or retaining business, influencing any act or decision
 of the recipient, or securing any improper advantage; or (C) made any payment of funds of the Company or any Subsidiary or received or retained
 any funds in violation of any Anti-Corruption Laws.

(ss) <u>No Use of Free Writing Prospectuses</u>. The Company shall not prepare, use, refer to or distribute
 any "written communication" that constitutes a "free writing prospectus"
 as such terms are defined in Rule 405 under the Securities Act with respect to the offering
 contemplated by this Agreement so long as the Company remains an "ineligible issuer"
 as such term is defined under Rule 405 under the Securities Act.

(tt) <u>No Misstatement or Omission in an Issuer Free Writing Prospectus</u>. Each Issuer Free Writing
 Prospectus, as of its issue date and as of each Applicable Time (as defined in <u>Section 23</u> below), did not, does not and will not include any information that conflicted,
 conflicts or will conflict with the information contained in the Registration Statement or
 the Prospectus, including any incorporated document deemed to be a part thereof that has
 not been superseded or modified. The foregoing sentence does not apply to statements in or
 omissions from any Issuer Free Writing Prospectus based upon and in conformity with written
 information furnished to the Company by the Agent specifically for use therein.

(uu) <u>No Conflicts</u>. Neither the execution of this Agreement, nor the issuance, offering or sale
 of the Placement Shares, nor the consummation of any of the transactions contemplated herein
 and therein, nor the compliance by the Company with the terms and provisions hereof and thereof
 will conflict with, or will result in a breach of, any of the terms and provisions of, or
 has constituted or will constitute a default under, or has resulted in or will result in
 the creation or imposition of any lien, charge or encumbrance upon any property or assets
 of the Company pursuant to the terms of any contract or other agreement to which the Company
 may be bound or to which any of the property or assets of the Company is subject, except
 (i) such conflicts, breaches or defaults as may have been waived and (ii) such conflicts,
 breaches and defaults that would not have a Material Adverse Effect; nor will such action
 result (x) in any violation of the provisions of the organizational or governing documents
 of the Company, or (y) in any material violation of the provisions of any statute or any
 order, rule or regulation applicable to the Company or of any Governmental Authority having
 jurisdiction over the Company.

(vv) <u>Sanctions</u>.
 (i) The Company represents that, neither the Company nor any of its Subsidiaries (collectively,
 the "  **<u>Entity</u>**") or any director, officer, or employee or, to its
 knowledge, any agent, affiliate or representative of the Entity, is a government, individual,
 or entity (in this paragraph (vv), "  **<u>Person</u>**") that is, or is owned
 or controlled by a Person that is:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury's Office of Foreign Assets Control ("**<u>OFAC</u>**"), the United Nations Security Council, the European Union, or His Majesty's Treasury, or other relevant sanctions authorities, including, without limitation, designation on OFAC's Specially Designated Nationals and Blocked Persons List or OFAC's Foreign Sanctions Evaders List (as amended, collectively, "**<u>Sanctions</u>**"), nor

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) located, organized or resident in a country or territory that is the subject of comprehensive Sanctions that broadly prohibit dealings with that country or territory (including, without limitation, Cuba, Iran, North Korea, Syria (before July 1, 2025), the so-called Donetsk People's Republic, the so-called Luhansk People's Republic and the Crimea Region of the Ukraine) (the "**Sanctioned Countries**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or is a Sanctioned Country; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Entity represents and covenants that, except as detailed in the Registration Statement and the Prospectus, since April 24, 2019, it has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned Country, in each case, in violation of Sanctions.

(ww) <u>Stock Transfer Taxes</u>. On each Settlement Date, all stock transfer or other taxes (other than
 income taxes) which are required to be paid in connection with the sale and transfer of the
 Placement Shares to be sold hereunder will be, or will have been, fully paid or provided
 for by the Company and all laws imposing such taxes will be or will have been fully complied
 with.

(xx) <u>Compliance with Applicable Laws</u>. The Company (A) to its knowledge, is and at all times has been in material compliance with all statutes,
 rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
 marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development,
 manufactured or distributed by the Company, including all applicable fraud and abuse statutes, rules and regulations
 ("  **<u>Applicable Laws</u>** "), (B) has not received any Form 483 from the FDA, notice of adverse finding, warning
 letter, or other written correspondence or notice from the FDA, the EMA, or any other federal, state, local or foreign Governmental
 Authority or third party alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates,
 approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws
 ("  **<u>Authorizations</u>** "), which would, individually or in the aggregate, result in a Material Adverse Effect;
 (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in
 material violation of any term of any such Authorizations; (D) has not received written notice of any claim, action, suit,
 proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, the EMA, or any other federal, state,
 local or foreign Governmental Authority or third party alleging that any Company product, operation or activity is in material
 violation of any Applicable Laws or Authorizations and has no knowledge that the FDA, the EMA, or any other or any other federal,
 state, local or foreign Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit,
 investigation or proceeding against the Company; (E) has not received notice that the FDA, the EMA, or any other federal, state,
 local or foreign Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any
 material Authorizations and has no knowledge that the FDA, the EMA, or any other federal state, local or foreign Governmental
 Authority is considering such action; and (F) to its knowledge, has filed, obtained, maintained or submitted all reports, documents,
 forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or
 Authorizations except where the failure to file such reports, documents, forms, notices, applications, records, claims, submissions
 and supplements or amendments would not result in a Material Adverse Effect, and that all such reports, documents, forms, notices,
 applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or
 were corrected or supplemented by a subsequent submission). Except in each case as disclosed in the Registration Statement or the
 Prospectus, neither the Company, any of its subsidiaries, nor, to the Company's knowledge, any of their respective employees,
 officers, directors, or agents is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement
 orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, with respect to the
 business operations of the Company. Additionally, except in each case as disclosed in the Registration Statement or the Prospectus,
 neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been
 excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the
 knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could
 reasonably be expected to result in debarment, suspension, or exclusion.

(yy) <u>Statistical and Market-Related Data</u>. The statistical, demographic and market-related data included
 in the Registration Statement and Prospectus are based on or derived from sources that the
 Company believes to be reliable and accurate or represent the Company's good faith
 estimates that are made on the basis of data derived from such sources.

(zz) <u>Cybersecurity</u>.
 The Company and its subsidiaries' information technology assets and equipment, computers,
 systems, networks, hardware, software, websites, applications, and databases (collectively,
 "  **<u>IT Systems</u>**") are, to the Company's knowledge, adequate for,
 and operate and perform in all material respects as required in connection with the operation
 of the business of the Company as currently conducted, free and clear of all material bugs,
 errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and,
 to the Company's knowledge, its subsidiaries have implemented and maintained commercially
 reasonable physical, technical and administrative controls, policies, procedures, and safeguards
 to maintain and protect their material confidential information and the integrity, continuous
 operation, redundancy and security of all IT Systems and data, including all "Personal
 Data" (as defined below) and all sensitive, confidential or regulated data ("  **<u>Confidential Data</u>**") used in connection with their businesses. "Personal Data"
 means, any definition provided by Privacy Laws for any similar term (e.g., "personal
 data," "personally identifiable information," "PII" or "protected
 health information"), information regarding or capable of being associated with an
 identified or identifiable individual, household or device. To the Company's knowledge,
 there have been no breaches, violations, outages or unauthorized uses of or accesses to same,
 except for those that have been remedied without material cost or liability or the duty to
 notify any other person, nor any incidents under internal review or investigations relating
 to the same. The Company and, to the Company's knowledge, its subsidiaries are presently
 in material compliance with all applicable Privacy Laws (as defined below) and all judgments,
 orders, rules and regulations of any court or arbitrator or governmental or regulatory authority
 and contractual obligations relating to the IT Systems, Confidential Data, and Personal
 Data and to the protection of such IT Systems, Confidential Data, and Personal Data from
 unauthorized use, access, misappropriation or modification.

(aaa) <u>Compliance with Data Privacy Laws</u>. The Company and, to the Company's knowledge, its subsidiaries
 are, and at all prior times were, in material compliance with all applicable state and federal
 data privacy and security laws and regulations, including without limitation the Health Insurance
 Portability and Accountability Act of 1996, as amended by the Health Information Technology
 for Economic and Clinical Health Act (collectively, "  **<u>HIPAA</u>** "), the
 California Consumer Privacy Act ("  **<u>CCPA</u>** "), and the European Union
 General Data Protection Regulation ("  **<u>GDPR</u>**") (EU 2016/679) (collectively,
 the "  **<u>Privacy Laws</u>** "). The Company has in place, complies with, and
 takes commercially reasonable steps to comply in all material respects with their policies
 and procedures relating to data privacy and security and the collection, storage, use, processing,
 disclosure, handling, and analysis of Personal Data and Confidential Data (the "  **<u>Policies</u>** ").
 The Company has at all times made all material disclosures to users or customers required
 by applicable laws and regulatory rules or requirements, and none of such disclosures made
 or contained in any Policy have been inaccurate or in violation of any applicable laws and
 regulatory rules or requirements in any material respect. The Company further certifies that
 neither it nor any subsidiary: (i) has received notice of any actual or potential material
 liability under or relating to, or actual or potential violation of, any of the Privacy Laws,
 and has no knowledge of any event or condition that would reasonably be expected to result
 in any such notice; (ii) is currently conducting or paying for, in whole or in part, any
 material investigation, remediation, or other corrective action pursuant to any Privacy Law;
 or (iii) is a party to any order, decree, or agreement that imposes any material obligation
 or liability under any Privacy Law.

(bbb) <u>Listing</u>.
 The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act and
 is listed on the Exchange, and the Company has taken no action designed to, or likely to
 have the effect of, terminating the registration of the Common Stock under the Exchange Act
 or delisting the Stock from the Exchange, nor has the Company received any notification that
 the Commission or the Exchange is contemplating terminating such registration or listing.
 To the Company's knowledge, it is in compliance with all applicable listing requirements
 of the Exchange in all material respects.

(ccc) <u>Outbound Investment Security Program</u>. Neither the Company nor any of its subsidiaries is a "covered
 foreign person", as that term is defined in 31 C.F.R. § 850.209. Neither the Company
 nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly,
 in a "covered activity", as that term is defined in in 31 C.F.R. § 850.208
 ("Covered Activity"). The Company does not have any joint ventures that engages
 in or plans to engage in any Covered Activity. The Company also does not, directly or indirectly,
 hold a board seat on, have a voting or equity interest in, or have any contractual power
 to direct or cause the direction of the management or policies of any person or persons that
 engages or plans to engage in any Covered Activity.

Any certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth therein.

7. <u>Covenants of the Company</u>. The Company covenants and agrees with the Agent that:

(a) <u>Registration Statement Amendments</u>. After the date of this Agreement and during any period in which
 a Prospectus relating to any Placement Shares is required to be delivered by the Agent under
 the Securities Act (including in circumstances where such requirement may be satisfied pursuant
 to Rule 172 under the Securities Act or similar rule), (i) the Company will notify the Agent
 promptly of the time when any subsequent amendment to the Registration Statement, other than
 documents incorporated by reference, has been filed with the Commission and/or has become
 effective or any subsequent supplement to the Prospectus related to the Placement Shares
 has been filed and of any request by the Commission for any amendment or supplement to the
 Registration Statement or Prospectus or for additional information, (ii) the Company will
 prepare and file with the Commission, promptly upon the Agent's request, any amendments
 or supplements to the Registration Statement or Prospectus that, in the Agent's reasonable
 opinion, may be necessary or advisable in connection with the distribution of the Placement
 Shares by the Agent (*provided*, *however*, that the failure of the Agent to make
 such request shall not relieve the Company of any obligation or liability hereunder, or affect
 the Agent's right to rely on the representations and warranties made by the Company
 in this Agreement and *provided*, *further*, that the only remedy the Agent shall
 have with respect to the failure to make such filing shall be to cease making sales under
 this Agreement until such amendment or supplement is filed); (iii) the Company will not file
 any amendment or supplement to the Registration Statement or Prospectus relating to the Placement
 Shares or a security convertible into the Placement Shares unless a copy thereof has been
 submitted to Agent within a reasonable period of time before the filing and the Agent has
 not objected thereto (*provided*, *however*, that (A) the failure of
 the Agent to make such objection shall not relieve the Company of any obligation or liability
 hereunder, or affect the Agent's right to rely on the representations and warranties
 made by the Company in this Agreement and (B) the Company has no obligation to provide the
 Agent any advance copy of such filing or to provide the Agent an opportunity to object to
 such filing if the filing does not name the Agent or does not relate to a Placement or other
 transaction contemplated hereunder in respect of Placement Shares, and *provided*, *further*,
 that the only remedy the Agent shall have with respect to the failure by the Company to obtain
 such consent shall be to cease making sales under this Agreement) and the Company will furnish
 to the Agent at the time of filing thereof a copy of any document that upon filing is deemed
 to be incorporated by reference into the Registration Statement or Prospectus, except for
 those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement
 to the Prospectus to be filed with the Commission as required pursuant to the applicable
 paragraph of Rule 424(b) of the Securities Act or, in the case of any document to be incorporated
 therein by reference, to be filed with the Commission as required pursuant to the Exchange
 Act, within the time period prescribed (the determination to file or not file any amendment
 or supplement with the Commission under this <u>Section 7(a)</u>, based on the Company's
 reasonable opinion or reasonable objections, shall be made exclusively by the Company).

(b) <u>Notice of Commission Stop Orders</u>. The Company will advise the Agent, promptly after it receives
 notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission
 of any stop order suspending the effectiveness of the Registration Statement, of the suspension
 of the qualification of the Placement Shares for offering or sale in any jurisdiction, or
 of the initiation or threatening of any proceeding for any such purpose; and it will promptly
 use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain
 its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly
 after it receives any request by the Commission for any amendments to the Registration Statement
 or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or
 for additional information related to the offering of the Placement Shares or for additional
 information related to the Registration Statement, the Prospectus or any Issuer Free Writing
 Prospectus, in all cases, solely to the extent any such request relates to the transactions
 contemplated hereby.

(c) <u>Delivery of Prospectus; Subsequent Changes</u>. During any period in which a Prospectus relating to
 the Placement Shares is required to be delivered by the Agent under the Securities Act with
 respect to the offer and sale of the Placement Shares, (including in circumstances where
 such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar
 rule), the Company will comply with all requirements imposed upon it by the Securities Act,
 as from time to time in force, and to file on or before their respective due dates (taking
 into account all available extensions and/or grace periods) all reports and any definitive
 proxy or information statements required to be filed by the Company with the Commission pursuant
 to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act.
 If the Company has omitted any information from the Registration Statement pursuant to Rule
 430B under the Securities Act, it will use its best efforts to comply with the provisions
 of and make all requisite filings with the Commission pursuant to said Rule 430B and to notify
 the Agent promptly of all such filings. If during such period any event occurs as a result
 of which the Prospectus as then amended or supplemented would include an untrue statement
 of a material fact or omit to state a material fact necessary to make the statements therein,
 in the light of the circumstances then existing, not misleading, or if during such period
 it is necessary to amend or supplement the Registration Statement or Prospectus to comply
 with the Securities Act, the Company will promptly notify the Agent to suspend the offering
 of Placement Shares during such period and the Company will promptly amend or supplement
 the Registration Statement or Prospectus (at the expense of the Company) so as to correct
 such statement or omission or effect such compliance.

(d) <u>Listing of Placement Shares</u>. Prior to the date of the first Placement Notice, the Company will
 use its reasonable best efforts to cause the Placement Shares to be listed on the Exchange.

(e) <u>Delivery of Registration Statement and Prospectus</u>. The Company will furnish to the Agent and its
 counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus
 (including all documents incorporated by reference therein) and all amendments and supplements
 to the Registration Statement or Prospectus that are filed with the Commission during any
 period in which a Prospectus relating to the Placement Shares is required to be delivered
 under the Securities Act (including all documents filed with the Commission during such period
 that are deemed to be incorporated by reference therein), in each case as soon as reasonably
 practicable and in such quantities as the Agent may from time to time reasonably request
 and, at the Agent's request, will also furnish copies of the Prospectus to each exchange
 or market on which sales of the Placement Shares may be made; *provided*, *however*,
 that the Company shall not be required to furnish any document (other than the Prospectus)
 to the Agent to the extent such document is available on EDGAR.

(f) <u>Earning Statement</u>. The Company will make generally available to its security holders as soon
 as practicable, but in any event not later than 15 months after the end of the Company's
 current fiscal quarter, an earning statement covering a 12-month period that satisfies the
 provisions of Section 11(a) and Rule 158 of the Securities Act.

(g) <u>Use of Proceeds</u>. The Company will use the Net Proceeds as described in the Prospectus in
 the section entitled "Use of Proceeds."

(h) <u>Notice of Other Sales</u>. Without the prior written consent of the Agent, the Company will not,
 directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or
 otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to
 this Agreement) or securities convertible into or exchangeable for Common Stock, warrants
 or any rights to purchase or acquire, Common Stock during the period beginning on the fifth
 (5<sup>th</sup>) Trading Day immediately prior to the date on which any Placement Notice
 is delivered to Agent hereunder and ending on the fifth (5<sup>th</sup>) Trading Day immediately
 following the final Settlement Date with respect to Placement Shares sold pursuant to such
 Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the
 sale of all Placement Shares covered by a Placement Notice, the date of such suspension or
 termination); and will not directly or indirectly in any other "at the market"
 or continuous equity transaction offer to sell, sell, contract to sell, grant any option
 to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
 pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock,
 warrants or any rights to purchase or acquire, Common Stock prior to the sixtieth (60th)
 day immediately following the termination of this Agreement; *provided*, *however*,
 that such restrictions will not be required in connection with the Company's issuance
 or sale of (i) Common Stock, options to purchase Common Stock or other equity awards for
 Common Stock, or Common Stock issuable upon the exercise of options or upon vesting and settlement
 of equity awards, in each case, pursuant to any employee or director stock option or benefits
 plan, stock ownership plan or dividend reinvestment plan (but not Common Stock subject to
 a waiver to exceed plan limits in its dividend reinvestment plan) or other compensation plan
 of the Company whether now in effect or hereafter implemented (including any amendment(s)
 or modifications to the foregoing), (ii) Common Stock issuable upon conversion of securities
 or the exercise of warrants, options or other rights in effect or outstanding, and disclosed
 in filings by the Company available on EDGAR or any successor system or otherwise in writing
 to the Agent and (iii) Common Stock or securities convertible into or exchangeable for shares
 of Common Stock as consideration for mergers, acquisitions, other business combinations,
 joint ventures, or strategic alliances marketing or distribution arrangements, collaboration
 agreements, co-promotion agreements or intellectual property license agreements occurring
 after the date of this Agreement which are not issued for the primary purpose of capital
 raising.

(i) <u>Change of Circumstances</u>. The Company will, at any time during the pendency of a Placement Notice,
 advise the Agent promptly after it shall have received notice or obtained knowledge thereof,
 of any information or fact that would alter or affect in any material respect any opinion,
 certificate, letter or other document required to be provided to the Agent pursuant to this
 Agreement.

(j) <u>Due Diligence Cooperation</u>. During the term of the Agreement, the Company will cooperate with
 any reasonable due diligence review conducted by the Agent or its representatives in connection
 with the transactions contemplated hereby, including, without limitation, providing information
 and making available documents and senior corporate officers, during regular business hours
 and at the Company's principal offices, as the Agent may reasonably request.

(k) <u>Required Filings Relating to Placement of Placement Shares</u>. The Company shall disclose, in its
 quarterly reports on Form 10-Q and in its annual report on Form 10-K to be filed by the Company
 with the Commission from time to time, the number of the Placement Shares sold through the
 Agent under this Agreement and the Net Proceeds to the Company during the relevant quarter
 or, in the case of an Annual Report on Form 10-K, during the fiscal year covered by such
 Annual Report and the fourth quarter of such fiscal year. The Company agrees that on such
 dates as the Securities Act shall require, the Company will (i) file a prospectus supplement
 with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act
 (each and every filing date under Rule 424(b), a "  **<u>Filing Date</u>** "),
 which prospectus supplement will set forth, within the relevant period, the number of Placement
 Shares sold through the Agent under this Agreement, the Net Proceeds to the Company and the
 compensation payable by the Company to the Agent with respect to such Placement Shares, and
 (ii) deliver such number of copies of each such prospectus supplement to each exchange or
 market on which such sales were effected as may be required by the rules or regulations of
 such exchange or market.

(l) <u>Representation Dates; Certificate</u>. (1) Prior to the date of the first Placement Notice and (2) each
 time the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment to the previously filed Form 10-K);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) files its quarterly reports on Form 10-Q under the Exchange Act; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) files a current report on Form 8-K containing amended financial information (other than information "furnished" pursuant to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a "**<u>Representation Date</u>**");

the Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained in such Form 8-K is material) with a certificate dated the Representation Date, in form and substance reasonably satisfactory to the Agent and its counsel. The requirement to provide a certificate under this <u>Section 7(l)</u> shall be automatically waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date the Company relied on such waiver or a Suspension was in effect and did not provide the Agent with a certificate under this <u>Section 7(l)</u>, then before the Company delivers the Placement Shares or the Agent sells any Placement Shares, the Company shall provide the Agent with a certificate in conformity with this <u>Section 7(l)</u> dated the date of the Placement Notice.

(m) <u>Legal Opinion</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5)
 Trading Days of each Representation Date with respect to which the Company is obligated to
 deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and
 excluding the date of this Agreement, the Company shall cause to be furnished to the Agent
 a written opinion and negative assurance letter of Jones Day ("  **<u>Company Counsel</u>** "),
 or other counsel reasonably satisfactory to the Agent, in form and substance reasonably satisfactory
 to the Agent and its counsel, substantially similar to the form previously provided to the
 Agent and its counsel, modified, as necessary, to relate to the Registration Statement and
 the Prospectus as then amended or supplemented; *provided*, that in lieu of such opinions
 for subsequent periodic filings under the Exchange Act, counsel may furnish the Agent with
 a letter (a "  **<u>Reliance Letter</u>**") to the effect that the Agent may
 rely on a prior opinion delivered under this <u>Section 7(m)</u> to the same extent as if
 it were dated the date of such letter (except that statements in such prior opinion shall
 be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented
 as of the date of the Reliance Letter).

(n) <u>Comfort Letter</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading
 Days of each Representation Date with respect to which the Company is obligated to deliver
 a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding
 the date of this Agreement, the Company shall cause its independent registered public accounting
 firm to furnish the Agent letters (the "  **<u>Comfort Letters</u>** "), dated
 the date the Comfort Letter is delivered, which shall meet the requirements set forth in
 this <u>Section 7(n)</u>; *provided*, that if requested by the Agent, the Company shall
 cause a Comfort Letter to be furnished to the Agent within ten (10) Trading Days of the date
 of occurrence of any material transaction or event requiring the filing of a Current Report
 on Form 8-K containing financial information (including the restatement of the Company's
 financial statements). The Comfort Letter from the Company's independent registered
 public accounting firm shall be in a form and substance reasonably satisfactory to the Agent,
 (i) confirming that they are an independent registered public accounting firm within the
 meaning of the Securities Act and the Public Company Accounting Oversight Board ("  **<u>PCAOB</u>** "),
 (ii) stating, as of such date, the conclusions and findings of such firm with respect to
 the financial information and other matters ordinarily covered by accountants' "comfort
 letters" to underwriters in connection with registered public offerings (the first
 such letter, the "  **<u>Initial Comfort Letter</u>**") and (iii) updating the
 Initial Comfort Letter with any information that would have been included in the Initial
 Comfort Letter had it been given on such date and modified as necessary to relate to the
 Registration Statement and the Prospectus, as amended and supplemented to the date of such
 letter.

(o) <u>Market Activities</u>. The Company will not, directly or indirectly, (i) take any action designed
 to cause or result in, or that constitutes or might reasonably be expected to constitute,
 the stabilization or manipulation of the price of any security of the Company to facilitate
 the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation
 of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement
 Shares other than the Agent.

(p) <u>Investment Company Act</u>. The Company will conduct its affairs in such a manner so as to reasonably
 ensure that neither it nor any of its Subsidiaries will be or become, at any time prior to
 the termination of this Agreement, required to register as an "investment company,"
 as such term is defined in the Investment Company Act.

(q) <u>No Offer to Sell</u>. Other than an Issuer Free Writing Prospectus approved in advance by the
 Company and the Agent in its capacity as agent hereunder, neither the Agent nor the Company
 (including its agents and representatives, other than the Agent in its capacity as such)
 will make, use, prepare, authorize, approve or refer to any written communication (as defined
 in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes
 an offer to sell or solicitation of an offer to buy Placement Shares hereunder.

(r) <u>Blue Sky and Other Qualifications</u> *.* The Company will use its commercially reasonable
 efforts, in cooperation with the Agent, to qualify the Placement Shares for offering and
 sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the
 applicable securities laws of such states and other jurisdictions (domestic or foreign) as
 the Agent may reasonably designate and to maintain such qualifications and exemptions in
 effect for so long as reasonably required for the distribution of the Placement Shares; *provided*, *however*, that the Company shall not be obligated to file any general consent to service
 of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction
 in which it is not so qualified or to subject itself to taxation in respect of doing business
 in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which
 the Placement Shares have been so qualified or exempt, the Company will file such statements
 and reports as may be required by the laws of such jurisdiction to continue such qualification
 or exemption, as the case may be, in effect for so long as reasonably required for the distribution
 of the Placement Shares.

(s) <u>Sarbanes-Oxley Act</u>. The Company and the Subsidiaries will maintain and keep accurate books and records
 reflecting their assets and maintain internal accounting controls in a manner designed to
 provide reasonable assurance regarding the reliability of financial reporting and the preparation
 of financial statements for external purposes in accordance with GAAP and including those
 policies and procedures that (i) pertain to the maintenance of records that in reasonable
 detail accurately and fairly reflect the transactions and dispositions of the assets of the
 Company, (ii) provide reasonable assurance that transactions are recorded as necessary to
 permit the preparation of the Company's consolidated financial statements in accordance
 with GAAP, (iii) that receipts and expenditures of the Company are being made only in accordance
 with management's and the Company's directors' authorization, and (iv)
 provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
 use or disposition of the Company's assets that could have a material effect on its
 financial statements. The Company and the Subsidiaries will maintain such controls and other
 procedures, including, without limitation, those required by Sections 302 and 906 of the
 Sarbanes-Oxley Act, and the applicable regulations thereunder that are designed to ensure
 that information required to be disclosed by the Company in the reports that it files or
 submits under the Exchange Act is recorded, processed, summarized and reported, within the
 time periods specified in the Commission's rules and forms, including, without limitation,
 controls and procedures designed to ensure that information required to be disclosed by the
 Company in the reports that it files or submits under the Exchange Act is accumulated and
 communicated to the Company's management, including its principal executive officer
 and principal financial officer, or persons performing similar functions, as appropriate
 to allow timely decisions regarding required disclosure and to ensure that material information
 relating to the Company or the Subsidiaries is made known to them by others within those
 entities, particularly during the period in which such periodic reports are being prepared.

(t) Secretary's
Certificate; Further Documentation. Prior to the date of the first Placement Notice, the Company shall deliver to the Agent a certificate
of the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date, certifying as to (i) the
Certificate of Incorporation of the Company, (ii) the By-laws of the Company, (iii) the resolutions of the Board of Directors of the
Company authorizing the execution, delivery and performance of this Agreement and the issuance of the Placement Shares and (iv) the incumbency
of the officers duly authorized to execute this Agreement and the other documents contemplated by this Agreement. Within five (5) Trading
Days of the earlier of (i) each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant
to Section 7(l) for which no waiver is applicable or (ii) the date such request from the Agents is received by the Company, the Company
shall have furnished to the Agent such further information, certificates and documents as the Agent may reasonably request.

8. <u>Payment of Expenses</u>. The Company will pay all expenses incident to the performance of its obligations
 under this Agreement, including (i) the preparation and filing of the Registration Statement,
 including any fees required by the Commission, and the printing or electronic delivery of
 the Prospectus as originally filed and of each amendment and supplement thereto, in such
 number as the Agent shall deem necessary, (ii) the printing and delivery to the Agent of
 this Agreement and such other documents as may be required in connection with the offering,
 purchase, sale, issuance or delivery of the Placement Shares, (iii) the preparation, issuance
 and delivery of the certificates, if any, for the Placement Shares to the Agent, including
 any stock or other transfer taxes and any capital duties, stamp duties or other duties or
 taxes payable upon the sale, issuance or delivery of the Placement Shares to the Agent, (iv)
 the reasonable and documented fees and disbursements of the counsel, accountants and other
 advisors to the Company, (v) the fees and expenses of Agent including but not limited to
 the fees and expenses of the counsel to the Agent, payable upon the execution of this Agreement,
 (a) in an amount not to exceed $125,000 in connection with the execution of this Agreement,
 (b) in an amount not to exceed $25,000 per calendar quarter thereafter payable in connection
 with each Representation Date with respect to which the Company is obligated to deliver a
 certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding
 the date of this Agreement, and (c) in an amount not to exceed $40,000 for each program "refresh"
 (filing of a new registration statement, prospectus or prospectus supplement relating to
 the Placement Shares and/or an amendment of this Agreement) executed pursuant to this Agreement,
 (vi) the qualification or exemption of the Placement Shares under state securities laws in
 accordance with the provisions of <u>Section 7(r)</u> hereof, including filing fees, but
 excluding fees of the Agent's counsel, (vii) the printing and delivery to the Agent
 of copies of any Permitted Issuer Free Writing Prospectus and the Prospectus and any amendments
 or supplements thereto in such number as the Agent shall deem necessary, (viii) the preparation,
 printing and delivery to the Agent of copies of the blue sky survey, (ix) the fees and expenses
 of the transfer agent and registrar for the Common Stock, (x) the filing and other fees incident
 to any review by FINRA of the terms of the sale of the Placement Shares including the reasonable
 and documented fees of the Agent's counsel (subject to the cap, set forth in clause
 (v) above), and (xi) the fees and expenses incurred in connection with the listing of the
 Placement Shares on the Exchange. The Company agrees to pay the reasonable and documented
 fees and expenses of counsel to the Agent set forth in clause (v) above by wire transfer
 of immediately available funds directly to such counsel upon presentation of an invoice containing
 the requisite payment information prepared by such counsel.

9. <u>Conditions to Agent's Obligations</u>. The obligations of the Agent hereunder with respect to
 a Placement will be subject to the continuing accuracy and completeness of the representations
 and warranties made by the Company herein, to the due performance by the Company of its obligations
 hereunder, to the completion by the Agent of a due diligence review satisfactory to it in
 its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its
 sole discretion) of the following additional conditions:

(a) <u>Registration Statement Effective</u>. The Registration Statement shall have become effective and shall
 be available for the (i) resale of all Placement Shares issued to the Agent and not yet sold
 by the Agent and (ii) sale of all Placement Shares contemplated to be issued by any Placement
 Notice.

(b) <u>No Material Notices</u>. None of the following events shall have occurred and be continuing:
 (i) receipt by the Company of any request for additional information from the Commission
 or any other federal or state Governmental Authority during the period of effectiveness of
 the Registration Statement, the response to which would require any post-effective amendments
 or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the
 Commission or any other federal or state Governmental Authority of any stop order suspending
 the effectiveness of the Registration Statement or the initiation of any proceedings for
 that purpose; (iii) receipt by the Company of any notification with respect to the suspension
 of the qualification or exemption from qualification of any of the Placement Shares for sale
 in any jurisdiction or the initiation or threatening of any proceeding for such purpose;
 or (iv) the occurrence of any event that makes any statement of a material fact made in the
 Registration Statement or the Prospectus or any document incorporated or deemed to be incorporated
 therein by reference untrue in any material respect or that requires the making of any changes
 in the Registration Statement, the Prospectus or documents so that, in the case of the Registration
 Statement, it will not contain an untrue statement of a material fact or omit to state any
 material fact required to be stated therein or necessary to make the statements therein not
 misleading and, that in the case of the Prospectus, it will not contain an untrue statement
 of a material fact or omit to state a material fact required to be stated therein or necessary
 to make the statements therein, in the light of the circumstances under which they were made,
 not misleading.

(c) <u>No Misstatement or Material Omission</u>. Agent shall not have advised the Company that the
 Registration Statement or Prospectus, or any amendment or supplement thereto, contains an
 untrue statement of fact that in the Agent's reasonable opinion is material, or omits
 to state a fact that in the Agent's reasonable opinion is material and is required
 to be stated therein or is necessary to make the statements therein not misleading.

(d) <u>Material Changes</u>. Except as contemplated in the Prospectus,
or disclosed in the Company's reports filed with the Commission, there shall not have been any material adverse change, on a consolidated
basis, in the authorized capital stock of the Company or any Material Adverse Effect or any development that would cause a Material Adverse
Effect, or a downgrading in or withdrawal of the rating assigned to any of the Company's securities (other than asset backed securities)
by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of
any of the Company's securities (other than asset backed securities), the effect of which, in the case of any such action by a
rating organization described above, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability
it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares
on the terms and in the manner contemplated in the Prospectus.

(e) <u>Legal Opinions</u>. The Agent shall have received the opinions and negative assurance letters required
 to be delivered pursuant to <u>Section 7(m)</u> on or before the date on which such delivery
 of such opinions is required pursuant to <u>Section 7(m)</u>.

(f) <u>Comfort Letter</u>. The Agent shall have received the Comfort Letter required to be delivered pursuant
 to <u>Section 7(n)</u> on or before the date on which such delivery of such Comfort Letter
 is required pursuant to <u>Section 7(n)</u>.

(g) <u>Representation Certificate</u>. The Agent shall have received the certificate required to be delivered pursuant
 to <u>Section 7(l)</u> on or before the date on which delivery of such certificate is required
 pursuant to <u>Section 7(l)</u>.

(h) <u>No Suspension</u>. Trading in the Common Stock shall not have been suspended on the Exchange
 and the Common Stock shall not have been delisted from the Exchange.

(i) <u>Other Materials</u>. On each date on which the Company is required to deliver a certificate pursuant
 to <u>Section 7(l)</u>, the Company shall have furnished to the Agent such appropriate further
 information, opinions, certificates, letters and other documents as the Agent may reasonably
 request. All such opinions, certificates, letters and other documents will be in compliance
 with the provisions hereof.

(j) <u>Securities Act Filings Made</u>. All filings with the Commission required by Rule 424 under the Securities
 Act to have been filed prior to the issuance of any Placement Notice hereunder shall have
 been made within the applicable time period prescribed for such filing by Rule 424.

(k) <u>Approval for Listing</u>. The Placement Shares shall either have been (i) approved for listing on
 the Exchange, subject only to notice of issuance, or (ii) the Company shall have filed an
 application for listing of the Placement Shares on the Exchange at, or prior to, the issuance
 of any Placement Notice.

(l) <u>FINRA</u>.
 If applicable, FINRA shall have raised no objection to the terms of this offering and the
 amount of compensation allowable or payable to the Agent as described in the Prospectus.

(m) <u>No Termination Event</u>. There shall not have occurred any event that would permit the Agent
 to terminate this Agreement pursuant to <u>Section 12(a)</u>.

10. <u>Indemnification and Contribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Company Indemnification</u>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members, directors, officers, employees and agents and each person, if any, who controls the Agent or any affiliate within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; *provided* that (subject to <u>Section 10(d)</u> below) any such settlement is effected with the written consent of the Company, which consent shall not unreasonably be delayed or withheld; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) against any and all reasonable and documented expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or not a party), to the extent that any such expense is not paid under (i) or (ii) above,

*provided*, *however*, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Agent Information (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Agent Indemnification</u>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in <u>Section 10(a)</u>, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto), the Prospectus (or any amendment or supplement thereto) or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the Agent and furnished to the Company in writing by the Agent expressly for use therein. The Company hereby acknowledges that the only information that the Agent has furnished to the Company expressly for use in the Registration Statement, the Prospectus, any Prospectus Supplement or any Issuer Free Writing Prospectus (or any amendment or supplement thereto) are the statements set forth in the seventh and eighth paragraphs under the caption "Plan of Distribution" in the Prospectus Supplement (the "**<u>Agent Information</u>**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Procedure</u>. Any party that proposes to assert the right to be indemnified under this <u>Section 10</u> will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this <u>Section 10</u>, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this <u>Section 10</u> and (ii) any liability that it may have to any indemnified party under the foregoing provision of this <u>Section 10</u> unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice of the commencement of the action; in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this <u>Section 10</u> (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an express and unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Settlement Without Consent if Failure to Reimburse. If an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 10(a)(ii) effected without its written consent if (1) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Contribution</u>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this <u>Section 10</u> is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent (before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this <u>Section 10(e)</u> were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this <u>Section 10(e)</u> shall be deemed to include, for the purpose of this <u>Section 10(e)</u>, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with <u>Section 10(c)</u> hereof. Notwithstanding the foregoing provisions of this <u>Section 10(e)</u>, the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of <u>Section 11(f)</u> of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <u>Section 10(e)</u>, any person who controls a party to this Agreement within the meaning of the Securities Act, any affiliates of the Agent and any officers, directors, partners, employees or agents of the Agent or any of its affiliates, will have the same rights to contribution as that party, and each director of the Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this <u>Section 10(e)</u>, will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this <u>Section 10(e)</u> except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of <u>Section 10(c)</u> hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to <u>Section 10(c)</u> hereof.

11. <u>Representations and Agreements to Survive Delivery</u>. The indemnity and contribution agreements contained
 in <u>Section 10</u> of this Agreement and all representations and warranties of the Company
 herein or in certificates delivered pursuant hereto shall survive, as of their respective
 dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling
 persons, or the Company (or any of their respective officers, directors, employees or controlling
 persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii)
 any termination of this Agreement.

12. <u>Termination</u>.

(a) The
 Agent may terminate this Agreement, by notice to the Company, as hereinafter specified at
 any time (1) if there has been, since the time of execution of this Agreement or since the
 date as of which information is given in the Prospectus, any change, or any development or
 event involving a prospective change, in the condition, financial or otherwise, or in the
 business, properties, earnings, results of operations or prospects of the Company
 and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary
 course of business, which individually or in the aggregate, in the sole judgment of the Agent
 is material and adverse and makes it impractical or inadvisable to market the Placement Shares
 or to enforce contracts for the sale of the Placement Shares, (2) if there has occurred any
 material adverse change in the financial markets in the United States or the international
 financial markets, any outbreak of hostilities or escalation thereof or other calamity or
 crisis or any change or development involving a prospective change in national or international
 political, financial or economic conditions, in each case the effect of which is such as
 to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement
 Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the
 Common Stock has been suspended or limited by the Commission or the Exchange, or if trading
 generally on the Exchange has been suspended or limited, or minimum prices for trading have
 been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company
 on any exchange or in the over-the-counter market shall have occurred and be continuing,
 (5) if a major disruption of securities settlements or clearance services in the United States
 shall have occurred and be continuing, or (6) if a banking moratorium has been declared by
 either U.S. Federal or New York authorities. Any such termination shall be without liability
 of any party to any other party except that the provisions of <u>Section 8</u> (Payment of
 Expenses), <u>Section 10</u> (Indemnification and Contribution), <u>Section 11</u> (Representations
 and Agreements to Survive Delivery), <u>Section 17</u> (Governing Law and Time; Waiver of
 Jury Trial) and <u>Section 18</u> (Consent to Jurisdiction) hereof shall remain in full force
 and effect notwithstanding such termination. If the Agent elects to terminate this Agreement
 as provided in this <u>Section 12(a)</u>, the Agent shall provide the required notice as
 specified in <u>Section 13</u> (Notices).

(b) The
 Company shall have the right, by giving ten (10) days' notice as hereinafter specified
 to terminate this Agreement in its sole discretion at any time after the date of this Agreement.
 Any such termination shall be without liability of any party to any other party except that
 the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full force and effect notwithstanding such termination.

(c) The
 Agent shall have the right, by giving ten (10) days' notice as hereinafter specified
 to terminate this Agreement in its sole discretion at any time after the date of this Agreement.
 Any such termination shall be without liability of any party to any other party except that
 the provisions of <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> hereof shall remain in full force and effect notwithstanding such termination.

(d) This
 Agreement shall remain in full force and effect unless terminated pursuant to <u>Sections 12(a)</u>, <u>(b)</u>, or <u>(c)</u> above or otherwise by mutual agreement of the parties; *provided*, *however*, that any such termination by mutual agreement shall in all
 cases be deemed to provide that <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u> shall remain in full force and effect.

(e) Any
 termination of this Agreement shall be effective on the date specified in such notice of
 termination; *provided*, *however*, that such termination shall not be effective
 until the close of business on the date of receipt of such notice by the Agent or the Company,
 as the case may be. If such termination shall occur prior to the Settlement Date for any
 sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions
 of this Agreement.

(f) Subject
 to the additional limitations set forth in Section 8, in the event of termination of this
 Agreement prior to the sale of any Placement Shares, the Agent shall be entitled only to
 reimbursement of its out-of-pocket expenses actually incurred.

13. <u>Notices</u>.
 All notices or other communications required or permitted to be given by any party to any
 other party pursuant to the terms of this Agreement shall be in writing, unless otherwise
 specified, and if sent to the Agent, shall be delivered to:

.

Cantor Fitzgerald & Co.

110 East 59<sup>th</sup> Street

New York, NY 10022

Attention: Capital Markets

Email: CFCEO@cantor.com

and:

Cantor Fitzgerald & Co.

110 East 59<sup>th</sup> Street

New York, NY 10022

Attention: General Counsel

Email: legal-IBD@cantor.com

with a copy to:

Cooley LLP

55 Hudson Yards

New York, NY 10001

Attention: Daniel I. Goldberg

E-mail: dgoldberg@cooley.com

and if to the Company, shall be delivered to:

Cassava Sciences, Inc.

6801 N. Capital of Texas Highway

Building 1, Suite 300

Austin, TX 78731

Attention: R. Christopher Cook

E-mail: [\*\*\*]; [\*\*\*]

with a copy to:

Jones Day

250 Vesey Street

New York, NY 10281

Attention: Peter Devlin and Ferrell Keel

E-mail: <u>pdevlin@jonesday.com</u>; <u>fkeel@jonesday.com</u>

Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice, as set forth below, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iv) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, "**<u>Business Day</u>**" shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

An electronic communication ("**<u>Electronic Notice</u>**") shall be deemed written notice for purposes of this Section 13 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form ("**<u>Nonelectronic Notic</u>e**") which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

14. <u>Successors and Assigns</u>. This Agreement shall inure to the benefit of and be binding upon the Company
 and the Agent and their respective successors and the parties referred to in Section 10 hereof.
 References to any of the parties contained in this Agreement shall be deemed to include the
 successors and permitted assigns of such party. Nothing in this Agreement, express or implied,
 is intended to confer upon any party other than the parties hereto or their respective successors
 and permitted assigns any rights, remedies, obligations or liabilities under or by reason
 of this Agreement, except as expressly provided in this Agreement. Neither party may assign
 its rights or obligations under this Agreement without the prior written consent of the other
 party; *provided*, *however*, that the Agent may assign its rights and obligations
 hereunder to an affiliate thereof without obtaining the Company's consent.

15. <u>Adjustments for Stock Splits</u>. The parties acknowledge and agree that all share-related numbers contained
 in this Agreement shall be adjusted to take into account any stock split, stock dividend
 or similar event effected with respect to the Placement Shares.

16. <u>Entire Agreement; Amendment; Severability; Waiver</u>. This Agreement (including all schedules and
 exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire
 agreement and supersedes all other prior and contemporaneous agreements and undertakings,
 both written and oral, among the parties hereto with regard to the subject matter hereof.
 Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument
 executed by the Company and the Agent. In the event that any one or more of the provisions
 contained herein, or the application thereof in any circumstance, is held invalid, illegal
 or unenforceable as written by a court of competent jurisdiction, then such provision shall
 be given full force and effect to the fullest possible extent that it is valid, legal and
 enforceable, and the remainder of the terms and provisions herein shall be construed as if
 such invalid, illegal or unenforceable term or provision was not contained herein, but only
 to the extent that giving effect to such provision and the remainder of the terms and provisions
 hereof shall be in accordance with the intent of the parties as reflected in this Agreement.
 No implied waiver by a party shall arise in the absence of a waiver in writing signed by
 such party. No failure or delay in exercising any right, power, or privilege hereunder shall
 operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any
 other or further exercise thereof or the exercise of any right, power, or privilege hereunder.

17.  **<u>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</u>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.** 

18.  **<u>CONSENT TO JURISDICTION</u>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.** 

19. <u>Counterparts</u>.
 This Agreement may be executed in two or more counterparts, each of which shall be deemed
 an original, but all of which together shall constitute one and the same instrument. Delivery
 of an executed Agreement by one party to the other may be made by facsimile, electronic mail
 (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
 Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable
 law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered
 shall be deemed to have been duly and validly delivered and be valid and effective for all
 purposes.

20. <u>Construction</u>.
 The section and exhibit headings herein are for convenience only and shall not affect the
 construction hereof. References herein to any law, statute, ordinance, code, regulation,
 rule or other requirement of any Governmental Authority shall be deemed to refer to such
 law, statute, ordinance, code, regulation, rule or other requirement of any Governmental
 Authority as amended, reenacted, supplemented or superseded in whole or in part and in effect
 from time to time and also to all rules and regulations promulgated thereunder.

21. <u>Permitted Free Writing Prospectuses</u>. The Company represents, warrants and agrees that, unless it
 obtains the prior written consent of the Agent, and the Agent represents, warrants and agrees
 that, unless it obtains the prior written consent of the Company, it has not made and will
 not make any offer relating to the Placement Shares that would constitute an Issuer Free
 Writing Prospectus, or that would otherwise constitute a "free writing prospectus,"
 as defined in Rule 405, required to be filed with the Commission. Any such free writing prospectus
 consented to by the Agent or by the Company, as the case may be, is hereinafter referred
 to as a "Permitted Free Writing Prospectus." The Company represents and warrants
 that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
 as an "issuer free writing prospectus," as defined in Rule 433, and has complied
 and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing
 Prospectus, including timely filing with the Commission where required, legending and record
 keeping. For the purposes of clarity, the parties hereto agree that all free writing prospectuses,
 if any, listed in <u>Exhibit 21</u> hereto are Permitted Free Writing Prospectuses.

22. <u>Absence of Fiduciary Relationship</u>. The Company acknowledges and agrees that:

(a) the
 Agent is acting solely as agent in connection with the public offering of the Placement Shares
 and in connection with each transaction contemplated by this Agreement and the process leading
 to such transactions, and no fiduciary or advisory relationship between the Company or any
 of its respective affiliates, stockholders (or other equity holders), creditors or employees
 or any other party, on the one hand, and the Agent, on the other hand, has been or will be
 created in respect of any of the transactions contemplated by this Agreement, irrespective
 of whether or not the Agent has advised or is advising the Company on other matters, and
 the Agent has no obligation to the Company with respect to the transactions contemplated
 by this Agreement except the obligations expressly set forth in this Agreement;

(b) it
 is capable of evaluating and understanding, and understands and accepts, the terms, risks
 and conditions of the transactions contemplated by this Agreement;

(c) neither
 the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice
 with respect to the transactions contemplated by this Agreement and it has consulted its
 own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;

(d) it
 is aware that the Agent and its affiliates are engaged in a broad range of transactions which
 may involve interests that differ from those of the Company and the Agent and its affiliates
 have no obligation to disclose such interests and transactions to the Company by virtue of
 any fiduciary, advisory or agency relationship or otherwise; and

(e) it
 waives, to the fullest extent permitted by law, any claims it may have against the Agent
 or its affiliates for breach of fiduciary duty or alleged breach of fiduciary duty in connection
 with the sale of Placement Shares under this Agreement and agrees that the Agent and its
 affiliates shall not have any liability (whether direct or indirect, in contract, tort or
 otherwise) to it in respect of such a fiduciary duty claim or to any person asserting a fiduciary
 duty claim on its behalf or in right of it or the Company, employees or creditors of Company.

23. <u>Definitions</u>.
 As used in this Agreement, the following terms have the respective meanings set forth below:

"**<u>Applicable Time</u>**" means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement and (iii) each Settlement Date.

"**<u>Governmental Authority</u>**" means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision of any of the foregoing.

"**<u>Issuer Free Writing Prospectus</u>**" means any "issuer free writing prospectus," as defined in Rule 433, relating to the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a "road show" that is a "written communication" within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g) under the Securities Act Regulations.

"**<u>Rule 164</u>**," "**<u>Rule 172</u>**," "**<u>Rule 405</u>**," "**<u>Rule 415</u>**," "**<u>Rule 424</u>**," "**<u>Rule 424(b)</u>**," "**<u>Rule 430B</u>**," and "**<u>Rule 433</u>**" refer to such rules under the Securities Act Regulations.

All references in this Agreement to financial statements and schedules and other information that is "contained," "included" or "stated" in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.

All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to "supplements" to the Prospectus shall include, without limitation, any supplements, "wrappers" or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.

[***Signature Page Follows***]

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CASSAVA SCIENCES, INC. | CASSAVA SCIENCES, INC. |
| By: | */s/ Richard J. Barry* |
| Name: | Richard J. Barry |
| Title: | President and Chief Executive Officer |

---

---

| | |
|:---|:---|
| ACCEPTED as of the date first-above written: | ACCEPTED as of the date first-above written: |
| CANTOR FITZGERALD & CO. | CANTOR FITZGERALD & CO. |
| By: | */s/ Sameer Vasudev* |
| Name: | Sameer Vasudev |
| Title: | Managing Director |

---

**SCHEDULE 1**

**Form of Placement Notice**

From: Cassava Sciences, Inc.

To: Cantor Fitzgerald & Co. Attention: [●]

Subject: Placement Notice

Date: [●], 202[●]

Ladies and Gentlemen:

Pursuant to the terms and subject to the conditions contained in the Sales Agreement between Cassava Sciences, Inc., a Delaware corporation (the "**<u>Company</u>**"), and Cantor Fitzgerald & Co. ("**<u>Agent</u>**"), dated November [●], 2025, the Company hereby requests that the Agent sell up to [•] of the Company's common stock, par value $0.001 per share, at a minimum market price of $[●] per share, during the time period beginning [month, day, time] and ending [month, day, time].

**SCHEDULE 2**

**Compensation**

The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount up to 3.0% of the aggregate gross proceeds from each sale of Placement Shares.

**SCHEDULE 3**

**Notice Parties**

<u>The Company</u>

R. Christopher Cook [\*\*\*]

Richard J. Barry [\*\*\*]

With copies to:

Eric Schoen [\*\*\*]

<u>The Agent</u>

Sameer Vasudev (svasudev@cantor.com)

With copies to:

CFCEO@cantor.com

**SCHEDULE 4**

**Subsidiaries**

Incorporated by reference to Exhibit 21 of the Company's most recently filed Form 10-K, as applicable.

**<u>Exhibit 21</u>**

**Permitted Free Writing Prospectus**

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

250 Vesey Street • New York, New York 10281.1047

TELEPHONE: +1.212.326.3939 • FACSIMILE: +1.212.755.7306

November 12, 2025

Cassava Sciences, Inc.<br> 6801 N. Capital of Texas Highway,<br> Building 1; Suite 300<br> Austin, Texas 78731

Re: <u>Registration Statement on Form S-3 filed by Cassava Sciences, Inc.</u>

Ladies and Gentlemen:

We have acted as counsel for Cassava Sciences, Inc., a Delaware corporation ("***Cassava***"), in connection with the authorization of the possible issuance and sale from time to time, on a delayed basis, by Cassava of up to $200,000,000 aggregate initial offering amount of: (i) shares of common stock, par value $0.001 per share, of Cassava ("***Common***  ***Stock***"); (ii) shares of preferred stock, par value $0.001 per share, of Cassava ("***Preferred Stock***"), in one or more series, certain of which may be convertible or exchangeable for Common Stock; (iii) depositary shares representing fractional interest in Preferred Stock of one or more series ("***Depositary Shares***"); (iv) warrants to purchase Common Stock, Preferred Stock, Debt Securities (as defined below) or a combination thereof ("***Warrants***"); (v) rights to purchase Common Stock, Preferred Stock, Debt Securities or other securities ("***Rights***"); (vi) senior debt securities of Cassava ("***Senior Debt Securities***"), in one or more series, certain of which may be convertible into or exchangeable for Common Stock or other securities; (vii) subordinated debt securities of Cassava ("***Subordinated Debt Securities***" and, collectively with the Senior Debt Securities, "***Debt Securities***"), in one or more series, certain of which may be convertible into or exchangeable for Common Stock or other securities; and (viii) units consisting of one or more of the securities described in clauses (i) through (vii) above (the "***Units***"), in each case, as contemplated by Cassava's Registration Statement on Form S-3 to which this opinion is an exhibit (as the same may be amended from time to time, the "***Registration Statement***"). The Common Stock, Preferred Stock, Depositary Shares, Warrants, Rights, Debt Securities and Units are collectively referred to herein as the "***Securities***." The Securities may be offered and sold from time to time pursuant to Rule 415 under the Securities Act of 1933 (the "***Securities Act***").

In connection with the opinions expressed herein, we have examined such documents, records and matters of law as we have deemed relevant or necessary for purposes of such opinions. Based on the foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The shares of Common Stock, upon receipt by Cassava of such lawful consideration
therefor having a value not less than the par value thereof as Cassava's Board of Directors (or an authorized committee or subcommittee
thereof) may determine, will be validly issued, fully paid and nonassessable.

AMSTERDAM • ATLANTA • BEIJING • BOSTON • BRISBANE • BRUSSELS • CHICAGO • CLEVELAND • COLUMBUS • DALLAS<br> DETROIT • DUBAI • DÜSSELDORF • FRANKFURT • HONG KONG • HOUSTON • IRVINE • LONDON • LOS ANGELES • MADRID<br> MELBOURNE • MEXICO CITY • MIAMI • MILAN • MINNEAPOLIS • MUNICH • NEW YORK • PARIS • PERTH • PITTSBURGH<br> SAN DIEGO • SAN FRANCISCO • SÃO PAULO • SHANGHAI • SILICON VALLEY • SINGAPORE • SYDNEY • TAIPEI • TOKYO • WASHINGTON

![](ex5-1_002.jpg)

Cassava Sciences, Inc.

November 12, 2025

&nbsp;&nbsp;&nbsp;&nbsp;2. The shares of Preferred Stock, upon receipt by Cassava of such lawful consideration therefor having a
value not less than the par value thereof as Cassava's Board of Directors (or an authorized committee or subcommittee thereof) may
determine, will be validly issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Depositary Shares, upon receipt by Cassava of such lawful consideration therefor as Cassava's
Board of Directors (or an authorized committee or subcommittee thereof) may determine, will be validly issued, and the depositary receipts
representing the Depositary Shares will entitle the holders thereof to the rights specified therein and in the Deposit Agreement (as defined
below) pursuant to which they are issued.

&nbsp;&nbsp;&nbsp;&nbsp;4. The Warrants, upon receipt by Cassava of such lawful consideration therefor as Cassava's
Board of Directors (or an authorized committee or subcommittee thereof) may determine, will constitute valid and binding obligations of
Cassava.

&nbsp;&nbsp;&nbsp;&nbsp;5. The Rights, upon receipt by Cassava of such lawful consideration therefor as Cassava's
Board of Directors (or an authorized committee or subcommittee thereof) may determine, will constitute valid and binding obligations of
Cassava.

&nbsp;&nbsp;&nbsp;&nbsp;6. The Senior Debt Securities, upon receipt
by Cassava of such lawful consideration therefor as Cassava's Board of Directors (or
an authorized committee or subcommittee thereof) may determine, will constitute valid and
binding obligations of Cassava.

&nbsp;&nbsp;&nbsp;&nbsp;7. The Subordinated Debt Securities, upon
receipt by Cassava of such lawful consideration therefor as Cassava's Board of Directors
(or an authorized committee or subcommittee thereof) may determine, will constitute valid
and binding obligations of Cassava.

&nbsp;&nbsp;&nbsp;&nbsp;8. The Units, upon receipt by Cassava of such lawful consideration therefor as Cassava's Board of Directors (or an authorized committee or subcommittee thereof) may determine, will constitute valid and binding obligations of
Cassava.

![](ex5-1_002.jpg)

Cassava Sciences, Inc.

November 12, 2025

In rendering the foregoing opinions, we have assumed that: (i) the Registration Statement, and any amendments thereto, will have become effective (and will remain effective at the time of issuance of any Securities thereunder); (ii) a prospectus supplement describing each class or series of Securities offered pursuant to the Registration Statement, to the extent required by applicable law and relevant rules and regulations of the Securities and Exchange Commission (the "***Commission***"), will be timely filed with the Commission; (iii) the definitive terms of each class or series of Securities will have been established in accordance with the authorizing resolutions adopted by Cassava's Board of Directors (or an authorized committee or subcommittee thereof), Cassava's Restated Certificate of Incorporation, as amended (the "***Certificate of Incorporation***"), and applicable law; (iv) Cassava will issue and deliver the Securities in the manner contemplated by the Registration Statement and any Securities that consist of shares of capital stock will have been authorized and reserved for issuance, in each case within the limits of the then remaining authorized but unissued and unreserved amounts of such capital stock; (v) the resolutions authorizing Cassava to issue, offer and sell the Securities will have been adopted by Cassava's Board of Directors (or an authorized committee or subcommittee thereof) and will be in full force and effect at all times at which the Securities are offered or sold by Cassava; (vi) all Securities will be issued in compliance with applicable federal and state securities laws; and (vii) any Deposit Agreement, Warrant Agreement, Subscription Rights Agreement, Indenture and Unit Agreement (each as defined below) will be governed by and construed in accordance with the laws of the State of New York and will constitute a valid and binding obligation of each party thereto other than Cassava.

With respect to any Securities consisting of Preferred Stock, we have further assumed that Cassava will issue and deliver the shares of Preferred Stock being issued and delivered after the filing with the Secretary of State of the State of Delaware of a certificate of amendment to the Certificate of Incorporation, approved by us, establishing the designations, preferences and rights of the class or series of Preferred Stock being issued and delivered.

With respect to any Securities consisting of Depositary Shares, we have further assumed that the Depositary Shares will be: (i) issued and delivered after authorization, execution and delivery of the deposit agreement, approved by us, relating to the Depositary Shares (the "***Deposit Agreement***") to be entered into between Cassava and an entity selected by Cassava to act as depository (the "***Depositary***"); and (ii) issued after Cassava deposits with the Depositary shares of the Preferred Stock to be represented by such Depositary Shares that are authorized, validly issued, fully paid and nonassessable as contemplated by the Registration Statement and the Deposit Agreement.

With respect to any Securities consisting of Warrants, we have further assumed that: (i) the warrant agreement, approved by us, relating to the Warrants (the "***Warrant Agreement***") to be entered into between Cassava and an entity selected by Cassava to act as the warrant agent (the "***Warrant Agent***") will have been authorized, executed and delivered by Cassava and the Warrant Agent and (ii) the Warrants will be authorized, executed and delivered by Cassava and the Warrant Agent in accordance with the provisions of the Warrant Agreement.

![](ex5-1_002.jpg)

Cassava Sciences, Inc.

November 12, 2025

With respect to any Securities consisting of Rights, we have further assumed that: (i) the rights agreement, approved by us, relating to the Rights (the "***Subscription Rights Agreement***") to be entered into between Cassava and an entity selected by Cassava to act as the purchase rights agent (the "***Purchase Rights Agent***") will have been authorized, executed and delivered by Cassava and the Purchase Rights Agent and (ii) the Rights will be authorized, executed and delivered by Cassava and the Purchase Rights Agent in accordance with the provisions of the Subscription Rights Agreement.

With respect to any Securities consisting of any series of Debt Securities, we have further assumed that: (i) such Debt Securities will have been issued pursuant to an indenture that has been executed and delivered by Cassava and the applicable trustee in a form approved by us (the "***Indenture***"), and the Indenture will have been qualified under the Trust Indenture Act of 1939; (ii) all terms of such Debt Securities not provided for in the applicable Indenture will have been established in accordance with the provisions of the applicable Indenture and reflected in appropriate documentation approved by us and, if applicable, authorized, executed and delivered by Cassava and the applicable trustee; and (iii) such Debt Securities will be executed, authenticated, issued and delivered in accordance with the provisions of the applicable Indenture.

With respect to any Securities consisting of Units, we have further assumed that each component of such Unit will be authorized, validly issued, fully paid and nonassessable (to the extent applicable) and will constitute a valid and binding obligation of Cassava or any third party (to the extent applicable) as contemplated by the Registration Statement and the applicable unit agreement (the "***Unit Agreement***"), if any.

The opinions expressed herein are limited by bankruptcy, insolvency, reorganization, fraudulent transfer and fraudulent conveyance, voidable preference, moratorium or other similar laws and related regulations and judicial doctrines from time to time in effect relating to or affecting creditors' rights generally, and by general equitable principles and public policy considerations, whether such principles and considerations are considered in a proceeding at law or at equity.

![](ex5-1_002.jpg)

Cassava Sciences, Inc.

November 12, 2025

As to facts material to the opinions and assumptions expressed herein, we have relied upon oral or written statements and representations of officers and other representatives of Cassava and others. The opinions expressed herein are limited to the laws of the State of New York and the General Corporation Law of the State of Delaware, in each case as currently in effect, and we express no opinion as to the effect of the laws of any other jurisdiction.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to Jones Day under the caption "Legal Matters" in the prospectus constituting a part of the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Jones Day |

---

## Exhibit 5.2

**Exhibit 5.2**

![](ex5-2_001.jpg)

250 Vesey Street • New York, New York 10281.1047

TELEPHONE: +1.212.326.3939 • FACSIMILE: +1.212.755.7306

November 12, 2025

Cassava Sciences, Inc.<br> 6801 N. Capital of Texas Highway, <br> Building 1; Suite 300<br> Austin, Texas 78731

---

| | |
|:---|:---|
| Re: | <u>Up to $50,000,000 of Shares of Common Stock, Par Value $0.001 Per Share, to Be Offered Pursuant to the Controlled Equity Offering<sup>SM</sup> Sales Agreement</u> |

---

Ladies and Gentlemen:

We are acting as counsel for Cassava Sciences, Inc., a Delaware corporation ("***Cassava***"), in connection with the issuance and sale of up to $50,000,000 aggregate offering price of shares of common stock, par value $0.001 per share, of Cassava (the "***Shares***"), pursuant to the Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated as of November 12, 2025 (the "***Sales Agreement***"), by and between Cassava and Cantor Fitzgerald & Co. (the "***Agent***"). The Shares may be offered and sold from time to time pursuant to Rule 415 under the Securities Act of 1933 (the "***Securities Act***") in accordance with the terms of the Sales Agreement.

In connection with the opinion expressed herein, we have examined such documents, records and matters of law as we have deemed relevant or necessary for purposes of this opinion. Based upon the foregoing and subject to the further assumptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued and delivered pursuant to the terms of the Sales Agreement against payment of the consideration therefor as provided therein, will be validly issued, fully paid and nonassessable; provided that such consideration is at least equal to the stated par value of the Shares.

In rendering the opinion above, we have assumed that the resolutions of the Board of Directors authorizing Cassava to issue and deliver and sell the Shares pursuant to the Sales Agreement will be in full force and effect at all times at which the Shares are issued and delivered or sold by Cassava, and Cassava will take no action inconsistent with such resolutions.

The opinion expressed herein is limited to the General Corporation Law of the State of Delaware, as currently in effect, and we express no opinion as to the effect of the laws of any other jurisdiction.

AMSTERDAM • ATLANTA • BEIJING • BOSTON • BRISBANE • BRUSSELS • CHICAGO • CLEVELAND • COLUMBUS • DALLAS<br> DETROIT • DUBAI • DÜSSELDORF • FRANKFURT • HONG KONG • HOUSTON • IRVINE • LONDON • LOS ANGELES • MADRID<br> MELBOURNE • MEXICO CITY • MIAMI • MILAN • MINNEAPOLIS • MUNICH • NEW YORK • PARIS • PERTH • PITTSBURGH<br> SAN DIEGO • SAN FRANCISCO • SÃO PAULO • SHANGHAI • SILICON VALLEY • SINGAPORE • SYDNEY • TAIPEI • TOKYO • WASHINGTON

![](ex5-2_002.jpg)

Cassava Sciences, Inc.

November 12, 2025

We hereby consent to the filing of this opinion as Exhibit 5.2 to the Registration Statement on Form S-3 (the "***Registration Statement***") filed on the date hereof by Cassava with the Securities and Exchange Commission (the "***Commission***") to effect registration of the offer and sale of the Shares under the Securities Act and to the reference to us under the caption "Legal Matters" in the prospectus constituting a part of such Registration Statement. In giving such consent, we do not hereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Jones Day |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm**

We consent to the reference to our firm under the caption "Experts" in this Registration Statement (Form S-3) and related Prospectus of Cassava Sciences, Inc for the registration of common stock and to the incorporation by reference therein of our report dated March 3, 2025, with respect to the consolidated financial statements of Cassava Sciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Austin, Texas<br> November 12, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-3** (Form Type)

**Cassava Sciences, Inc.** (Exact Name of Registrant as Specified in its Charter)

<u>Table 1—Newly Registered and Carry Forward Securities</u>

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class Title** | **Fee Calculation or Carry Forward Rule** | **Amount Registered<sup>(1)</sup>** | **Proposed Maximum Offering Price Per Unit<sup>(2)</sup>** | **Maximum Aggregate Offering Price<sup>(3)</sup>** | **Fee Rate** | **Amount of Registration Fee** | **Carry Forward Form Type** | **Carry Forward File Number** | **Carry Forward Initial Effective Date** | **Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to Be Paid | Equity | Common Stock, par value $0.001 per share | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Equity | Preferred Stock, par value $0.001 per share | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Other | Depositary Shares | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Other | Warrants | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Other | Rights | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Debt | Debt Securities | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Other | Units | 457(o) |  |  |  |  |  |  |  |  |  |
| Fees to Be Paid | Unallocated (Universal Shelf) | N/A | 457(o) |  |  | $200000000 | 0.00013810 | $27620 |  |  |  |  |
| Fees Previously Paid | N/A | N/A | N/A | N/A | N/A | N/A |  | N/A |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities | N/A | N/A | N/A | N/A | N/A | N/A |  | N/A |  |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $200000000 |  | $27620 |  |  |  |  |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  | N/A |  |  |  |  |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $85701.62 |  |  |  |  |
|  | **Net Fees Due** | **Net Fees Due** | **Net Fees Due** | **Net Fees Due** |  |  |  | $0 |  |  |  |  |

---

<u>Table 2—Fee Offset Claims and Sources</u>

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Registrant**<br> **or Filer**<br> **Name** | **Form or**<br> **Filing**<br> **Type** | **File Number** | **Initial Filing**<br> **Date** | **Filing Date** | **Fee Offset Claimed** | **Security**<br> **Type**<br> **Associated**<br> **with Fee**<br> **Offset**<br> **Claimed** | **Security Title**<br> **Associated with**<br> **Fee Offset**<br> **Claimed**<br> **** | **Unsold**<br> **Securities**<br> **Associated**<br> **with Fee**<br> **Offset**<br> **Claimed**<br> **** | **Unsold**<br> **Aggregate**<br> **Offering**<br> **Amount**<br> **Associated**<br> **with Fee**<br> **Offset**<br> **Claimed** | **Fee Paid**<br> **with Fee**<br> **Offset**<br> **Source** |
| **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** |
| Fee Offset Claims | Cassava Sciences, Inc. | 424B5 | 333-271542 | May 1, 2023 |  | $22040<br><sup>(4)</sup> | Common Stock<br><sup>(4)</sup> |  |  | $200000000 |  |
| Fee Offset Claims | Cassava Sciences, Inc. | 424B2 | 333-271542 | January 3, 2024 |  | $63661.62<sup>(5)</sup> | Common Stock<sup>(5)</sup> |  |  | $431311782 |  |
| Fee Offset Sources | Cassava Sciences, Inc. | 424B5 | 333-271542 |  | May 1, 2023 |  |  |  |  |  | $22040<sup>(4)</sup> |
| Fee Offset Sources | Cassava Sciences, Inc. | 424B2 | 333-271542 |  | January 3, 2024 |  |  |  |  |  | $63661.62<sup>(5)</sup> |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) There are being registered hereunder an indeterminate number of each identified class of
securities of Cassava Sciences, Inc. (the "Registrant"), which securities may be offered and sold, on a primary basis, in
such amount in U.S. dollars or the equivalent thereof in foreign currencies as shall result in an aggregate public offering price for
all securities of $200,000,000.00 after the date hereof. The securities registered hereunder also include such indeterminate amount of
securities that may be issued upon exercise, conversion, settlement or exchange of any securities being registered hereunder. Any securities
registered hereunder may be sold separately or as units with other securities registered hereunder. Pursuant to Rule 416(a) under the
Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover an indeterminate
number of additional securities to be offered as a result of share splits, share dividends or similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The proposed maximum offering price per unit will be determined from time to time by the
Registrant in connection with the issuance by the Registrant of the securities registered hereunder. Prices, when determined, may be
in U.S. dollars or the equivalent thereof in one or more foreign currencies, foreign currency units or composite currencies. If any Debt
Securities or shares of preferred stock are issued at an original issue discount, then the amount registered will include the principal
or liquidation amount of such securities measured by the initial offering price thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o).

&nbsp;&nbsp;&nbsp;&nbsp;(4) The Registrant previously registered shares of Common Stock, par value $0.0001 per share
("Common Stock"), of the Registrant having an aggregate offering price of up to $200,000,000 pursuant to a Form 424B5, filed
on May 1, 2023, to the Registration Statement on Form S-3 No. 333-271542, filed on May 1, 2023 (the "Prior Registration Statement"),
and paid a total registration fee of $22,040. Pursuant to Rule 457(p), $22,040 of the registration fees paid in connection with a portion
of the unsold securities registered on the Prior Registration Statement is being applied to this Registration Statement. The offering
of such unsold securities from the Prior Registration Statement has been terminated or completed.

&nbsp;&nbsp;&nbsp;&nbsp;(5) The Registrant previously registered 25,342,150 shares of Common Stock underlying warrants
to purchase shares of Common Stock (the "Warrants") pursuant to a Form 424B2, filed on January 3, 2024, to the Prior Registration
Statement, and paid a total registration fee of $82,291.03. Pursuant to Rule 457(p), $63,661.62 of the registration fees paid in connection
with the 19,605,081 shares of Common Stock registered on the Prior Registration Statement underlying the Warrants that were not exercised
is being applied to this Registration Statement. The offering of such unsold securities from the Prior Registration Statement has been
terminated or completed.